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INTRODUCTION 
In order to distinguish between harmless antigens and potential pathogenic 
invaders the immune system has developed several tolerance mechanisms. 
Tolerance towards self-antigens is induced after encountering self-antigens by 
immature lymphocytes in the central lymphoid organs such as bone marrow and 
thymus. This is termed central tolerance. Alternatively, peripheral tolerance can be 
initiated when mature lymphocytes are exposed to self antigens in the peripheral 
tissues. In there situation, the ensuring tolerance arises because the effective 
immune responses are suppressed or tightly regulated. Peripheral tolerance 
mechanisms not only suppress peripheral self-reactive T cells, and thus prevent the 
induction of autoimmune-diseases, but are also involved in the prevention of graft-
versus-host diseases, and tumor growth. These tolerance mechanisms also play a 
role in hypersensitivity reactions against innocuous antigens such as cow’s milk, 
insect venom, pollen, house dust mites, drugs and nickel ions. One naturally 
occurring method to prevent these hypersensitivity reactions is by oral application 
of the antigen.  
This thesis begins with a general overview of delayed-type hypersensitivity 
(DTH) reactions and the immunological knowledge surrounding the most common 
DTH reaction, allergic contact dermatitis induced by direct skin contact with 
nickel. The chapter then progresses to describe the different mechanisms known to 
regulate nickel-induced allergic contact dermatitis and to induce oral tolerance 
towards these Th1 responses. At the end of the introduction the aims of this thesis 
are described.  
 
HYPERSENSITIVITY  
Hypersensitivity reactions are strong immune responses to normally harmless self- or 
exogenous- antigens. These antigens predispose the immune system to cause cell damage and 
tissue injury upon re-exposure with the antigen. Normally, different types of hypersensitivity 
reactions do not occur exclusively from one another. However, Coombs and Gell classified these 
reactions into the following four types (1): 
Type I hypersensitivity reactions are immediate reactions mediated by allergen-specific IgE, 
which binds via the Fcε-receptor to mast cells (1, 2). After re-exposure to soluble allergens like 
pollen and house-dust mites, the allergen cross-links specific IgE molecules on the surface of the 
mast cells of sensitized individuals are activated within minutes. This Fcε-mediated triggering of 
mast cells leads to a degranulation of mediators causing symptoms like asthma, urticaria, rhinitis, 
and anaphylactic shock. 
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Type II hypersensitivity reactions are cytotoxic reactions mediated by IgG, which are directed 
against membrane-bound antigens (1, 3). Once the IgG has bound to the antigenic determinants 
on the target cell, the latter is lysed, predominantly by macrophages bearing Fcγ-receptors but 
also by complement-mediated effector mechanisms. Examples of such reactions are (drug-
induced) autoimmune haemolytic anaemia or transfusion reaction. 
The type III hypersensitivity reactions are also IgG-mediated responses but towards soluble 
antigens (1, 4). The main damage in these responses is caused by deposition of antigen-antibody 
complexes. These small immune complexes tend to accumulate in the local blood vessel walls, 
where they cause Fcγ-mediated activation of mast cells, and consequently a local inflammation. 
Alternatively, the immune complexes in the blood circulation can activate complement, and 
ultimately lead to severe organ damage. An example of this type of hypersensitivity reaction is 
(drug-induced) systemic lupus erythematosus and serum sickness. 
The delayed or type IV hypersensitivity reactions are mediated by allergen-specific effector T 
cells and in there situations are no antibodies involved (1, 5). Cell-associated antigens presented 
by antigen-presenting cells (APCs) on major histocompatibility complex (MHC) class I-
molecules can activate cytotoxic CD8+ T (Tc1) cells, leading to the lysis of the APC. An example 
of this Tc1-mediated effector mechanism is the autoimmune disease diabetes mellitus, in which 
insulin-producing pancreatic β cells are destroyed (1). Soluble antigens, embedded in MHC class 
II-molecules on APCs, can induce inflammatory responses by activating CD4+ effector T helper 
(Th1) cells. This type of Th1-mediated effector mechanism occurs in the autoimmune disease 
multiple sclerosis (MS). During a MS relapse Th1 cells, directed against myelin components, 
infiltrate the brain and recruit myelinotoxin-releasing cells which, in turn, lead to demyelination 
and axonal loss (6). Compared to immediate type I, II and III hypersensitivity reactions, the 
delayed type IV hypersensitivity reactions show a delayed time course, since both local cytokine 
production which initiate the migration of specific effector T cells and the migration of specific 
effector T cells itself need 24 to 48 hours to become fully effective. 
 
 
ALLERGIC CONTACT DERMATITIS   
Besides self-antigens, also haptens can induce delayed hypersensitivity reactions. When the 
skin is exposed to haptens such as dinitrofluorobenzene (DNFB), pentadecylcatechol from poison 
ivy or metals ions (Ni2+ or Co2+ ions) this can lead to the generation of Ag-specific effector T 
cells (sensitization phase, Fig. 1 (7, 8)). Upon dermal re-exposure with the contact allergen 
(elicitation phase, Fig. 1), activation of the effector T cells causes erythema, induration, and 
cellular infiltrate, leading to allergic contact dermatitis (ACD) (8).  
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Figure 1. Immunological events in ACD. Early after hapten exposure, DCs in the skin become activated 
and migrate to the draining lymph nodes where they present the hapten and costimulatory molecules to 
naive T cells. Naive T cells receiving both signals differentiate towards hapten-specific effector T cells. 
The sensitization phase is complete when the individual has generated hapten-specific effector T cells. 
Upon re-challenge the cytotoxicity of the activated hapten-specific effector T cells results in clinical 
manifestation of ACD.  
 
Haptens 
Classical contact sensitizing haptens are chemically reactive molecules which are too small to 
be immunogenic by themselves, but these haptens can penetrate into the skin and form readily 
immunogenic conjugates with epidermal and dermal proteins. Lipophilic organic haptens such as 
those derived from poison ivy have been shown to directly penetrate into skin residing 
Langerhans cells or other resident dendritic cells (DCs), where they can covalently bind to 
nucleophilic ligands such as thiol-, amino-, or hydroxyl-groups of cytoplasmic proteins (9). These 
hapten-carrier complexes are predominantly processed along the “endogenous” processing route, 
thus favouring association with MHC class I molecules (10). Hence, ACD reactions against 
activated DC 
 
elicitation phase 
(epi-)dermis 
sensitization phase 
Hapten 
lymph node 
hapten presentation 
costimulation 
naive  
T cell 
DC 
 
hapten- 
specific  
T
 
cell 
Chapter 1 
16 
lipophilic haptens are mainly mediated by CD8+ T cells. In contrast, hydrophilic haptens, such as 
metal ions, can form non-covalent coordination complexes with dermal proteins, which are 
processed along the “exogenous” route of antigen processing, since they can be engulfed by 
dermal DCs via endocytosis (5, 11). Thus, hydrophilic haptens are predominantly presented by 
MHC class II molecules, leading to a CD4+ T cell-mediated ACD reaction. Although most 
haptens can spontaneously form hapten-carrier or coordination complexes, some act as pro-
haptens and need activation via mechanisms such as enzyme-induced metabolic conversion or 
oxidation to become capable of activating dermal DCs (12, 13).  
 
Sensitization phase 
Dermal DCs release interleukin-1β (IL-1β) very early after hapten application, which, in turn, 
stimulates the release of tumor necrosis factor (TNF)-α and granulocyte-macrophage colony-
stimulating factor (GM-CSF) from keratinocytes (14) (Fig. 2). These three cytokines facilitate the 
activation of DCs, as shown by the increase of the expression of costimulatory molecules, such as 
CD40, CD80, CD86, cellular adhesion molecules, such as intercellular adhesion molecule-1 
(ICAM-1/ CD54), and molecules mediating antigen-presentation (e.g. MHC class I and II, CD1). 
Furthermore, activated dermal DCs migrate from the epidermis via the afferent lymphatic vessels 
into the draining lymph nodes (15). Within the draining lymph nodes, activated DCs strongly 
facilitate multiple cell contacts, leading to the presentation of the allergen (signal 1) and co-
stimulatory molecules (signal 2) to naive T cells (15). Activation of naive T cells with both 
signals leads to their proliferation and differentiation into hapten-specific effector T cells.  
 
Migration of dermal DCs 
The migration of activated dermal DCs and naive T cells to the draining lymph nodes is 
mediated by chemokines (16). Chemokines are small molecules which regulate the leukocyte 
migration across the blood vessel wall (extravasation) (17). Rolling, or slowing down of the 
leukocytes, is the first step in extravasation, and is followed by cell arrest, firm adhesion and 
spreading onto the vessel wall, leading to the transmigration (diapedesis) of the leukocytes 
through the endothelium. Finally, leukocytes migrate along a concentration gradient of 
chemokines (chemotaxis) to the site of inflammation. The gradient is created by cells at the site 
of inflammation. 
Activated or mature dermal DCs have an enhanced expression of the chemokine receptor 
CCR7, whereas CCR6 is reduced compared to immature DCs (18). The ligand for CCR6, 
General introduction 
17 
CD40 
CD80 / CD86 
CD54 
T cells 
CD40 Ligand 
CD28 
LFA-1  
               TCR-CD3 complex 
with CD4 or CD8 co-receptor 
lymph node 
 activated  
   DC 
 
 
Figure 2. Simplified scheme of the immunological events in the sensitization phase of ACD. 
Epidermis  
Hapten 
        afferent 
lymphatic vessel 
IL-1β 
keratinocyte 
dermal DC 
CCR6high CCR7low TNF-α, 
 GM-CSF 
naiveT cell 
CD62Lhigh 
LFA-1high 
CCR7high 
 
PNad 
ICAM-1 
ICAM-2 
artery 
naive 
T cell 
T cell zone 
CCL19high 
CCL21high 
CCL21high 
vein 
efferent 
lymphatic vessel 
APCs 
   MHC-peptide complex 
activated DC 
CCR6low CCR7high 
Chapter 1 
18 
macrophage inflammatory protein-3α (MIP-3α/CL20), is expressed in the skin and attracts 
immature DCs to screen for antigens (19). The activated, and thus CCR7+ DCs home to lymphoid 
organs where the CCR7 ligands EBV-induced molecule 1 ligand chemokine (ELC/CCL19) and 
secondary lymphoid-tissue chemokine (SLC/CCL21) are expressed (20). Although both 
chemokines are expressed in the T cell zone of the lymph nodes, CCL21 is additionally expressed 
by high endothelial cells in the afferent lymphatic vessels (21, 22). In the lymphatic vessels, 
CCL21 triggers the arrest of rolling lymphocytes in the high endothelial cells of peripheral lymph 
nodes (23). Hence, this switch in chemokine receptor expression on dermal DCs upon hapten-
mediated activation promotes the migration of these DCs from the skin to the T cell areas of the 
draining lymph nodes (see Fig. 2). 
 
Migration of naive T cells 
The migration of naive T cells to the lymph nodes is mediated by the adhesion molecule L-
selectin (CD62L), the integrin leukocyte functional antigen-1 (LFA-1, CD11a/CD18)), and CCR7 
(Fig. 2). Whereas CD62L allows the rolling interaction along the vessel walls by binding to 
peripheral node adressins (PNad), such as GlyCAM-1, the interaction of LFA-1 with endothelial 
ICAM-1 and ICAM-2 has a major role in T-cell adhesion to and migration through the wall of the 
venule into the lymph node (24, 25). Since naive T cells also express CCR7, the before 
mentioned receptors CCL19 and CCL21 also promote the infiltration of naive T cells into the T 
cell areas of the peripheral draining lymph nodes (21, 26).  
 
 
T cell proliferation and differentiation  
The proliferation of naive T cells depends on the production of cytokines, in particular the T-
cell growth factor IL-2, which binds to a high affinity receptor on activated T cells (27). After 
proliferation, these T cells are subsequently released via the efferent lymphatic vessels into the 
blood flow. Thus, the frequency of specific T cells in the blood increases. In the absence of 
further allergen contacts, their frequency gradually decreases in subsequent weeks/months, but 
does not return to the low levels found in naive individuals.  
For the differentiation (also called priming or sensitization) of naive T cells to effector T cells, 
the TCR triggering alone is insufficient. The relatively high activation threshold of naive T cells 
can only be overcome by elevated expression levels of costimulatory molecules on APCs and the 
local abundance of cytokines. Upon this activation, T-cell progeny differentiates within a few 
days into effector cells. Thereby, they down-regulate the expression of CD62L and CCR7 (see 
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“migration of naive T cells”) but up-regulate the adhesion molecules very late antigen-4 (VLA-
4/α4β1), P-selectin glycoprotein ligand (PSGL-1/CD162), and LFA-1 (28). The expression of 
VLA-4 and CD162 and the increased expression of LFA-1, which bind to vascular cell adhesion 
molecule-1 (VCAM-1), P-selectin (CD62P) and ICAM-1, respectively, initiates the extravasation 
of the effector T cells and, thus, rapidly recruits effector T cells to the site of inflammation. Just 
like the earlier mentioned ICAM-1, VCAM-1 and CD62P, VLA-4, CD162 and LFA-1 are 
induced on activated peripheral vascular endothelial cells by cytokines released at the 
inflammatory site. Furthermore, the tissue microenvironment and/or tissue-specific DC instruct 
effector T cells for tissue selective trafficking. For example, DCs from mesenteric lymph nodes 
induce the constitutive expression of the gut homing receptor α4β7 during T cell differentiation, 
whereas during priming with dermal DCs, such as langerhans cells (LC), the constitutive 
expression of the skin homing receptor cutaneous lymphocyte-associated ntigen (CLA) is 
induced on effector T cells (29, 30). CLA mediates rolling of effector T cells over E-selectin 
(CD62E), expressed on activated endothelial cells in the dermis. Hence, dermal application of 
contact sensitizing haptens makes it possible to rapidly induce the expression of CD62E (31), and 
thus start the trafficking of effector T cells specific for contact allergens to the skin.  
Not only the expression of homing receptors is regulated during the differentiation of naive T 
cells towards effector T cells, but also the subtype of effector T cells with different effector 
functions (Fig. 3). Type-1 effector cells make up the effector mechanism of cell-mediated 
immunity. Macrophages are activated by type-1 CD4+ T (Th1) cells, since activated Th1 cells 
release predominantly the macrophage-activating effector molecule INF-γ (27). Another effector 
mechanism of Th1 cells is Fas-mediated apoptosis (32). Type-1 CD8+ T (Tc1) cells release 
beside INF-γ also perforin and granzymes (cytotoxic effector molecules), which mediate the 
destruction of infected cells (27). B cells activated by type-2 CD4+ T (Th2) cells produce 
neutralizing antibodies. Therefore, Th2 cells have to produce mainly IL-4 and IL-5, which are B-
cell activating effector molecules. However, IL-4 can also inhibit the activation of type-1 T cells 
(27). Hence, Th2 cells drive the effector mechanism of humoral immune responses and suppress 
the type-1 responses. Type-3 T (Th3) cells have an anti-inflammatory capacity by the production 
of IgA and secretion of the cytokines IL-4, IL-10 and transforming growth factor-β (TGF-β). 
Hence, these Th3 cells neutralize gut pathogens or their toxins to prevent their entry along the 
mucosal surfaces, and suppress the Th1 and Th2 responses in a mainly TGF-β-dependent manner 
(33). A similar regulatory T cell population, which prevents the activation of naive T cells and 
suppresses the Th1 and Th2 responses in a mainly IL-10-dependent manner, have been named T 
regulatory 1 (Tr1) cells (34). It needs to be remarked that the patterns of cytokine secretion by T 
cells are very complicated and this subdivision of T cells is a considerable oversimplification. 
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Figure 3. Differentiation of naive T cells to more polarized T-cell subsets and their effector mechanism. 
Depending on the immunological microenvironment naive T cells differentiate into Th1, Tc1, and Th2 
cells which remove the antigen, or Th3 and Tr1 cells which (down-)regulate the immune-response.  
 
 
The factors that determine the polarization of naive T cells towards these different phenotypes 
is not fully understood, but the site and cytokine environment of first allergen contact can 
profoundly influence this differentiation. Differentiation of T cells towards Th1 cells is strongly 
promoted by CD40-dependent IL-12 production by the DCs (35), whereas the presence of IL-4 
contributes to preferential differentiation of naive T cells towards Th2 cells. The production of 
IL-4 by T cells is promoted by IL-6 and the interaction between CD28 on T cells and CD86 on 
APCs (36, 37). The differentiation of regulatory Th3 cells is more prominent after mucosal 
contacts with contact allergens. In the mucosa, DCs release only small quantities of IL-12, 
whereas the TGF-β-rich environment contributes to the differentiation of naive T cells towards 
Th3 cells (38). In contrast, Tr1 cells are induced in an IL-10-rich environment (39). Another 
factor that determines the profile of cytokine production is the molecular character and 
concentration of the allergen. Prolonged allergenic contact ultimately leads to a predominance of 
specific type-2 T cells, however, the mechanism is still poorly understood (40). 
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Elicitation phase  
Once sensitized, individuals can develop ACD upon re-exposure to the contact allergen. This 
elicitation phase leads to the dermal accumulation of contact allergen-specific effector T cells 
resulting in erythema and swelling (Fig. 4). The accumulation of allergen-specific effector T cells 
is initiated by irritative properties of the haptens resulting in the release of TNF-α and IL-1β by 
keratinocytes and LCs, respectively. These cytokines not only activate dermal DCs, but also 
loosen intercellular junctions, and increase the expression of adhesion molecules on local blood 
vessels. Herewith, extravasation of leukocytes, including allergen-specific T cells, is strongly 
promoted. Furthermore, haptens can stimulate nitric oxide production by LCs and keratinocytes, 
which contributes to local edema, vasodilatation and cellular extravasation (14).  
Keratinocytes activated by the irritative properties of the haptens release the chemokines 
monocyte chemoattractant protein (MCP-1/CCL2) and IL-8 (41-43). Whereas IL-8 recruits 
neutrophils, which are able to induce the innate immune response, CCL2 strongly recruits 
mononuclear cells including monocytes, macrophages, B cells and T cells to the skin (44). 
Subsequently, the professional and non-professional APCs within the mononuclear cells take up 
antigen and activate the also infiltrating specific effector T cells, which can be triggered in the 
absence of costimulation. INF-γ released by these activated specific effector T cells is the most 
efficient stimulus for the activation of keratinocytes. INF-γ-stimulated keratinocytes release the 
INF-inducible CXCR3 ligands, such as monokine induced by IFN-γ (MIG/CXCL9), IFN-γ-
inducible protein 10 (IP-10/CXCL10) and IFN-inducible T cell α chemoattractant (I-
TARC/CXCL11), which are critical for the massive infiltration of CXCR3+ effector T cells, 
which are predominantly type 1 T cells (45). The frequency of specific T cells may increase even 
further, due to allergen-induced proliferation and rescue from apoptosis (14). The resulting skin 
damage is due to the antigen-presenting keratinocytes being lysed by either Fas-mediated or 
perforin-mediated mechanisms. The perforin-mediated effector mechanisms are induced by 
specific Tc1 cells, which are mainly generated by lipophilic haptens, whereas Fas-mediated 
effector mechanisms can be induced by FasL-expressing specific Tc1 and Th1 cells. Hence, the 
elicitation of ACD requires a non-antigen-specific proinflammatory signal which initiates the 
antigen-specific cytotoxic effector mechanisms. Notably, in ongoing ACD reactions, the 
chemokine and cytokine release results not only in activation of specific effector T cells but also 
in the non-specific recruitment and activation of leukocytes. Thus, like the very early events in 
the effector phase reaction, the final response to a contact allergen is antigen-nonspecific (14).  
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 Figure 4. Simplified scheme of the immunological events in the 
effector phase of ACD. A) The irritative properties of the 
hapten initiate the extravasation of leukocytes. B) INF-γ release 
by infiltrated specific T cells, activated by infiltrated hapten-
presenting mononuclear cells, stimulates the keratinocytes to 
produce the chemokines CXCL9, CXCL10 and CXCL11, 
which  further  attract  type  1   T   cells.  C)   Hapten-activated  
type  1  T  cells release proinflammatory cytokines and induce apoptosis by the two different pathways 
described in D and E. D) Perforin and granzym-mediated apoptosis: perforin released from the lytic 
granules of Tc1 cells forms pores in the membrane of keratinocytes and granzyme activates apoptosis, 
once in the cytoplasma of the keratinocytes. E) Fas-mediated apoptosis: INF-γ-stimulated keratinocytes 
express Fas, which makes them susceptible to Fas-mediated apoptosis induced by FasL+ Th1 and Tc1 
cells. F) ACD is caused by pro-inflammatory cytokines and the lysis of antigen-presenting 
keratinocytes, which leads to erythema, induration, and cellular infiltration. 
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 SENSITIZATION PHASE OF NICKEL-INDUCED ACD  
In industrialized countries, nickel is the most common cause of ACD (46). In the sensitization 
phase, APCs which simultaneously present nickel-induced neoantigens and up-regulate their 
costimulatory molecules, induce the differentiation of naive T cells into nickel-specific effector T 
cells (13). In sensitized individuals, ACD is elicited after dermal exposure to Ni2+ ions released 
from nickel containing items or as present, for instance, in NiCl2 and NiSO4 (13). 
 
Nickel 
Although nickel is a well known contact allergen and is able to up-regulate costimulatory 
molecules at high concentration on monocyte-derived DCs in vitro (47), an experimental animal 
model for nickel-induced ACD has proven difficult to develop (48). Van Hoogstraten et al. 
succeeded to develop nickel-induced ACD in BALB/c mice, kept and bred for at least two 
generations in metal-free cages, by intradermal injection of 2.4 µmol Ni2+-ions in complete 
Freund’s adjuvant (CFA) (49). Ishii et al. used cotton gauze painted with 100 µl of a highly 
concentrated (20 %) solution of NiSO4, and fixed this with a bandage to the clipped flanks for 7 
days in order to sensitize conventionally-kept C3H/He mice towards nickel (50). It is noteworthy 
that in this study the dermal application of NiSO4 alone, i.e. without additional adjuvant, sufficed 
to sensitize. Presumably, this can be explained by the fact that the bandage attached to the clipped 
flank caused skin damage and/or irritation and that this provided the costimulatory signals needed 
for the sensitization to nickel.  
My colleague Suzan Artik could sensitize C57Bl/6 mice by intradermal injection of NiCl2 (2 
µmol) together with either H2O2, a skin irritant, or IL-12 as adjuvant (13). These animals were 
reared and kept under conventional conditions, i.e. with cage covers and water bottle outlets 
made of nickel-containing stainless steel. We assume that during priming, H2O2 up-regulates the 
costimulation, because the intrinsic adjuvanticity of nickel, and thus its capacity to induce 
costimulation is too low. Nevertheless, Ni2+ ions alone are sufficient to activate existing nickel-
specific effector T cells, which are much less dependent on costimulation than naive T cells (13). 
This could explain the clinical experience that nickel allergy usually develops in an irritated or 
inflamed skin, such as pierced skin (51), since the enhanced costimulation in such skin, does not 
require additional adjuvant administration for de novo sensitization towards nickel.  
 
Chapter 1 
24 
Nickel-induced neo-antigens 
Nickel is no ‘classical’ hapten; it can form many different neo-antigens by different means 
(Fig. 5). First, nickel is ubiquitous present in all tissues (Fig. 5A). Second, in contrast to classical 
hydrophilic haptens, which form hapten-carrier complexes that are processed by the exogenous 
route before being presented by MHC class II-molecules, nickel does not require processing 
before presentation (52) (Fig. 5B). Furthermore, nickel-induced neoantigens, presented by the 
MHC molecules via the process-independent pathway, can be formed by the direct binding of 
nickel to peptides already presented by MHC-molecules and/or to the MHC-molecule itself 
independent of the peptide (Fig. 5C). Moreover, Ni2+-ions carry up to six possible binding sites, 
which can bind to ligands on amino acids such as histidine and cysteine (Fig. 5D). Recent data 
from Lu et al. propose that Ni2+-ions can bind to histidine 81 (His81) on the MHC β chain (53). 
This His81 is conserved in nearly all MHC class II alleles and isotypes of all species 
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 (53). The NH2-terminal part of the peptide also contains two possible ligands when they are in 
close proximity to the His81 on the MHC β chain (53). Consequently, since many MHC-peptide 
complexes contain these three distinct nickel ligands, nickel can induce multiple different neo-
antigens. 
 
Nickel-specific T cell Receptors 
With regard to T cells, it has been shown that CD4+ T cells, but not CD8+ T cells, from 
patients with severe nickel-induced ACD-reactions have an increased expression of the T cell 
receptor (TCR) Vβ17 sequence (54). Although the complementarity-determining region (CDR) 
1β sequence of the Vβ17 TCR contains the unique nickel-binding motif His27-Asp28-Ala29, to 
present date, mutations in this motif have failed to influence the nickel-reactivity of nickel-
specific T cell hybridomas (55). Hence, the CDR1β region is not crucial for the recognition of 
nickel by nickel-specific T cell hybridomas. The TCR Vβ sequence is the major part of the 
CDR3β sequence, which defines the specificity of the TCR and thus of the T cells (56). Although 
the conserved Arg95-Asp96 motif in the CDR3β sequence of the nickel-specific TCR has been 
shown to be involved in the recognition of nickel-induced neo-antigens of one nickel-specific 
Vβ17+ T cell clone, the nickel-specificity of another Vβ17+ T cell clone largely depended on the 
Vα22 sequence of the TCR (53, 55). Activation of this Vα22+ T cell clone was demonstrated to 
be dependent on the Tyr29 residue in the CDR1α sequence and the Tyr94 residue in the CDR3α 
sequence (57). Altogether, the nickel-binding sides on nickel-specific TCR remain unknown, 
recent study shows that nickel may form and stabilize intramolecular bridges between TCR and 
MHC, independent of MHC-associated proteins (58). This might lead to TCR triggering which 
would not occur in the absence of nickel (Fig. 5E).   
 
 
ELICITATION PHASE OF NICKEL-INDUCED ACD  
Although theoretically CD4+ effector T cells should predominantly elicit ACD reactions 
towards hydrophilic haptens, this is not a universal rule. For example, whereas formaldehyde-
mediated ACD is predominantly induced by Th1 effector cells (5), FITC-mediated ACD is 
mediated by Th2 effector cells (59). In the case of nickel, which can be presented by the 
processing-independent route and thus by MHC class I-molecules as well as MHC class II-
molecules, CD8+ effector T cells may participate, or even take a leading role (60). Hence, in 
principle both CD4+ and CD8+ T cells are able to function as effector T cells in nickel-induced 
ACD reactions (5).  
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Nickel-specific T cells in vitro 
In vitro, T cells or T cell clones isolated from the blood of nickel-allergic individuals 
proliferated and secreted substantial amounts of IL-2 and INF-γ but little or no IL-4 after 
restimulation with nickel in vitro (61, 62). In contrast, nickel-specific Th1 or Tc1 clones, isolated 
from patients with skin lesions caused by nickel-induced contact dermatitis failed to produce 
INF-γ (63, 64). However, T cells from peripheral blood of nickel-allergic patients were found to 
secrete more IL-5 and IL-4 in response to nickel ions than T cells from non-allergic patients (63, 
64). The production of these cytokine is characteristic for Th2 cells, which are known to suppress 
Th1 responses. Hence, it has been proposed that these skin derived Th2 cells could regulate the 
magnitude and duration of the Th1-mediated ACD (65), whereas others suggested that the Th2 
cells may enhance the nickel-induced ACD (66).  
Furthermore, different research groups have found nickel-reactive T cells in the peripheral 
blood from both nickel-allergic and non-allergic individuals (61, 62). The specificity of the 
proliferation of these T cells from non-allergic individuals was demonstrated by showing that 
mitogen-driven T cell clones or mononuclear cells derived from cord blood could not be 
stimulated by nickel (61). This indicates the presence of nickel-specific T cells in peripheral 
blood of non-allergic individuals, although they require a higher concentration of nickel for their 
stimulation than the corresponding T cells in nickel-allergic individuals (61). Hence, non-allergic 
individuals can have a negative patch test possibly due to the fact that they are never sensitized to 
nickel, but it is more likely that their nickel-specific T cells have regulatory capacity which 
makes them tolerant towards nickel. Cavani et al. have demonstrated that non-allergic individuals 
have only nickel-specific CD4+ regulatory T cells, whereas allergic individuals possess both 
nickel-specific CD8+ effector T cells and CD4+ regulatory T cells (60, 67).  
  
Nickel-reactive T cells in vivo. 
The nickel-induced ACD reaction is characterized by the T cell-mediated damage of nickel-
loaded keratinocytes (68). Alongside the chemokines induced by the irritative properties of the 
hapten, the recruitment of these specific effector T cells is mediated by the type 1-associated 
chemokines receptors CXCR3, CCR4 and CCR5. CD8+ effector T cells have a higher expression 
of CXCR3 and are therefore more strongly attracted to its ligand CXCL10 than CD4+ effector T 
cells (69). Furthermore, the CXCL10 produced by keratinocytes, can be detected early on in the 
skin after re-exposure to nickel (69). CCR5, on the other hand has two ligands in ACD reactions: 
regulated on activation, normal T expressed and secreted (RANTES/CCL5) and macrophage 
inflammatory protein-1β (MIP-1β/CCL4). CCL5 is expressed early on in the skin after nickel 
challenge, whereas CCL4 shows a more delayed kinetic response (68, 69). In addition, nickel-
specific activated Th1 cells, and to a much less extent Tc1 cells, also express CCR4 (69). The 
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ligands of CCR4, thymus- and activation-regulated chemokine (TARC/CCL17) and macrophage 
derived chemokine (MDC/CCL22), have been demonstrated to augment the rolling of CCR4+ T 
cells on high endothelial cells in the lymphatic vessels, which mediates the transmigration of T 
cells (70, 71). However, the expression of CCR4 on type 1 T cells is activation dependent, so Th1 
cells mainly migrate during the later phase of the ACD reaction in the challenged skin (69). In 
contrast, nickel-specific Th2 cells constitutively express CCR4, and thus migrate early on in the 
skin immediately after re-exposure to nickel. It has been demonstrated that these Th2 cells 
increase the recruitment of CXCR3+ Tc1 and Th1 cells, since IL-4 enhances the INF-γ-mediated 
activation of keratinocytes, and in turn, the production of CXCL10, and the other CXCR3 
ligands, CXCL9 and CXCL11 (32). In addition, nickel-specific Th2 cells express CCR3 and this 
expression is reduced upon activation, suggesting a role of CCR3 and its ligand eotaxin (CCL11) 
in the migration of Th2 cells early on in the ACD reaction (69, 72).  
In conclusion, the ACD reaction has been shown to be mediated by the early recruitment of 
nickel-specific effector Tc1 cells, which induce perforin-mediated lysis of resting nickel-loaded 
keratinocytes (32). At later stage, the nickel-loaded INF-γ-stimulated keratinocytes become 
activated and thus express Fas, which also makes them susceptible to Fas-mediated cytotoxicity 
which is induced by specific FasL+ effector Tc1 and Th1 cells (32). Finally, although the Th2 
cells are not directly involved in the cytotoxic effector mechanism, they enhance the infiltration 
of CXCR3+ Tc1 and Th1 cells and, thus, keratinocyte damage. 
 
 
REGULATION OF NICKEL-INDUCED ACD  
Epidemiological studies revealed that sensitization to nickel, in general, is the result of a 
prolonged direct epidermal exposure. Although most individuals have prolonged nickel contact at 
least once during their lifetime, only 15% of the population develops hypersensitivity to nickel 
(46). Whether the immune system of the 85% of non-allergics is just indifferent to nickel or 
tolerant is not yet clear. There are several lines of evidence which favor the tolerance hypothesis. 
Although the regulation of existing ACD by oral administration of nickel is unfortunately only 
transient, it has been demonstrated that oral administration of nickel has a beneficial effect on the 
induction of nickel allergy (73). Van Hoogstraten et al. showed that oral contact with nickel-
releasing dental braces reduced the frequency of the induction of nickel allergy in humans, but 
only when the braces were fitted prior to nickel sensitizing events such as ear piercing (73). In an 
experimental mouse model, the same authors showed that oral administration of nickel to naive 
animals lead to the development of CD8+ Treg cells, which upon adoptive transfer into naive 
recipients prevented the development of nickel allergy in the latter (49).  
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More recently, Cavani et al. have developed a model to study human nickel responses and 
have shown that CD8+ T cells only act as effector T cells, while Ag-specific CD4+ T cells also 
can perform regulatory functions (60). They have also demonstrated that the magnitude and 
duration of nickel-induced ACD in humans is mediated by IL-10-producing CD4+ regulatory T 
(Treg) cells. These cells impair the ability of APCs to activate nickel-specific Tc1 and Th1 
effector lymphocytes (74). Although these Treg cells co-express functional Th1- and Th2-
associated chemokine receptors, the high expression of CCR8 on both resting and activated Treg 
cells may have a critical role in regulating the nickel-induced ACD reaction (72). This role is 
highlighted by the observation that CCL1 (I-309), the ligand of CCR8, is expressed early on in 
skin lesions of individuals with nickel-induced ACD but not in unaffected skin lesions. 
Furthermore, this ligand more potently attracts IL-10-producing Treg cells than type 1 effector T 
cells (72). However, Treg cells only regulate the existing ACD reaction but fail to prevent the 
induction of a nickel allergy. Only recently, Cavani et al. have suggested that CD4+CD25+ Treg 
cells from non-allergic individuals, but not from nickel-allergic individuals, not only suppress the 
activation of nickel-specific effector T cells but also prevent the generation of nickel-specific 
effector T cells (75). However, how these CD4+CD25+ Treg cells are generated in non-allergic 
individuals remains unclear.  
 
 
ORAL TOLERANCE 
Oral tolerance is the result of a complex immunoregulatory strategy used by the gut and its 
associated lymphoid tissues to render the peripheral immune system unresponsive to non-
pathogenic proteins, such as food or commensal bacteria (76). The gut-associated lymphoid 
tissue (GALT) is a well-developed immune network that has not only developed the inherent 
property of preventing the host from reacting to ingested proteins, but has also evolved to protect 
the host from ingested pathogens. GALT consist of vital immune components such as Peyer's 
patches (PP), mesenteric lymph nodes (MLN), the intraepithelial lymphocytes (IELs) and the 
lamina propria (LP). Current models of oral tolerance suggest that luminal antigen are absorbed 
by specialized epithelial cells called M cells, which have been shown to transport the antigen 
efficiently from the gut lumen to APCs in the underlying lymphoid tissues (34). To which APCs 
the antigens are passed however, depends on the dose of the antigen. Kunkel et al. have shown 
that at low peptide doses the peptide presentation was exclusively detected on DCs of the PP and 
MLN, whereas during high doses of oral peptides, the peptide is presented by all the major APC 
populations in all lymphoid organs (77). At these high oral doses of peptide, the DC population 
was found to be the most frequent peptide-loaded APC, however due to the higher absolute 
number, B cells are also an important element (77). 
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Tolerogenic DCs 
There is evidence to suggest that the regulatory capacity of Treg cells arising in the periphery 
is not an innate property of these cells, but is acquired through contact with tolerogenic DCs. 
Different subsets of DCs are suggested to be involved in the generation, selection, expansion, or 
enhancement of the suppressive capacity of Treg cells.  
Non-professional APCs, like intestinal epithelial cells, have the capacity to modulate local 
immune responses through the activation of CD8+ T cells. Although in some circumstances CD8+ 
T cells have been reported to mediate suppression after oral administration of antigens, many 
experiments have shown that CD8+ T cells are dispensable for oral tolerance. 
DCs modified by IL-10 or TGF-β have been shown to be immature and tolerogenic (78, 79), 
characterized by a reduced expression of CD40, and/or reduced secretion of IL-12. IL-10 can be 
produced by NKT cells and TGF-β is present in high levels in the gut. Both cytokines can also be 
produced by macrophages (80). The latter have been shown to secrete IL-10 and TGF-β after 
phagocytosis of apoptotic cells, whereas the uptake of necrotic cells results in a secretion of IL-
12 (80).  
More recent studies have shown that the CD8α+CD11c+ DCs may enhance Th1 
differentiation, whereas after the uptake of apoptotic cells they transmit a tolerogenic signal to T 
cells (81, 82). In fact, it is known that apoptotic cells are sampled by splenic CD8α+ DCs (83) 
and that such DCs can suppress an ongoing immune-response, induce specific CD4+ Treg cells, 
and cross-tolerize CD8+ T cells (81, 84-87). Interestingly, uptake of haptenated splenocytes by 
CD40-activated CD8α+CD11c+ DCs failed to induce Treg cells (81). Hence, the tolerogenic 
capacity of these DCs upon uptake of apoptotic vesicles may also be due to an impaired 
maturation (88). In conclusion, there are different pathways by which DCs prime Treg cells. In 
addition to the immature state and the secretion of immunosuppressive cytokines, the phenotype 
of the Ag-presenting DCs may also determine the differentiation of naive T cells towards Treg 
cells. 
 
 
OVERVIEW OF T CELL-MEDIATED TOLERANCE MECHANISMS 
The hypothesis that the regulatory capacity of T cells arise in the periphery through contact 
with tolerogenic APCs and the fact that it is the dose which determines which type of APC 
presents the antigen, indicates that the dose of antigen determines by which mechanism tolerance 
is induced. It has been hypothesised that low doses of antigen favour the induction of Treg cells, 
whereas high doses of antigen predominantly induce tolerance by either anergy and/or depletion. 
Different cell populations involved in different mechanisms of oral tolerance, including 
tolerogenic APCs are listed below. 
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Table 1: Overview of different cell populations involved in tolerance  
Cell population   Mechanism Ref 
Tolerogenic APCs Non-professional 
APCs or immature 
DCs 
 reduced costimulation (90, 
93) 
 CD8α+ DCs  tolerogenic phenotype 
upon uptake of apoptotic 
vesicles 
(81) 
Anergy CD4+ T cells  growth arrest (89) 
 CD8+ T cells  growth arrest (89) 
Regulatory T cells CD4+ T cells Th3/Tr1 cells TGF-β and/or IL-10 
production  
(94) 
  CD25+ T cells cell-contact dependent 
mechanism 
(95) 
  iNKT cells IL-4 and/or IL-10 
production 
(96) 
 CD8+ T cells CD28-CD101+CD103+ cell-contact dependent 
mechanism 
(97) 
 
 
T cell anergy 
Clonal anergy is a growth arrest state of T cells induced by an impaired triggering of the IL-2 
receptor pathway. Hence, T cells become anergic when they are weakly or incompletely 
activated, as induced by delivery of a strong TCR signal in the absence of costimulation or by 
stimulation with a low-affinity ligand in the presence of costimulation (89). Another way to 
induce anergic T cells is by T-T presentation of the tolerogen (90). When human and rat T cell 
clones are co-cultured with activated T cell clones with the same reactivity, they become anergic 
(91). The molecular mechanism responsible for anergy induction by T-T presentation is not yet 
clear, Lombardi et al. suggested that an altered TCR-CD3 signalling is involved here (92). Also 
the expression of MHC molecules and other costimulatory molecules such as CD80 and CD86 by 
activated human and rat T cells might play a role (98). Mouse T cells fail to express high levels 
of MHCII molecules, but they can take up MHC class II , CD80 and CD86 molecules from APCs 
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and thus can function as APCs (99). Clonal anergy is characterized by an unusual pattern of 
cytokine production in response to TCR stimulation. On restimulation of anergic T cells with 
antigen and APCs, IL-2 production is most profoundly affected, whereas IL-4 and INF-γ 
production are only slightly impaired (89). However, exogenous IL-2 can completely reverse the 
anergic state (89). Although in most studies clonal anergy is studied in CD4+ T cells, CD8+ T 
cells stimulated by APCs which provide insufficient costimulation also attain an anergic state 
characterized by inhibition of IL-2 production and proliferation (100). Similar to anergic CD4+ T 
cells, the anergic state of CD8+ T cell clones has little effect on their INF-γ production or 
cytotoxic activity, and can be reversed by IL-2, which is provided either exogenously or by CD4+ 
T cell help (89). Hence, anergy is not a passive state of unresponsiveness, but an active process in 
which CD4+ as well as CD8+ T cells fail to produce IL-2 and thus fail to expand in response to 
their antigen.  
 
Regulatory CD4+ T cells 
The term Treg cells refers to cells that actively regulate the function of other cells, generally in 
an inhibitory fashion. At least three major types of CD4+ Treg cells have been described: Th3 
cells, Tr1 cells, CD4+CD25+ Treg cells. Th3 cells are a unique CD4+ T-cell subset that is 
generated in a TGF-β rich environment, such as in the gut (101). Th3 cells exert their suppressive 
properties for both Th1 and Th2 responses by the release of the immunosuppressive cytokine 
TGF-β (101, 102). Tr1 cells are elicited by chronic activation of CD4+ T cells in the presence of 
IL-10, and they suppress the proliferation of CD4+ T cells in response to antigen by the 
production of IL-10 and varying amounts of TGF-β (103, 104). Hence, after the generation in an 
antigen-specific fashion, these Th3 and/or Tr1 cells regulate the immune response in an antigen-
non-specific, cell-cell contact- independent, and TGF-β- and/or IL-10-dependent manner when 
they re-encounter the fed antigen. 
Naturally occurring CD4+CD25+ Treg cells are essential for the maintenance of tolerance 
towards self-antigen (105). They prevent the induction of various autoimmune diseases by active 
suppression of peripheral effector T cells specific for self-antigens (106, 107). Increasing 
evidence suggests that CD4+CD25+ Treg cells are not only generated in the thymus, but may also 
arise in the periphery upon exposure to tolerogen (108). For instance, oral administration of 
antigen primed antigen-specific CD4+CD25+ Treg cells and resulted in their expansion and 
increase in suppressive capacity (109). Layland et al. showed that adoptive transfer of 
CD4+CD25+ Treg cells primed by oral administration of procainamide can prevent formation of 
procainamide-induced antinuclear autoantibodies and thus autoimmunity in the naive syngeneic 
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recipients (4). Similarly, Dubois et al. demonstrated that CD4+CD25+ Treg cells, which were 
induced by oral administration of DNFB, prevented the development of ACD by blocking the 
differentiation of DNFB-specific CD8+ effector T cells (110). Furthermore, it has been shown 
that CD4+CD25+ Treg cells primed with a contact allergen express CCR7, which enables them to 
migrate to the lymphoid organs were they can regulate the primary response. These cells also 
express CLA so they can suppress the secondary immune response in the skin after dermal 
application of this contact allergen (75). In contrast, CD4+CD25+ Treg cells induced by 
epicutaneous application of contact allergen to UV-exposed skin express the lymph node-homing 
receptor CD62L but not skin-homing receptors CD62E and CD62P (111). Hence, these Treg cells 
can only inhibit the generation of effector T cells, but can not suppress the elicitation of ACD.  
The mechanisms underlying the suppressive effects of CD4+CD25+ T cells are only 
incompletely understood. Treg cells are characterized by a high expression of the transcription 
factor forkhead box P3 (Foxp3), also known as Scurfin (112, 113). The absence of Foxp3 from 
CD4+CD25+ Treg cells leads to a generalized, lethal autoimmune disease (114), whereas 
expression of Foxp3 in CD4+CD25- T cells renders the latter CD25+ and endows them with the 
same characteristics as naturally occurring CD4+CD25+ Treg cells (115). Furthermore, 
costimulatory molecules which have been suggested to be involved in their regulatory capacity 
are cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152) (116), and glucocorticoid-
induced tumor necrosis factor receptor (GITR) (117). CTLA-4 is a negatively regulating 
molecule expressed by CD25+CD4+ T cells (116), whereas stimulation of CD25+CD4+ regulatory 
T cells through GITR reverses suppression (117, 118). Hence, one of the suppressive pathways 
used by these cells could be the down-regulation of costimulatory molecules on APCs in a cell-
cell contact-dependent fashion (119). Another remarkable pathway by which human CD4+CD25+ 
Treg cells can become regulatory is the infectious spread of the suppressive capacity to other T 
cells, and, at least in vitro, this can occur in the absence of professional APCs (120, 121). Thus, 
pre-activated CD4+CD25+ Treg cells can convey suppressor activity to CD4+CD25- T cells in a 
cytokine independent, cell-cell contact-dependent fashion. The CD4+CD25- T cells, which thus 
acquire suppressor activity, subsequently inhibit the activation of yet other T cells in a cytokine-
dependent, cell-cell contact-independent fashion. Whereas Jonuleit et al. showed that α4β1+ 
CD4+CD25+ Treg cells convey suppressor activity by inducing TGF-β-producing “Th3” cells, 
Dieckmann et al. demonstrated that α4β7+ CD4+CD25+ Treg cells induce IL-10-producing “Tr1” 
cells (120-122). Hence, CD4+CD25+ Treg cells, which can arise in the periphery upon oral 
administration of the tolerogen, regulate the immune response in a cell-cell contact-dependent 
manner. However, the exact mechanisms and molecules involved are still unclear. 
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Regulatory CD8+ T cells 
Many studies showed that CD8+ T cells can act as Treg cells upon priming by the respective 
(self- and foreign) tolerogen in the periphery (reviewed in (123)). Their antigen-specific 
immunosuppression can be mediated by direct killing of CD4+ Th cells (124) and APCs (125), or 
by non-cytolytic pathways, such as the induction of Treg cells (126-128).  
One of the mechanisms by which naive human CD8+ T cells can acquire regulatory capacity is 
through the interaction of both their CD8 and TCR molecules with a complex generated by the 
CD8 ligand gp180 associated with the non-classical class I molecule CD1d, the complex being 
located on the surface of intestinal epithelial cells, thereby functioning as APCs (129). The CD8+ 
Treg cells thus generated express the mucosal markers CD101 and CD103 and, notably, are 
CD28 negative (129). Interestingly, in man triggering of CD101 on T cells blocks their 
proliferation by inhibiting IL-2 transcription (130), whereas triggering of CD101 on DCs inhibits 
T cell activation via IL-10 (131). CD101 has not (yet) been defined in the mouse. CD103 on the 
other hand is a gut-homing receptor, which expression is regulated by TGF-β (132). Interestingly, 
CD103 is involved in the expansion and recruitment of CD8+ intraepithelial lymphocytes in both 
men and mice (129, 133).  
These CD8+CD28-CD101+CD103+ Treg cells were shown to exert suppression by rendering 
APCs tolerogenic in a MHC class I-restricted, cell-cell contact-dependent, but cytokine-
independent manner (127, 128). The tolerogenic APCs thus induced have a reduced ability to up-
regulate CD40-mediated costimulatory molecules, such as CD80 and CD86, and have an 
increased expression of the inhibitory receptors ILT3 and ILT4 (134, 135). The naive CD4+ Th 
cells activated by these tolerogenic APCs differentiate into anergic CD4+CD25+ Treg cells, 
which, in turn, continue the cascade of suppression by tolerizing other DCs (136, 137).  
 
Regulatory iNKT cells 
Another population of Treg cells, so called NKT cells, are either CD4+ or CD4-CD8- double-
negative, and depend on IL-15 for survival (138). NKT cells express a limited αβTCR repertoire 
which is dominated by the invariant Vα14-Jα18 TCR (formally Vα14-Jα281 TCR) in mice and 
the Vα24-Jα15 TCR in humans, so called invariant NKT (iNKT) cells (139). Through their TCR, 
NKT cells recognize glycolipid antigens presented by the non-polymorphic, MHC-class-I-like 
protein CD1d. There is suggestive evidence that not only foreign, but also self-glycolipids can be 
recognized by the NKT cells (140).When activated, NKT cells rapidly produce large quantities of 
IL-4 and IFNγ which allows them to exert strong regulatory activity (139). 
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INFECTIOUS SPREAD OF TOLERANCE  
The term infectious tolerance describes the amplification mechanism by which Treg cells can 
transmit their specific unresponsiveness and suppressive capacity to naive T cells (141). As 
mentioned before, Dieckmann et al. (120) and Jonuleit et al. (121) have observed this infectious 
spread of tolerance amongst human T cells in vitro, when activated CD4+CD25+ Treg cells were 
co-cultured with CD4+CD25- T cells in the presence of either APCs or anti-CD3 mAb. Hence, to 
convey the suppressive capacity of Treg cells to naive T cells, the T cells require cell-cell contact 
without the presence of APCs (120, 121). Whether MHC class II molecules expressed on these 
activated human T cells enabled them to function as APCs (cf. refs. (91, 99)) is not known, but it 
is interesting that human T cell clones that are cultured with antigen in the absence of “classical” 
APCs become suppressive (91).  
According to the current literature, there are two models that describe the direct conveyance of 
tolerance from Treg cells to naive T cells in vivo. Cobbold and Waldmann have shown an 
infectious spread of tolerance from donor T cells to host T cells in a transplantation model (142). 
Due to the presentation of allo-antigens by the donor APCs in the graft, the role of APCs in this 
model cannot be examined, but also not be excluded. In the other model, nasal OVA application 
generates CD4+ Treg cells, which can convey tolerance to a new cohort of naive CD4+ T cells 
(143, 144). Although the adoptive transfer of splenic CD11c+ DCs, isolated from donor mice 
tolerized by nasal administration of OVA, failed to inhibit the DTH response in the recipients, 
also in this model, the role of DCs as intermediate cell types in the spread of tolerance from 
donor to recipient T cells cannot be excluded (144).  
 
 
AIM OF THIS THESIS 
The aim of this thesis was to investigate the mechanisms of tolerance, induced after the oral 
administration of nickel, which has been shown to prevent the development of nickel-induced 
ACD in mice. As a model for the nickel-induced ACD we used the mouse model established by 
Artik et al. in which naive C57Bl/6 mice were sensitized by the dermal administration of NiCl2 
and H2O2. Following this introduction, chapter 2 describes the effects that different doses of oral 
nickel have on the induction of nickel-induced ACD. Also in that chapter, we studied the effects 
that occurred on the function of the T cells following a 4-week period in which 10 mM NiCl2 was 
given in the drinking water. The T cells from these tolerized mice were anergic and had 
regulatory capacities. Chapter 3 describes the effects of oral nickel application on APCs and 
demonstrated that APCs, after oral application of nickel, possess a tolerogenic phenotype 
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displayed by the reduced expression of CD40, have a reduced stimulatory capacity, and have the 
ability to transfer tolerance. Furthermore, we studied the infectious spread of tolerance from 
tolerogenic APCs to naive T cells and from Treg cells to APCs. In chapter 4, the mechanism of 
infectious tolerance is studied in more detail. Here, we demonstrate in two situations that CD1-
restricted, IL-4- and IL-10-producing CD4+ iNKT cells are needed to convey the tolerance. In the 
first, tolerance is exchanged from tolerogenic APCs to T cells during the oral application of 
tolerance and thus in the absence of costimulation. In the second situation they “aid” in the 
transfer of tolerance by tolerogenic APCs and thus in the presence of costimulation. Finally, 
chapter 5 reviews the oral tolerance model to nickel as it stands now, leading to the conclusions 
as described in Chapter 6.   
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ABSTRACT 
We adapted our mouse model of allergic contact hypersensitivity to nickel 
(Ni) for the study of tolerance. Sensitization in this model is achieved by the 
administration of Ni ions with H2O2; Ni ions alone are unable to prime naive T 
cells, but can restimulate primed ones. A 4-week course of oral or i.p. 
administration of 10 mM NiCl2 to naive mice induced tolerance, preventing the 
induction of hypersensitivity for at least 20 wks; long-term desensitization of 
Ni–sensitized mice, however, required continuous NiCl2 administration. When 
splenic T cells of orally tolerized donors, even after a treatment-free interval of 
20 wks, were transferred to naive recipients, as with lymph node cells (LNC), 
they specifically prevented sensitization of the recipients. The LNC of such 
donors were anergic, because upon in vivo sensitization with NiCl2 in H2O2 and 
in vitro restimulation with NiCl2, they failed to show the enhanced proliferation 
and IL-2 production as seen with LNC of mice not tolerized prior to 
sensitization. As few as 102 bulk T cells, consisting of both CD4+ and CD8+ 
cells, were able to specifically transfer tolerance to Ni. A hypothesis is provided 
to account for this extraordinarily high frequency of Ni-reactive, suppressive T 
cells; it takes into account that Ni ions fail to act as classical haptens, but form 
versatile, unstable metal-protein and metal-peptide complexes. Furthermore, a 
powerful amplification mechanism, such as infectious tolerance, must operate 
which allows but a few donor T cells to tolerize the recipient.  
 
 
INTRODUCTION 
Nickel (Ni) is one of the most common contact sensitizers (1). As a component of a variety of 
different alloys, including stainless steel, it is contained in a great variety of different items used 
in the work place and in every-day life (2, 3). By far the most common, since stable, ionic form 
of Ni is Ni2+; it is present, for instance, in NiCl2 and NiSO4, the Ni salts commonly used in 
allergology. Its ubiquitous occurrence notwithstanding, the majority of people do not suffer from 
allergy to Ni and fail to react to challenge with Ni ions in the patch test. Exogenous co-factors 
seem to influence the decision whether or not exposure to this ubiquitous agent will lead to de 
novo sensitization. Clinical experience indicates that allergic contact hypersensitivity to Ni 
preferentially develops in irritated compared to healthy skin. Consistent with this, ear-piercing for 
the purpose of wearing Ni-releasing costume jewelry results in a high rate of Ni allergy (4). Ni 
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ions are released from different alloys at varying rates, depending on the alloy, when they are 
exposed to body fluids, such as sweat. In Ni-sensitized individuals, this may be sufficient to elicit 
allergic contact hypersensitivity reactions (5). Interestingly, however, adolescents having worn 
Ni-releasing orthodontic braces prior to ear-piercing showed a lower incidence of Ni allergy 
when compared with those individuals wearing no braces at all or braces after ear-piercing (6, 7). 
These observations suggest that de novo sensitization to Ni was prevented due to prior induction 
of oral tolerance by Ni ions released from the braces.  
The situation in humans is comparable with that seen in mouse models. Whereas 
administration of Ni ions alone failed to sensitize naive mice, sensitization was achieved by the 
combined administration of NiSO4 and CFA (8), NiCl2 plus irritant, or NiCl2 and H2O2 (9); the 
latter is produced at high levels by inflammatory phagocytes and can act as an endogenous 
adjuvant (10). In mice already sensitized to Ni however, Ni ions alone sufficed to elicit 
hypersensitivity reactions (8, 9, 11). Likewise, when T cells from Ni-sensitized mice (9) or men 
(12 - 16) were exposed to Ni ions on APCs in vitro, this sufficed to restimulate them. The 
collective evidence prompted us to conclude (9) that the combined administration of Ni ions and 
H2O2 induces both signal 1 and signal 2 required for T cell priming and induction of Ni allergy, 
whereas Ni ions alone can generate the neoantigens recognized by Ni-specific T cells and thus 
provide signal 1, but are unable to induce the costimulation, or signal 2. 
Two groups of investigators have shown that tolerance to Ni can be induced in naive animals 
by several weeks of oral exposure to Ni ions, thus preventing subsequent sensitization of the 
animals (8, 11, 17). In orally tolerized guinea pigs, Ni tolerance lasted up to 24 months (17), in 
mice, the maximal duration of the tolerant state has not yet been determined. The mechanism 
underlying tolerance to Ni has not been elucidated. Based on findings obtained with Ni-specific 
human T cell clones, new concepts implicate IL-10, immature dendritic cells, and chemokines in 
Ni tolerance (15, 18, 19); however, it is unclear at present how far these findings may be 
generalized, since only a relatively small number of T cell clones was analyzed in detail and it is 
not known to what extent these clones were representative. Both Ni-allergic and non-allergic 
persons are known to harbor a variety of different subsets of Ni-reactive T cells that are partially 
identical in both groups (15, 16, 20).  
The aim of the present study was first to define the optimal conditions for tolerance induction 
to Ni in a mouse model (9). Applying these conditions, we determined the minimal number of T 
cells capable of adoptively transferring tolerance and studied their capacity to proliferate and 
produce IL-2 after in vivo sensitization with NiCl2 in H2O2 and in vitro restimulation with NiCl2. 
With respect to a possible therapeutic usage of orally applied Ni ions in man, we determined the 
duration of tolerance induced in naive mice and of desensitization of sensitized mice, 
respectively, and the concentration of Ni ions in different organs after administration of NiCl2. 
Oral tolerance to nickel 
49 
MATERIALS AND METHODS 
 
Reagents  
NiCl2·6 H2O (in the following denoted as NiCl2), and 2,4-dinitrofluorobenzene (DNFB) were 
purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany), 2,4-dinitrobenzene sulfonic acid 
(DNBS) was bought from ICN Biomedicals Inc. (Aurora, OH, USA), H2O2 was from E. Merck 
(Darmstadt, Germany). Recombinant mouse IL-2 and streptavidin-FITC were obtained from BD 
PharMingen (Heidelberg, Germany).  
 
Antibodies 
PE- or FITC-labeled anti-CD4 (clone RM4-5) and anti-CD8β.2 (clone 53-5.8) antibodies, biotin-
labeled anti-CD8β.2 (clone 53-5.8), APC-labeled anti-CD3ε (clone 145-2C11), FITC-labeled anti-CD19 
(clone 1D3), FITC-labeled anti-I-Ab (clone AF6-120.1), biotin-labeled anti-CD11b (clone M1/70), biotin-
labeled anti-CD11c (clone HL3), purified anti-mouse IL-2 (capture antibody: clone JES6-1A12) and 
biotin-labeled anti-mouse IL-2 (detecting antibody: JES6-5H4) were purchased from BD PharMingen 
(Heidelberg, Germany). CD4 Microbeads and Streptavidin Microbeads were from Miltenyi Biotec GmbH 
(Bergisch Gladbach, Germany). 
 
Mice  
Specific pathogen-free female C57Bl/6J (H-2b) mice obtained from Janvier (Le Genest St. Isle, France) 
were used throughout. Animals were 7 to 10 wks of age at the onset of experiments. They had free access 
to drinking water (tap water) and standard rodent lab chow (no. 1324, Altromin, Lage/Lippe, Germany). 
Other than in the study by van Hoogstraten et al. (8), no measures were taken to protect the animals from 
exposure to Ni: cages (made from plastic) were covered by stainless steel covers, and drinking water was 
provided in glass bottles covered with water outlets made from stainless steel. 
 
Sensitization of mice 
Mice were sensitized, as described previously (9). In the case of Ni, mice were injected intradermally 
into both flanks (50 µl each) with either 10 mM NiCl2 in sterile, pyrogen-free saline (negative control), or 
10 mM NiCl2 in saline containing 1% H2O2. In the case of DNFB, mice were primed by painting 0.5% 
(w/v) DNFB on the shaved flanks (25 µl each); DNFB was resolved in a 4:1 (v/v) mixture of acetone and 
olive oil.  
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Challenge for recall and ear-swelling test  
Ten days after priming, mice were challenged for recall by injecting 50 µl of 10 mM NiCl2 in sterile, 
pyrogen-free saline into the pinna of each ear, or by applying 50 µl of 0.2% DNFB onto each ear. Forty-
eight hours after challenge with NiCl2 and 24 hrs after challenge with DNFB, respectively, delayed-type 
hypersensitivity reactions were determined by measuring the increment in ear thickness compared to pre-
challenge value. For determination of pre-challenge values, mice were anaesthesized with ether, for 
measurement after challenge, the mice were killed by asphyxiation with CO2. Measurements were 
performed using a micrometer (Oditest D 1000 gauge, The Dyer Co., Lancaster, PA, USA) and in a 
blinded fashion. Data shown represents the mean ear-swelling response of groups comprising 5 to 6 mice, 
expressed in units of mm x 10-2 + SEM.  
 
Tolerance induction 
For oral tolerization, mice were treated with NiCl2 in the drinking water at the concentrations and for 
the periods of time specified in Table Ι. Control mice received tap water not enriched with Ni ions. For i.p. 
tolerization, mice received three weekly i.p. injections (50 µl each) of sterile, pyrogen-free saline 
containing NiCl2 at the concentrations and for the periods of time specified in Table Ι. Control mice 
received saline only. Based on the data shown in Table I, standard treatment protocols for oral and i.p. 
tolerization were selected, as described under Results. 
 
Desensitization  
Different NiCl2 concentrations, duration of treatment, and routes of administration effective in 
desensitizing sensitized mice were investigated, as specified in Table ΙΙ. Mice were first sensitized with 
NiCl2 in H2O2 and, starting 5 wks later, subjected to the desensitization treatment with oral or i.p. 
administration of NiCl2 indicated. After a treatment-free interval of 1 wk, the mice were challenged for 
recall with NiCl2. Two days later, the increase in ear thickness was determined. In one experiment, mice 
were first sensitized with 10 mM NiCl2 in saline containing 1% H2O2, left untreated for 5 wks, then treated 
with 10 mM NiCl2 in the drinking water for 4 wks, followed by a 20-wks oral maintenance treatment with 
0.1 and 1 mM NiCl2, respectively. After a treatment–free interval of 1 wk, mice were challenged and their 
ear-swelling responses measured.  
 
T cell enrichment and sorting for adoptive transfer studies 
Single-cell suspensions of erythrocyte-free spleen cells were prepared  in RPMI 1640 medium 
containing 10% FCS and passed through nylon wool columns once or twice, until the T cell fraction 
contained 80-85% of T cells. In one experiment, T cells enriched by nylon wool were divided into CD4+ 
and CD8+ cells, respectively, by depleting the opposite subset using magnetic cell sorting (MACS, 
Miltenyi Biotec, Bergisch Gladbach, Germany), as described (21). The enriched CD4+ and CD8+ T cell 
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fractions were contaminated with less than 3 % CD8+ and less than 2 % CD4+ T cells, respectively. In two 
other experiments, T cells were further purified by depletion of CD11b+, CD11c+, CD19+, and MHCII+ 
cells using the sorting unit of the FACSCalibur (Beckton Dickinson, San José, CA, USA). The sorted T 
cell fractions were contaminated with less than 0.5 % of CD11b+, CD11c+, CD19+, and MHCII+ cells, 
respectively. Furthermore, in one experiment enriched splenic T cells (104/ml) from naive donors were 
incubated in vitro with 100 µM NiCl2 for 30 min at 37°C, washed with sterile, pyrogen-free PBS, and then 
used for adoptive transfer. In yet another experiment, enriched splenic T cells (102/150µl) from orally 
tolerized donors were killed before transfer by three cycles of freezing (-196° C) and thawing (37° C). 
Finally, in one experiment pooled popliteal, inguinal, and auricular lymph node cells (LNC), instead of 
enriched or purified T cells, were transferred.  
 
Adoptive transfer  
After nylon wool enrichment or MACS sorting, cell suspensions were diluted 1:10 with trypan blue, 
whereas with FACS sorting only 1:2. Then either 0.4 or 0.8 µl of cell suspensions were counted in a 
Neubauer counting chamber. T cell fractions to be transferred were serially diluted to the desired 
concentration in sterile, pyrogen-free PBS with a maximal dilution factor of 10. Cell suspensions (150 µl), 
containing the type and the number of cells indicated, were injected i.v. into the tail vein of recipient mice. 
One day later, mice were sensitized intradermally, as described above. Ten days thereafter, they were 
challenged for recall at the ears, and 48 hrs later (24 hrs in the case of DNFB), their ear-swelling response 
was measured.  
 
In vitro restimulation of LNC 
Groups of tolerant and naive mice were injected s.c. into both hindfoot pads (50 µl each) with either 
saline containing 100 µM NiCl2, saline containing 100 µM NiCl2 plus 1% H2O2, or saline alone. For 
priming to DNFB, mice were painted at both hindfoot pads with 25 µl 0.5% DNFB. Ten days later, mice 
were sacrificed, draining popliteal and inguinal lymph nodes from each group (2 mice/group) were 
isolated and pooled, and single-cell suspensions prepared. The cells were pipetted into 96-well round-
bottom plates (105 cells/well) in triplicates or quadruplicates, cultured (37o C, 6.5% CO2) either in 
complete medium alone (200 µl/well) or in complete medium containing 75 µM NiCl2 or 100 µM DNBS. 
Complete medium contained RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 1 mM 
sodium pyruvate, essential and non essential amino acids, 10 U/ml penicillin/streptomycin, and 5 nl/ml β-
mercapto-ethanol. After 3 days, cultures were pulsed with 0.5 µCi/well [3H] thymidine  for 16 hours. Cells 
were then harvested onto Ready Filters with Xtalscint (Beckman Instruments, Fullerton, CA, USA) using 
a PHD Cell Harvester (Cambridge Technology, Cambridge, MA, USA), filters were dried, and [3H] 
thymidine incorporation was measured with a LS 6000 IC series Liquid Scintillation System (Beckman 
Instruments, Fullerton, CA, USA). The  results are expressed as stimulation index (SI) + SD (SI = mean 
cpm of restimulated cells/ mean cpm of cells cultured in medium only). 
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Sandwich ELISA for IL-2  
IL-2 in the supernatants of cultured LNC (5 x 105/well) was measured using an ELISA with a detection 
limit of 3-5 pg/ml.  
 
Immune flow cytometry 
As control for the separation procedure, enriched T cells and their subsets, respectively, were stained 
with anti-CD3ε, anti-CD4, anti-CD8β.2, anti-CD11b, anti-CD11c, anti-CD19 and anti-I-Ab mAbs. Flow 
cytometry analysis were performed on FACSCalibur (Becton Dickinson) and analyzed with CellQuest 
software. 
 
Experimental design of experiments  
This is depicted in Fig. 1. 
FIGURE 1.   Schematic design 
of experiments. (A) Naive mice 
were tolerized by oral or i.p. 
administration of 10 mM NiCl2 
for 4 wks, unless indicated 
otherwise (Table Ι). After a 
treatment-free interval of 1 wk 
or 20 wks, they were sensitized 
at both flanks. Ten days later, 
they were challenged for recall 
at the ears, and the ear-swelling 
response as an indicator of Ni-
allergic reaction was 
determined. (B) Naïve     mice      
were sensitized at both flanks 
by injection of NiCl2 with 
H2O2. After a treatment-free 
interval   of  5  wks,  they  were 
 subjected to desensitization treatment by oral or i.p. administration of 10 mM NiCl2 for 4 wks, unless indicated 
otherwise (Table ΙΙ). After a treatment-free interval of 1 or 20 wks, or a 20-wks period of oral maintenance treatment 
with 1 mM or 0.1 mM NiCl2, the mice were challenged for recall at the ears, and the ear-swelling was determined. 
(C) Prospective donor mice were tolerized by oral or i.p. administration of 10 mM NiCl2 for 4 wks. After a 
treatment-free interval of 1 to 5 wks, or 20 wks, splenic T cells, or LNC, were adoptively transferred to naive 
syngeneic recipients. One day later, the mice were sensitized at both flanks, as indicated. Ten days later, they were 
challenged for recall at the ears, and the ear-swelling was determined. Alternatively (not shown), in one experiment 
Ni-tolerant mice and control mice, respectively, were sensitized at their hindfeet, as indicated, and their LNC 
restimulated in vitro for determination of proliferative response and IL-2 production 
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Determination of Ni ion concentration  
After the indicated treatment, the mice were bled by heart puncture, and the indicated organs (Table 
III) were isolated with teflon-coated instruments to avoid Ni ion contamination. Ni analysis was 
performed by sector-field inductively coupled plasma mass spectrometry (SF-ICP-MS) in the medium 
resolution mode (22). Sample preparation was done by high pressure ashing in the case of tissue samples 
and by UV photolysis for blood.  
 
Statistical analysis  
Statistical significance of results was determined by analysis of variance (ANOVA) followed by 
Newman-Keuls test.  
 
 
RESULTS 
 
Optimal conditions and cumulative dose of NiCl2 needed for oral or i.p. induction of tolerance in 
naive mice 
In order to determine optimal experimental conditions for induction of tolerance to Ni, we 
compared a number of different oral and i.p. treatment regimens. The general experimental 
design is shown in Fig. 1A. As can be seen in Table Ι, both oral and i.p. administration of NiCl2 
to naive mice decreased the ear-swelling response to NiCl2 in a dose-dependent manner. If the 
mice were treated with 10 mM NiCl2 in the drinking water for periods of 10, 5, and 4 wks, 
respectively, complete tolerance was induced. If the animals received 2 mM NiCl2 in the drinking 
water for 5 wks, partial tolerance was induced. Administration of 10 mM NiCl2 for 4 wks was, 
therefore, selected as the standard treatment for oral induction of tolerance. Similarly, three 
weekly i.p. injections of 10 mM NiCl2 for a period of 4 wks resulted in complete tolerance, 
whereas i.p. injections of 1 or 0.3 mM NiCl2 for 4 wks only induced partial tolerance. The former 
treatment protocol was selected as the standard treatment for i.p. induction of tolerance. All other 
i.p. administration protocols studied failed to cause a statistically significant decrease in ear-
swelling response.  
The background concentration of Ni ions which mice received via their drinking water was 
negligible: whereas the concentration of Ni ions in tap water was below the detection limit of 1 
nM, it was 8.5 nM after release from the drinking bottles covered with stainless steel outlets. In 
the case of oral administration of 10 mM Ni ions (MW 58.7) for 4 wks, a total dose of 3.3 mg 
Ni/g body weight (bw) was taken up via the drinking water, assuming a daily intake of 4 ml 
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drinking water and a bw of 20 g per mouse. Since about 27 ± 17 % of Ni ions are absorbed from 
the human intestine (23), the estimated cumulative dose for oral induction of complete tolerance 
in mice was about 900 µg/g bw. In the case of repeated i.p. injections a cumulative dose of 17.6 
µg Ni/g bw was needed to induce complete tolerance.  
 
Table Ι. Tolerization of non-sensitized mice: effects of different concentrations of NiCl2, durations of 
treatment, and routes of administration  
NiCl2 treatment for tolerization  Ear-swelling response (mm x 10-2 ± SEM) 
Time  (wks) Concentration (mM) negative controla positive controlb  mice to be tolerizedc 
Oral (in drinking water) administration 
10 10 11.0 ± 0.1 19.0 ± 1.1 11.5 ± 0.9 ***  d 
5 10 11.9 ± 0.4 18.8 ± 0.7 
  9.8 ± 0.6 ***  d 
5 2 
  8.6 ± 0.4 17.3 ± 0.9 15.0 ± 0.3 e 
4 10 11.6 ± 0.8 17.1 ± 0.7 12.0 ± 0.63 ***  d 
2 2 10.8 ± 0.9 16.3 ± 1.5 13.7 ± 1.0  
1 10 10.8 ± 0.9 16.3 ± 1.5 12.4 ± 1.0  
1 2 10.8 ± 0.9 16.3 ± 1.5 13.7 ± 0.9  
i. p. (3 injections/wk) administration 
4 10 11.7 ± 0.8 19.0 ± 1.3 
  9.7 ± 0.6 ***  d 
4 1 
  9.3 ± 0.9 17.9 ± 0.5 13.0 ± 0.4 e 
4 0.3 11.5 ± 0.8 19.7 ± 0.9 17.4 ± 0.7 
4 0.1 10.7 ± 1.1 17.7 ± 1.4 14.5 ± 1.6  
2 1 10.8 ± 0.9 16.3 ± 1.5 13.1 ± 1.1 
1 10 10.8 ± 0.9 16.3 ± 1.5 14.5 ± 1.2  
1 1 10.8 ± 0.9 16.3 ± 1.5 13.4 ± 0.9 
a
 Mice in the negative control groups were s.c. injected with NiCl2 on day 0 and challenged with NiCl2 on day 10. 
Two days later, the increase in ear thickness was determined. 
b
 Mice in the positive control groups were sensitized with NiCl2 in H2O2 on day 0 and challenged with NiCl2 on day 
10. Two days later, the increase in ear thickness was determined. 
c
 Mice in these groups were subjected to the tolerization treatment with oral or i.p. administration of NiCl2 indicated. 
Then, after a treatment-free interval of 1 wk, the mice were sensitized with NiCl2 in H2O2, followed 10 days later 
by challenge for recall with NiCl2. Two days later, the increase in ear thickness was determined.  
d
 Complete tolerance: the ear-swelling response was significantly lower (***, p ≤ 0.001) than that of the 
corresponding positive control group, but not significantly different from the negative control group. 
e
 Partial tolerance: the ear-swellling response was significantly lower than that of the corresponding positive control 
group, but still significantly higher than that of the negative control group. 
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Specificity and duration of orally induced tolerance to Ni 
Based on the results shown in Table Ι, a 4-week course of 10 mM NiCl2 in the drinking water 
was chosen as the standard treatment regimen for induction of oral tolerance. When mice thus 
treated were sensitized 1 wk after the termination of oral treatment and challenged 10 days later, 
they only showed a background ear-swelling response to Ni, but a completely normal response to 
DNFB (Fig. 2A, groups 3 and 6). Virtually identical results were obtained when the mice were 
sensitized and challenged after a treatment-free interval of 20 wks (Fig. 2B), indicating that long-
term tolerance had been induced. 
 
 
Desensitization of sensitized mice  
The results of experiments aiming at desensitization of mice already sensitized to Ni are 
shown in Table ΙΙ. As schematically depicted in Fig. 1B, mice were first sensitized and left 
untreated for 5 wks before the different oral and i.p. treatment regimens were started. One wk 
after termination of the desensitization treatment, the mice were challenged at the ears. At that
FIGURE 2.   Oral tolerance to Ni induced in 
naive mice is specific and lasts for at least 20 
wks. Non-sensitized mice were treated with 10 
mM NiCl2 in the drinking water for a period of 4 
wks or were left untreated, as indicated. After a 
treatment-free interval of 1 wk (A) or 20 wks (B), 
mice were injected with either NiCl2 alone 
(negative control), NiCl2 in H2O2, or DNFB and 
challenged for recall as indicated, and their ear-
swelling response was determined. In this and 
the subsequent Figs., the symbol Ni denotes 
NiCl2. Asterisks indicate a significant difference 
(**, p ≤ 0.01, and ***, p ≤ 0.001) between the 
groups compared by brackets. Experiment (A) 
was performed five times and experiment (B) 
two times, and each time comparable results 
were obtained.  
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Table ΙI.  Desensitization of sensitized mice: effects of different concentrations of NiCl2, durations of     
treatment, and routes of administration   
NiCl2 treatment for tolerization  Ear-swelling response (mm x 10-2 ± SEM) 
Time Concentration (mM) negative controla positive controlb mice to be tolerizedc 
c
oral (in drinking water) administration 
5 10 11.5 ± 0.7 18.0 ± 0.9 11.8 ± 1.4 **  d 
5 2 10.3 ± 0.5 18.3 ± 0.8 14.0 ± 0.7 e 
2 10 10.8 ± 0.5 22.5 ± 0.9 15.0 ± 0.6 e 
2 2 10.8 ± 0.5 22.5 ± 0.9 15.2 ± 1.1 e 
i. p. (3 injections/week) administration 
4 10 10.5 ± 0.5 17.9 ± 0.6 13.6 ± 0.7 e 
4 1 10.5 ± 0.5 17.9 ± 0.6 15.7 ± 1.4 e 
2 10 10.8 ± 0.5 22.5 ± 0.9 15.8 ± 0.7 e 
a
  Mice in the negative control groups were s.c. injected with NiCl2 on day 0 and challenged with NiCl2 on day 10. 
Two days later, the increase in ear thickness was determined. 
b
  Mice in the positive control groups were sensitized with NiCl2 in H2O2 on day 0 and challenged with NiCl2 on day 
10. Two days later, the increase in ear thickness was determined. 
c
  Mice in these groups were sensitized with NiCl2 in H2O2 and, starting 5 wks later, subjected to the desensitization 
treatment with oral or i.p. administration of NiCl2 indicated. After a treatment-free interval of 1 wk, the mice were 
challenged for recall with NiCl2. Two days later, the increase in ear thickness was determined.  
d
  Complete desensitization: the ear-swelling response was significantly lower (***, p ≤ 0.001) than that of the 
corresponding positive control group, but not significantly different from the negative control group. 
e
  Partial desensitization: the ear-swellling response was significantly lower than that of the corresponding positive 
control group, but still significantly higher than that of the negative control group.  
 
time, treatment with 10 mM NiCl2 in the drinking water for a period of 5 wks had led to complete 
desensitization (Table ΙΙ). However, when mice thus treated were not challenged 1 wk after oral 
desensitization, but rested for 20 wks and then challenged with NiCl2 at the ears, they proved to 
be no longer desensitized (Fig. 3, group 3). Only if mice received an additional, continuous 
treatment with 1 mM NiCl2 in the drinking water after the 4-wks oral treatment with 10 mM 
NiCl2, their desensitization was maintained for 20 wks (Fig. 3, group 5). Partial desensitization 
was achieved if mice were orally treated with 2 mM NiCl2 for 5 wks, or 10 mM and 2 mM, 
respectively, for 2 wks (Table ΙΙ). All of the i.p. treatments studied induced only partial 
desensitization (Table ΙΙ). 
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Minimal cell number of splenic T cells required for adoptive transfer of orally induced tolerance, 
capacity of LNC for transfer of tolerance  
Adoptive transfers of enriched splenic T cells, or LNC, to naive syngeneic recipients were 
performed according to the general experimental design shown in Fig. 1C. We found that 107, 105 
(data not shown), 104, 103, and even as few as 102 bulk T cells from Ni-tolerant donors were able 
to transfer tolerance (Fig. 4A, groups 4 to 6). In contrast, when naive mice were used as donors, 
transfer of 107 (data not shown), or 104 enriched T cells failed to render the recipients resistant to 
subsequent sensitization with NiCl2 in H2O2 (Fig. 4A, group 7). Tolerance could also be 
transferred by 102 FACS-sorted (instead of nylon wool-enriched) tolerant T cells (Fig. 4B), by 
104 peripheral LNC of tolerant mice (Fig. 4C, group 6), and by 104 sorted T cells of tolerized 
mice left untreated for 20 wks before transfer (Fig. 5). In contrast, 101 tolerant T cells (Fig. 4A, 
group 3), 102 naive T cells that had been loaded with Ni ions in vitro (Fig. 4C, group 3), or 102 
killed tolerant T cells (Fig. 4C, group 4) failed to transfer tolerance to the recipients. The results 
obtained with the last two groups show that tolerance to Ni could only be transferred by living 
cells, and they exclude the possibility that the observed transfer of tolerance was merely due to 
inadvertently transferred tolerogen rather than specific T cell activity. The tolerance induced by 
transfer of Ni-tolerant T cells was specific for Ni ions, because recipients of such T cells showed 
a normal immune response to DNFB (Fig. 4C, group 7).  
 
FIGURE 3.   For desensitization to last continuous 
administration of an oral maintenance dose of 1 mM 
NiCl2 is required. Mice were first injected with 
either NiCl2 alone or NiCl2 in H2O2, as indicated. 
Starting 5 wks later, groups 3 to 5 were treated  with 
10  mM  NiCl2  in the  drinking water for a period of 
4 wks,  followed  by  a  20-wks period of administra- 
ting either drinking water without additional NiCl2 (group 3) or water containing a maintenance dose of NiCl2 at 
the concentration indicated (groups 4 and 5). Thereafter, mice were challenged with NiCl2, and the ear-swelling 
response was determined. Asterisks indicate a significant difference (*, p ≤ 0.05 and ***, p ≤ 0.001) between the 
groups compared by brackets. The experiment was performed twice yielding comparable results. 
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FIGURE 4.   As few as 102 live T cells from orally 
tolerized donors are sufficient for adoptive transfer of 
tolerance. Prospective donor mice were treated with 10 
mM NiCl2 in the drinking water for a period of 4 wks or 
left untreated, as indicated. (A) Four wks after 
termination of tolerance treatment, the indicated 
numbers of enriched splenic T cells were transferred to 
syngeneic recipients. (B) Two wks after termination of 
tolerance treatment, the enriched splenic T cells of 
tolerant and naive donors were further purified by 
depletion of CD11b+, CD11c+, CD19+, and MHCII+ 
cells using the FACScalibur, and the indicated numbers 
of T cells were transferred to syngeneic recipients. (C) 
Four wks after termination of tolerance treatment, 
indicated numbers of enriched splenic T cells or LNC 
were transferred to syngeneic recipients. The cells were 
obtained from donors that had or had not been orally 
treated with 10 mM NiCl2 for 4 wks, as indicated. The 
donor cells in group 3 were pulsed with 10 mM NiCl2 in 
vitro, and those in group 4 were killed by repeated 
freezing and thawing prior to transfer. One day after 
transfer, the recipients were sensitized and challenged 
for recall,   as  indicated.  After   challenge  their   ear-
swelling response was determined. Asterisks indicate  a  
significant difference (**, p ≤ 0.01 and ***, p ≤ 0.001) 
between the groups compared by brackets. The transfer 
of 102 enriched splenic T cells from tolerized donors 
and non-tolerized donors, respectively, was performed 
five times and the experiments shown in the other 
groups were performed at least twice, yielding 
comparable results each time. 
 
FIGURE 5. Persistence of the suppressive capacity 
of T cells obtained from orally tolerized donors. 
Prospective donor mice were treated with 10 mM 
NiCl2 in the drinking water for  a  period of 4 wks or   
were   left   untreated,  as   indicated.   After   a 
treatment-free  interval  of  20 wks (group 1) or 1 wk  
(group 2), 104 sorted splenic T cells of tolerized and naive donors, respectively, were transferred to syngeneic 
recipients. One day after transfer, the recipients were sensitized with NiCl2 in H2O2, 10 days later they were 
challenged for recall with NiCl2, and after 2 days the ear-swelling response was determined. Asterisks indicate a 
significant difference (***, p ≤ 0.001) between the groups compared by brackets. The figure is a representative of 
two independent experiments.  
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Both CD4+ and CD8+ T cells are needed to transfer orally induced tolerance to Ni 
Next, we asked which T cell subset was able to adoptively transfer tolerance to Ni. Whereas 
102 enriched splenic T cells from non-tolerized donors failed to induce tolerance in the recipient, 
as expected, 102 cells from orally tolerized donors, again, proved able to do so (Fig. 6, groups 1 
and 2). In contrast, neither 102 CD4+ nor 102 CD8+ sorted T cells of tolerized donors were 
sufficient to transfer the tolerance (Fig. 6, groups 4 and 6). However, when 50 CD4+ and 50 
CD8+ T cells were recombined after sorting, the mixed cells were able to transfer tolerance, just 
like 102 unseparated T cells (Fig. 6, group 8). 
 
 
 
 
 
 
Induction and transfer of i.p. tolerance  
Tolerance to Ni could also be induced by three weekly i.p. injections of 10 mM NiCl2 (Table 
Ι). The tolerance thus induced was specific for Ni ions (Fig. 7A, cf. groups 4 and 7), comparable 
to orally induced tolerance (Fig. 2A and B). A difference between the oral and i.p. tolerance is 
that 20 wks after termination of the tolerization treatment orally induced tolerance was still  
complete (Fig. 2B), whereas i.p. induced tolerance was only partial (Fig. 7, group 6). As with oral 
tolerance, the i.p. induced tolerance could specifically be transferred by enriched splenic T cells 
(Fig. 7B). This result was again comparable with orally induced tolerance to Ni except that 104 
enriched T cells from i.p. tolerized donors were needed for the transfer of tolerance (Fig. 7B, 
group 3), whereas only 102 cells were needed in the case of orally induced tolerance. 
 
FIGURE 6.   Both CD4+ and CD8+ cells are required 
for adoptive transfer of oral tolerance. Prospective 
donor mice were treated with 10 mM NiCl2 in the 
drinking water for a period of 4 wks or left untreated, 
as indicated. Five wks after termination of the 
tolerance treatment 102 enriched splenic T cells from 
these donors were transferred to syngeneic recipients. 
The enriched T cells were sorted for either CD8+ 
cells (groups 3 and 4) or CD4+ cells (groups 5 and 6). 
 In groups 7 and 8, 50 sorted CD8+ and 50 sorted CD4+ T cells of naive and tolerant donors, respectively, were 
recombined and 102 cells of this pool were transferred, as described above. One day after transfer, the recipients were 
sensitized with NiCl2 in H2O2 and after challenge with NiCl2 their ear-swelling response was determined. Asterisks 
indicate a significant difference (***, p ≤ 0.001) between the groups compared by brackets. Similar results were 
obtained in two independent experiments.  
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LNC of orally tolerized mice, which were subjected to Ni sensitization in vivo and restimulation 
in vitro, failed to proliferate and produce IL-2 in response to NiCl2 
The capacity of T cells from orally tolerized donors to actively transfer specific tolerance 
(Figs. 4 to 7) indicated that the tolerized cells, at least some of them, had not been deleted, but 
were able to exert specific suppressor function. We then asked whether the T cells of tolerized 
mice were anergic in the presence of NiCl2. To this end, we tested their capacity for proliferation 
and IL-2 production following in vivo sensitization with NiCl2 plus H2O2 and restimulation with 
Ni ions in vitro (Fig. 8). Tolerized and non-tolerized groups of mice were sensitized with either 
saline, NiCl2 alone, NiCl2 in H2O2, or DNFB. Ten days later, LNC were restimulated in vitro with 
NiCl2 and DNBS, respectively. As expected, LNC of non-tolerized mice sensitized with NiCl2 in 
H2O2 showed an enhanced cell proliferation and IL-2 production (group 4 in both Fig. 8A and B). 
In contrast, LNC of tolerized animals completely failed to do so (group 5 in both Fig. 8A and B). 
FIGURE 7. Features of the tolerance induced by 
repeated i.p. injections of NiCl2. (A) Mice received 
three weekly i.p. injections of either saline containing 
10 mM NiCl2 or saline alone for a period of 4 wks. 
After a treatment-free interval of 1 wk or 20 wks the 
mice were sensitized and challenged for recall, as 
indicated, and the ear-swelling response was 
determined. (B) Prospective donor mice received three 
weekly i.p. injections of either saline containing 10 
mM NiCl2 or saline alone for a period of 4 wks. Three 
wks after termination of i.p. tolerization of donor 
mice, the number of enriched splenic T cells indicated 
was transferred to syngeneic recipients. For control, 
donor mice in group 4 received 10 mM NiCl2 in the 
drinking water for 4 wks. One day later, the recipients 
were sensitized with NiCl2 in H2O2 or with DNFB, as 
indicated, and after challenge for recall their ear-
swelling response was determined. Asterisks indicate a 
significant difference (**, p ≤ 0.01, and ***, p ≤ 
0.001) between the groups compared by brackets. The 
experiment was performed twice yielding comparable 
results. 
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Their anergic state was specific for NiCl2, because they did respond to DNFB sensitization and 
restimulation with DNBS (group 10 in both Fig. 8A and B). These results obtained in vitro 
parallel those obtained in vivo, demonstrating Ni-specific unresponsiveness (cf. groups 3 and 6 in 
both Fig. 2A and B, and groups 2 and 7 in Fig. 4C). When the LNC of Ni-tolerant mice were 
tested by adoptive transfer, they prevented sensitization to Ni (Fig. 3C, group 6). Taken together, 
these data indicate that the LNC from tolerant donors were both anergic and suppressive. 
 
 
 
Ni ion concentrations in different tissues after four wks of oral NiCl2 treatment  
For toxicological assessment of treatment risk, Ni ion concentrations in six different organs 
and blood were determined after 4 wks of oral treatment with 10 mM NiCl2. Except for liver, in 
the other organs and in blood the Ni ion content of treated mice was increased by a factor of 2 to 
223 when compared with that of untreated mice (Table ΙΙΙ). The highest increase in Ni ion 
content was found in the small intestine and blood (factor 124 to 223). 
FIGURE 8.   LNC of Ni-tolerized mice fail to 
proliferate and produce IL-2 in response to Ni ions, 
but respond normally to DNFB. Non-sensitized mice 
were treated with 10 mM NiCl2 in the drinking water 
for a period of 4 wks or left untreated, as indicated. 
Six wks after the termination of tolerance treatment, 
they were injected with either saline, NiCl2 alone, 
NiCl2 in H2O2,  or DNFB. Ten days later, pooled cells 
from the draining lymph nodes of these mice were 
restimulated in vitro with Ni ions or DNBS, and cell 
proliferation and IL-2 secretion, respectively, were 
determined. In the proliferation assay (A), cultures 
were pulsed with [3H] thymidine three days after 
restimulation and the isotope incorporation was 
determined. Background values obtained from cells 
cultured in medium only varied between 310 ± 16.3 
and 825 ± 106 cpm. In the IL-2 secretion experiments 
(B), after 24 hours of culture, the supernatants were 
transferred to ELISA plates to measure   their  IL-2  
levels. Asterisks  indicate a significant difference (*, 
p ≤ 0.05, **, p ≤ 0.01, and *** p ≤ 0.001) between 
the groups compared by brackets. A representative 
result of four independent experiments is shown. 
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Table ΙΙΙ.  Tissue concentrations of Ni after treatment for tolerance induction 
Ni concentration measured after 
no treatment a oral treatment b 
 
(µg Ni/g) (µg Ni/l) (µg Ni/g) (µg Ni/l) 
Factor of 
increase c 
Thymus 0.37 
 
1.50 
 
4.1 
Lung 0.09 
 
0.26 
 
2.9 
Liver 0.04 
 
0.02 
 
0.5 
Spleen 0.07 
 
0.33 
 
4.7 
Small intestine 0.07 
 
8.67 
 
124 
Kidney 0.15 
 
0.35 
 
2.3 
Blood 
 
0.5 
 
111.4 223 
a
  Ni concentrations in different organs (µg Ni/g wet weight) and blood (µg/l blood) of age-matched, untreated mice 
were determined. 
b
  Mice were treated for 4 wks with 10 mM NiCl2 added to drinking water, resulting in a cumulative dose of 
approximately 3.3 mg Ni/g bw. One day after termination of NiCl2 treatment, Ni concentrations in the organs 
indicated (µg Ni/g wet weight) and blood (µg/l blood) were measured. 
c
  The increase in Ni concentration in the different tissues was calculated by dividing the mean Ni concentration in 
the tissues of treated mice (n = 2) through that of untreated mice (n = 2).  
 
 
Discussion 
We showed that oral administration of NiCl2 to naive mice prevented subsequent sensitization 
to this common contact allergen, but not to the control Ag used, confirming previous 
investigations (8, 11). We selected a 4-week treatment regimen with 10 mM NiCl2 in the drinking 
water as the standard treatment because it was found to induce complete tolerance. These 
treatment modalities differ from those of Ishii et al. (11) who used a 7 to 10-week period of 20 
mM NiSO4 in the drinking water, and of van Hoogstraten et al. (8) who used a 3-week period of 
0.75 mM NiSO4 in the drinking water as standard treatment. Assuming a daily intake of 4 ml 
drinking water, a body weight of 20 g per mouse, and an absorption rate comparable with the 
human absorption rate of 27 ± 17% (23), the cumulative dose of absorbed Ni ions was as high as 
4 mg/g bw in the study of Ishii et al. (11), only 50 µg/g bw in that of van Hoogstraten et al. (8), 
and 900 µg/g bw in the present investigation. Noteworthy is that all tested Ni concentrations 
lower than 10 mM and all treatment periods shorter than 4 wks were also effective, but they only 
induced partial tolerance or a statistically insignificant decrease in ear-swelling.  
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It is easier to induce tolerance in non-sensitized than in sensitized individuals. Confirming this 
rule, oral administration of NiSO4 induced long-lasting tolerance in naive guinea pigs, but only a 
transient desensitization of guinea pigs already sensitized to Ni (17). The present investigation 
confirmed this in mice. Moreover, we found that desensitization persisted, if the mice sensitized 
to Ni continued to receive 1 mM NiCl2 in the drinking water. The concentration of 1 mM NiCl2 
used for maintenance treatment was about 105 to 106 times higher than the background 
concentration of Ni ions routinely received via the drinking water by mice housed in our animal 
facility.  
It is known that continuous delivery of signal 1 in the absence of signal 2 induces T cell 
tolerance and anergy (24, 25). This concept helps to understand our observation that prolonged 
administration of Ni ions, which lack intrinsic adjuvanticity (9), succeeded to induce tolerance 
and anergy among the T cells reacting to this allergen. This view is further supported by our 
finding that tolerance induction to Ni was not dependent on the oral route of administration, 
which is known to favor tolerance (26), but could also be achieved by i.p. administration. 
Nonetheless, oral administration of Ni ions apparently induced a more profound state of tolerance 
than i.p. administration, because after a treatment-free period of 20 wks the i.p. induced Ni 
tolerance remained only partially, whereas it was still complete after oral administration (cf. Figs. 
2B and 7A). Moreover, the minimal number of T cells capable of transferring tolerance was only 
102 after oral administration, but 104 after i.p. administration (cf. Figs. 4A and 7B). In addition to 
the two different routes of administration used, however, there also was a difference in the 
cumulative Ni ion doses received after i.p. and after oral administration. The estimated total dose 
of Ni ions taken up after oral administration (about 900 µg/g bw) was 50 times higher than that 
received via the i.p. injections (17.6 µg/g bw). Since the level of peripheral T cell tolerance that 
can be achieved is known to be dose-dependent (27 - 29), the more complete and persistent state 
of tolerance seen after oral NiCl2 administration might also be explained by the higher dose of 
tolerogen received via this route. 
Several different mechanisms that may underly oral Ag-induced tolerance have been 
proposed: clonal deletion (30), anergy (31), active suppression (32), altered trafficking (33), and 
immune deviation due to a Th1-Th2 cytokine shift (34). Clonal deletion cannot be the mechanism 
responsible for the oral tolerance to Ni reported here, because the existence of Ni-specific T 
suppressor cells was demonstrated by adoptive transfer of splenic T cells and LNC, respectively, 
obtained from tolerized donors. When the LNC of orally tolerized and subsequently sensitized 
mice were restimulated in vitro with NiCl2, they failed to show the enhanced proliferation and IL-
2 production seen with the LNC of mice that were not tolerized, but only sensitized prior to 
restimulation (Fig. 8). Apparently, the Ni-specific T cells of the tolerized mice were anergic. A 
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congruence between a state of T cell anergy and suppressive activity has been also observed in 
other tolerance models (25, 35 - 37). In their in vitro studies of autoreactive T cell clones, in 
which anergy was induced with increasing doses of peptide, Taams and Wauben (27, 28) 
observed three distinct anergic phenotypes, ranging from simple unresponsiveness, to an 
unresponsive suppressive phenotype, to an unresponsive suppressive phenotype that was 
persistently present. In our in vivo model, the Ni-specific, primed suppressor T cells transferred 
after a treatment-free interval of 20 wks would seem to belong to the latter phenotype accounting 
for long-term tolerance. 
T cell anergy towards Ni has not been reported in non-allergic, patch test-negative humans 
(15, 16, 38, 39). This might be explained by the assumption that the average level of human 
exposure to tolerogenic Ni ions is considerably lower than that used in our mouse experiments 
resulting in less profound T cell tolerance (27, 28). This assumption is indirectly supported by the 
different concentrations of Ni ions detected in the tissues of men and of the mice studied by us. 
At the time of autopsy, the mice treated for tolerization by exogenous NiCl2 showed Ni ion 
concentrations in whole blood that were about 110 to 230 times higher than those found in 
untreated mice or humans not occupationally exposed to Ni (40), and were still about 10 times 
higher than those found in workers in a nickel refinery (41). However, humans showing transient 
intoxication after hemodialysis against Ni-contaminated dialysate had a 25 to 30- fold higher 
level of Ni ions in the blood (42). Apart from blood and the small intestine, the Ni ion content in 
different tissues of mice treated with NiCl2 was not considerably different from that in naive 
mice, and for unknown reason, the Ni ion content in the liver of NiCl2-treated mice was even 
lower than that of untreated mice. 
A different question concerns the phenotype of the cells preventing Ni hypersensitivity. In our 
experiments we used T cells either enriched by nylon wool passage (purity of 80 to 85 %) or 
sorted by FACSalibur (> 98 % pure). Numerous reports have described T cell-mediated 
suppression of cellular immune responses (43 - 46), but a uniform phenotype of the pertinent T 
suppressor cells has not emerged. The various T cell subsets include CD4+ CD25+ CTLA-4+ cells 
(47, 48) and CD8+ cells (32, 49). Apparently, several different T cell subsets may be involved, 
and conceivably this varies with both the level of tolerance achieved (27, 28) and the type of Ag 
studied. We found that among the 102 T cells transferred, both CD4+ and CD8+ T cells were 
needed for adoptive transfer of Ni tolerance. This differs from the results of van Hoogstraten et 
al. (8), who reported successful transfer of Ni tolerance with CD8+ cells from spleen and lymph 
nodes; however, they transferred 107 instead of 102 cells. In other mouse models, such as the 
anterior chamber-associated immune deviation model, it was shown that CD4+ T cells alone as 
well as CD8+ T cells alone were capable of transferring tolerance: afferent-regulatory CD4+ T 
cells suppressing the induction, and efferent-regulatory CD8+ T cells suppressing the elicitation 
of delayed-type hypersensitivity (50). Similarly, in murine EAE both CD4+ T cells alone and 
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CD8+ T cells alone were found to be capable of transferring the suppression induced by oral 
tolerance (32). 
An unexpected finding was that the orally induced Ni tolerance could be adoptively 
transferred by as few as 102 T cells. This was not due to inadvertent carry-over of Ni ions, the 
tolerizing agent, but required an active role of live T cells. To our knowledge, the successful 
transfer of tolerance with as few as 102 T cells has no precedence in the literature. In other mouse 
models, the number of T cells used for adoptive transfer of tolerance was several orders of 
magnitude higher. For instance, in the anterior chamber-associated immune deviation model 
5x107 spleen cells from intraocularly treated donors were used (50), in the UV light-induced 
tolerance to the hapten DNFB 108 unsorted or 5 x 105 CTLA-4+ spleen and regional lymph node 
cells were used (43), in a model of transplantation tolerance towards heart allografts 3.5 x 105 
CD4+ cells from tolerized donors were used (51), and even in a model using TCR-transgenic 
mice orally tolerized to OVA peptide 5x106 splenic T cells were used (52). Although this has not 
been explicitly reported, for the sake of the argument we suppose that transfers of smaller cell 
inocula were unsuccessful in those models. What then is special about Ni ions as a tolerogen and 
the manner it was used here when compared to foreign proteins, cells, or tissue grafts acting as 
tolerogens?  
Our finding that as few as fifty CD4+ plus fifty CD8+ T cells were able to transfer the tolerance 
indicates that at least one in fifty cells among both subsets were able to react to Ni ions. Such an 
extraordinarily high frequency of Ag-reactive, primed T cells can hardly be explained in terms of 
conventional concepts of T cell specificity, even though it is realized now that the αβ-TCR does 
not possess the exquisitely narrow specificity as previously assumed, but shows considerable 
cross-reactivity to different peptides (53, 54) and haptens (55) tested. Instead, it should be pointed 
out here that Ni ions differs from the above-mentioned classical Ags, or tolerogens, by the high 
tissue concentrations they can achieve and by their promiscuous behavior with regard to protein 
and peptide binding (56, 57). Moreover, unlike foreign proteins, cells, and tissues, Ni ions need 
not be processed in order to generate neoantigens, but can directly attach to MHC-embedded self 
peptides on the cell surface (9, 14). The basis of neoantigen formation by this metal appears to be 
its ability to form reversible metal-protein and metal-peptide coordination complexes (9, 56 - 59). 
In doing so, Ni ions can engage a variety of different protein side-chains as ligands, and these 
may vary both within each complex and from complex to complex (56, 58). The number of 
ligands engaged in Ni-protein and Ni-peptide complexes, respectively, also can vary from 
complex to complex (59, 60). In all likelihood, complexes formed by Ni ions may comprise more 
than one protein or peptide molecule. If so, Ni ions might act like a bioinorganic glue sticking 
together two different molecules. This could affect, for instance, appropriate MHC-embedded 
self peptides and certain TCRs (57, 60). In this context, it should be realized that the T cells 
rescued from thymic death are those whose TCR possesses a certain degree of low affinity for 
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self peptides-MHC complexes. According to the affinity-threshold concept of T cell activation 
(62), the TCR of peripheral T cells must not be engaged by unmodified self peptides, but will be 
engaged by even slightly modified ones, if these increase the binding affinity of the TCR and the 
overall avidity of a given T cell for those peptides. The ability of Ni ions for complex formation, 
their poorly selective chemical behavior in this process, and their potentially high tissue 
concentrations should enable them to generate a great diversity of changes, which enhance the 
avidity of a large variety of different T cell clones for the self peptides displayed in the periphery 
and prompt them to react. 
In fact, some authors (63, 64) previously hypothesized that Ni ions would act as mitogens, 
since bulk T cells from the vast majority of human subjects tested, including those who did not 
suffer from contact hypersensitivity to Ni and were patch test-negative, did proliferate in 
response to Ni ions (38, 39, 65). For the following three reasons the mitogen hypothesis is 
unlikely though: T cell clones reacting to Ni ions do so by using their αβ-TCR (59), they must be 
able to see MHC molecules on the APCs pulsed with Ni ions (9, 14, 66), and, last but not least, 
the majority of T cell clones in a given individual fail to react to Ni ions (9, 14, 16, 67). 
Nonetheless, the original observation remains valid that there is an unusually broad T cell 
reactivity towards this versatile, complex-building metal (16, 39, 65). 
A high frequency of Ni-reactive T cells cannot, of course, be the only explanation for the 
ability of only 102 bulk T cells to transfer the tolerant state. In addition, there must be a powerful 
amplification mechanism enabling so small a  number of Ni-specific, primed T suppressor cells 
of the donor to become dominant in the recipient, inactivating the numerous Ni-specific T cells of 
the latter. A candidate mechanism here is infectious tolerance (68), and, indeed, there is evidence 
that infectious tolerance operates in our model, involving both the tolerant T cells reported here 
and tolerogenic APCs (K. Haarhuis et al., manuscript in preparation). 
To conclude, we found that oral NiCl2 administration to naive mice induced a profound state 
of immunological tolerance due to the persistent suppressor activity exerted by an unusually high 
number of specific T cells.  
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ABSTRACT  
Previously, we reported that tolerance to nickel, induced by oral 
administration of Ni2+ ions, can be adoptively transferred to naive mice with 
only 102 splenic T cells. Here we show that 102 T cell-depleted spleen cells, i.e., 
APC, from orally tolerized donors can also transfer nickel tolerance. This 
cannot be explained by simple passive transfer of the tolerogen. The APC from 
orally tolerized donors displayed a reduced allostimulatory capacity, a 
tolerogenic phenotype and an increased expression of CD38 on B cells. In fact, 
it were B cells among the APC that carried the thrust of tolerogenicity. Through 
serial adoptive transfers with Ly5.1+ donors and two successive sets of Ly5.2+ 
recipients we demonstrated that nickel tolerance was infectiously spread from 
donor to host cells. Following the transfer of either T cells or APC from orally 
tolerized donors, the spread of tolerance to the opposite cell type of the 
recipients, i.e., APCs and T cells, respectively, required recipient immunization 
with NiCl2 / H2O2. For the spread of tolerance from a given donor cell type, T 
cell or APC, to the homologous host cell type, the respective opposite cell type 
in the host was required as intermediate. We conclude that Ts cells and 
tolerogenic APC induced by oral administration of nickel are part of a positive 
feedback loop that can enhance and maintain tolerance when activated by 
antigen associated with a danger signal. Under these conditions, APC and Ts 
effector cells infectiously spread the tolerance to naive T cells and APC, 
receptively. 
 
 
INTRODUCTION 
A hallmark of peripheral T cell tolerance is its dominance. The mechanisms underlying this 
phenomenon can be particularly well investigated by adoptively transferring T cells from tolerant 
donor animals into naive recipients, which thereafter become unresponsive to immunization with 
the specific Ag studied. The term infectious tolerance has been coined for this phenomenon, and 
denotes the ability of T cells from a tolerant donor to spread the unresponsiveness to Ag-specific 
T cells in naive recipients (1). A formal demonstration that the property of specific 
unresponsiveness, which was acquired by the T suppressor (Ts) cells of the tolerized donor, 
indeed was transmitted to the T cells of recipient mice has come from adoptive transfer 
experiments that used genetic markers to distinguish donor T cells from host T cells (2-4). One 
study, performed 25 years ago (5), reported that macrophages can act as intermediates in the 
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passage of suppressor signals between T cell subsets, but a more detailed analysis of the 
mechanisms involved remains incomplete.  
More recently, a number of studies performed in vitro indicated that, indeed, APC can mediate 
the contagious dissemination of T cell unresponsiveness (6-9). For instance, in one model it was 
demonstrated that T cells tolerant for peptide A could spread the tolerance to other T cells 
specific for peptide A in the culture, but only if the latter recognized the peptide on the same APC 
as the ‘infectious’ T cells (6). In fact, the authors specified a clear-cut sequence of events: after 
the first set of T cells had acquired tolerance, they were ‘infectious’ in that they rendered the 
APC in the culture tolerogenic. In other words, the Ts cells endowed APC with the capacity to 
tolerize new sets of T cells added to the culture. Similarly, unresponsive T cell clones, which 
suppressed proliferation of responsive T cells specific for the same alloantigen, required the 
presence of dendritic cells (DC) in the culture for the suppression to be mediated and become 
effective (7, 8). There is now general agreement that Ag presentation by DC, which are not fully 
competent or mature, fail to sensitize T cells for immunity and induce T cell tolerance instead 
((10-12); see ref. (13) for review). Taken together, these findings indicate that there is a 
reciprocal interplay of unresponsive, suppressive T cells and tolerogenic APC that accounts for 
the spread and, hence, the dominance of tolerance detectable in these in vitro systems. It should 
be noted, however, that some authors reported a model of infectious tolerance in vitro that is not 
dependent upon APC, but is based on direct T-T cell interactions (14, 15). With regard to the 
spread of T cell tolerance in vivo, the question remains whether this is mediated by direct T-T 
interactions or a reciprocal interplay of APC and Ts cells. 
We have developed a mouse model of contact hypersensitivity to nickel, one of the most 
common contact allergens in humans. Our results indicated that intradermal administration of 
Ni2+ ions, as present in NiCl2 and NiSO4, induce de novo immunization when co-administered 
with H2O2, a relevant, endogenous adjuvant (16). In contrast, administration of NiCl2 alone, given 
orally or intraperitoneally, induced a long-lasting tolerance towards nickel, which could be 
further adoptively transferred into naive recipients with as few as 102 bulk T cells. The splenic T 
cells possessing this ability were anergic in the presence of nickel ions and consisted of both 
CD4+ and CD8+ T cells. In order to explain how a minute number of anergic donor T cells could 
suppress the numerous nickel-reactive T cells in naive recipients, we postulated that infectious 
tolerance could be involved (17). In the present investigation, genetic cell markers were 
employed to demonstrate that infectious tolerance is, indeed, the amplification mechanism 
accounting for the spread of nickel unresponsiveness in vivo. Nickel-specific Ts cells and 
tolerogenic APC were found to interact in this process, but only if they were rescued from their 
state of inertia by immunization with NiCl2 in conjunction with H2O2. The APC used were T cell-
depleted spleen cells and amongst these B cells carried the thrust of tolerogenicity. 
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MATERIALS AND METHODS 
 
Mice   
Specific pathogen-free female C57BL/6J (H-2b) mice, which express Ly5.2 (CD45.2), and BALB/c 
(H-2d) mice were obtained from Janvier (Le Genest St. Isle, France); congenic Ly5.1+ (CD45.1+) 
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were kept in 
accordance to the animal husbandry as described in the previous papers (16, 17), they were 6 to 8 wk of 
age at the onset of experiments. 
 
Reagents  
NiCl2·6H2O (further referred to as NiCl2), and 2,4-dinitrofluorobenzene (DNFB) were purchased from 
Sigma-Aldrich Chemie GmbH (Steinheim, Germany), and hydrogen peroxide (H2O2) was obtained from 
E. Merck (Darmstadt, Germany). Streptavidin-PerCP and Streptavidin-APC were obtained from BD 
PharMingen (Heidelberg, Germany).  
 
Antibodies 
The following anti-mouse mAb were purchased from BD PharMingen (Heidelberg, Germany): APC-
labeled anti-CD3ε (clone 145-2C11), PerCP-labeled anti-CD4 (clone RM4-5), PE-labeled anti-CD8β.2 
(clone 53-5.8), FITC- and biotin-labeled anti-CD11c (clone HL3), FITC-labeled anti-CD19 (clone 1D3), 
biotin-labeled anti-CD38 (clone 90), FITC-labeled anti-CD40 (clone HM40-3), PE-labeled anti-CD45.1 
(clone A20), FITC-labeled anti-CD45.2 (clone 104), biotin-labeled anti-CD80 (clone 16-10A1), biotin-
labeled anti-CD86 (clone GL1), FITC-labeled anti-I-Ab (clone AF6-120.1), PE-labeled anti-I-A/I-E (clone 
M5/114.15.2), and FITC-labeled anti-TCRβ chain (clone H57-597). FITC-labeled anti-DEC205 (clone 
NLDC145) was purchased from DPC Biermann, Bad Nauheim, Germany. Magnetically-labeled anti-
CD11c, anti-CD19, anti-CD90, anti-MHC-II, and anti-PE mAb were purchased from Miltenyi Biotec 
GmbH (Bergisch Gladbach, Germany).  
 
Oral tolerance induction 
Mice were treated with 10 mM NiCl2 in the drinking water (17) for at least 4 and to a maximum of 8 
wk. Unless mentioned otherwise, they were sacrificed and their spleens excised directly after treatment. 
Age- and sex-matched control mice received tap water without any additional NiCl2. 
 
Immunization of mice 
Mice were immunized as described previously (16, 17). In the case of nickel, they were injected 
intradermally into both flanks (50 µl each) with either 10 mM NiCl2 in sterile, pyrogen-free saline 
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(negative control), or 10 mM NiCl2 in saline containing 1% H2O2. For DNFB treatment, mice were 
immunized by painting 0.5% (w/v) DNFB on the shaved flanks (20 µl each); DNFB was resolved in a 4:1 
(v/v) mixture of acetone and olive oil.  
 
Challenge for recall and ear-swelling test  
Ten days after immunization, mice were re-challenged by injecting 50 µl of 10 mM NiCl2 in sterile, 
pyrogen-free saline into the pinna of each ear, or by applying 20 µl of 0.2% DNFB onto each ear. Forty-
eight hours after re-challenge with NiCl2 and 24 h after re-challenge with DNFB, delayed-type 
hypersensitivity reactions were determined by measuring the increment in ear thickness in comparison to 
the pre-challenge values. To determine the pre-challenge values, mice were anaesthetized with di-ethyl-
ether, whereas for the measurement after challenge, mice were killed by asphyxiation with CO2. 
Measurements were performed in a blind fashion (16, 17), using a micrometer gauge (Oditest D 1000 
gauge, The Dyer Co., Lancaster, PA, USA). The following results represent the mean ear-swelling 
response from groups comprising 5 to 6 mice, and are expressed in units of mm x 10-2 + SEM.  
 
Sorting of T cells and APC for adoptive transfer studies 
For the transfer of T cells, single-cell suspensions of erythrocyte-free spleen cells, which contained 30-
35% T cells, 60-65% B cells, and 1-2% DC, were passed through nylon wool columns, followed by the 
depletion of CD11c+, CD19+, and MHC-II+ cells using a magnetic cell sorter (autoMACS, Miltenyi 
Biotec, Bergisch Gladbach, Germany). For the transfer of APC, single-cell suspensions of erythrocyte-free 
spleen cells were depleted of CD4+, CD8+, and CD90+ T cells using the autoMACS. Hereafter, these cells, 
containing 90-95% CD19+MHC-II+ B cells and 1-3% CD11c+MHC-IIhi DC, will be referred to as APC. 
The purity of the resulting T cell and APC fractions were then clarified by FACS analysis, and were found 
to be contaminated with less than 0.5% CD19+MHC-II+ or CD11c+MHC-IIhi APC and less than 0.5% 
CD4+CD3+ or CD8+CD3+ T cells, respectively. In the serial transfer assays using T cells and APC, an 
additional depletion of Ly5.1+ (CD45.1+) cells was performed between the first set of recipients (i.e., the 
second donors) and the second set of recipients. After this depletion, the fraction of cells required for 
transfer contained less than 0.1 % Ly5.1+ cells. For the transfer of B cells, single-cell suspensions of 
erythrocyte-free spleen cells were depleted of CD4+, CD8+, CD3+, and CD11c+ cells, using the 
FACSCalibur. The transferred B cell fractions, containing 90-95% CD19+MHC-II+ B cells, were 
contaminated with less than 0.5% CD4+ T cells (CD4+CD3+ cells), and CD8+ T cells (CD8+CD3+ cells), 
but contained no DC (CD11c+MHC-IIhi cells). 
   
In vitro treatment of APC prior to the adoptive transfer 
To assess the activities of APC, separated donor APC were subjected to various in vitro treatments 
prior to transfer. 1) Aliquots of APC (6.6 x 103 cells/ml) from orally tolerized donors were either killed by 
three cycles of freezing (-196° C) and thawing (37° C), or irradiated with 2000 rads. 2) For the transfer of 
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fixed APC from orally tolerized mice, APC were fixed with 2% paraformadehyde (2 x 106 cells/ml, 20 
min at RT), washed and diluted with sterile, pyrogen-free PBS, and then used for adoptive transfer (6.6 x 
103 cells/ml). 3) Further aliquots of APC, obtained from both orally tolerized donors and naive donors, 
were incubated in vitro with 1 µg/ml LPS (106 cells/ml, 18 h at 37°C), washed and diluted with sterile, 
pyrogen-free PBS, and then used for adoptive transfer (6.6 x 103 cells/ml). For control, APC from naive 
donors were incubated in vitro with RPMI 1640 medium containing 75 µM NiCl2 (106 cells/ml, 18 h at 37 
°C), washed and diluted with sterile, pyrogen-free PBS, and then used for adoptive transfer (6.6 x 103 
cells/ml). RPMI 1640 medium was supplemented with 10% FCS, 2 mM glutamine, 1 mM sodium 
pyruvate, essential and non essential amino acids, 10 U/ml penicillin/streptomycin, and 50 µM β-
mercaptoethanol. 
 
Adoptive cell transfers 
Cell suspensions, containing the type and the number of cells indicated, were diluted in sterile, 
pyrogen-free PBS and injected i.v. into recipient mice (150 µl). One day later, mice were immunized 
against NiCl2 or the control compounds indicated. Ten days thereafter, the recipients were re-challenged at 
the ears, and 48 h later (or 24 h in the case of DNFB), their ear-swelling response was measured. An 
exception here was the first set of Ly5.2+ recipients in the experiments on infectious tolerance, these 
animals were not re-challenged after the immunization. 
 
Allostimulation in the MLR 
In the MLR in vitro, the proliferative responses of BALB/c T cells to APC from C57BL/6 mice were 
studied. On day 0, single-cell suspensions of erythrocyte-free spleen cells were prepared in DMEM 
medium containing 10% FCS. APC and T cells fractions were obtained by the depletion of CD90+ and 
MHC-II+ cells, respectively, using MACS. The obtained fractions were tested for purity by FACS 
analysis: the sorted APC and T cells were found to be contaminated with less than 3% T cells and less 
than 1% APC, respectively. Cells were resuspended in complete medium, i.e., DMEM medium 
supplemented with 10% FCS, 2 mM glutamine, 4.5 g/l glucose, 1 mM sodium pyruvate, 10 U/ml 
penicillin/streptomycin, and 50 µM β-mercaptoethanol. Irradiated APC (2000 rads) from both naive and 
nickel-tolerant C57BL/6 mice, were pipetted into 96-well round-bottom plates (105 cells/well) in 
quadruplicates and cultured in either complete medium (100 µl/well) or in complete medium containing 
75 µM NiCl2; irradiated APC from BALB/c mice served as syngeneic controls. On day 1, freshly isolated 
T cells (105 cells/well), were added with or without 75 µM NiCl2 (to give a final volume of 200 µl/well). 
On day 5, [3H] thymidine (0.5 µCi/well) was added for the last 16 h. On day 6, cells were harvested, using 
the Inotech Sample Harvesting System (Inotech AG, Dottikon, Switzerland), and assessed for thymidine 
incorporation in a liquid scintillation counter (1450 MicroBeta TriLux Liquid Scintillation and 
Luminescence Counter, Wallac Oy, Turku, Finland). Results are expressed as stimulation indices (SI) + 
SD (SI = mean cpm of BALB/c T cells stimulated by C57BL/6 APC/ mean cpm of BALB/c T cells 
stimulated by BALB/c APC). 
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Immune flow cytometry 
For phenotyping of the APC, single-cell suspensions of erythrocyte-free spleen cells were prepared in 
PBS containing 0.02% NaN3 and pre-incubated with anti-CD16/CD32 mAb (Fc block). B cells were 
stained with anti-CD19, and either anti-CD40 or anti-CD38, whereas T cells were stained with anti-CD3, 
anti-CD4, and anti-CD38. DC were identified using anti-CD11c and anti-MHC-II, in addition they were 
stained with either anti-CD40, anti-CD80, or anti-CD86 mAb. Intracellular staining for DEC-205 was 
performed as previously described (18). Briefly, cells were fixed in PBS containing 2% paraformaldehyde 
and pre-incubated with anti-CD16/CD32 mAb. Permeabilization was performed in PBS containing 1% 
BSA and 0.5% saponin. Incubation with the DEC-205 mAb was carried out in the presence of BSA and 
saponin. Flow cytometry was performed using the FACSCalibur (BD Biosciences, Heidelberg, Germany), 
and the results were analyzed with CellQuest® software.  
To investigate the expression of costimulatory molecules on APC in the draining lymph nodes 
following nickel treatment, mice were injected intradermally into both flanks (50 µl each) with either 
pyrogen-free saline, 10 mM NiCl2, 10 mM NiCl2 containing 1% H2O2, or 1% H2O2. Single-cell 
suspensions of the draining axillary lymph nodes were prepared in PBS and pre-incubated with anti-
CD16/CD32 mAb. To characterize DC, the lymph node cells were stained with anti-CD11c and anti-
MHC-II, whereas for the characterization of B cells anti-CD19 and anti-MHC-II were used. Subsequently, 
both subpopulations were stained with either anti-CD80 or anti-CD86 mAb. Flow cytometry was then 
performed and the expression of CD80 and CD86 was calculated as the mean fluorescence intensity on the 
DC and B cells, respectively. 
  
Statistical analysis  
Statistical significance of results was determined by analysis of variance (ANOVA) followed by 
Newman-Keuls test.  
 
 
RESULTS 
 
APC from mice that were orally tolerized towards nickel display a tolerogenic phenotype 
With regard to the overall cellular composition of splenocytes, immune flow cytometry 
showed no significant differences between orally tolerized and untreated control mice. However, 
phenotypic difference were detected among the APC. Splenic DC from nickel-tolerant mice 
exhibited not only an increase in the expression of DEC-205 (Fig. 1A), but also displayed a 
profound decrease in CD40 (Fig. 1B). This decrease in CD40 was even more apparent on the B 
cell population (Fig. 1C). These alterations point to an immature, potentially tolerogenic 
phenotype of the APC, albeit that these cells did not show any alterations in the expression of  
Infectious spread of nickel tolerance in vivo 
79 
 
 
CD28, CD80, CD86, and MHC-II (data not shown). Furthermore, while the CD38 expression on 
the B cells of orally tolerized mice was markedly increased (Fig. 1D), it remained unchanged on 
the T cells derived from the same animals (Fig. 1E). 
 
APC from mice that were orally tolerized towards nickel show a reduced allostimulatory capacity  
The above described tolerogenic phenotype displayed on the APC from orally tolerized mice 
was mirrored by their reduced allostimulatory capacity in the MLR in vitro, where these cells 
were used as allostimulators. Irradiated APC from nickel-tolerant C57BL/6 mice (H-2b) were co- 
cultured with splenic T cells from untreated BALB/c mice (H-2d). The proliferative responses of 
 
Stimulation Index (SI+SD)
+
-
+
-
Naive
Naive
Ni-tolerant
Ni-tolerant
Naive
Naive
Naive
Ni in 
culture
Stimulator
APC
(C57Bl/6 )
Responder
T cells 
(BALB/c) 1   6   11   16   21   26  31
Naive *
*
*
*
*
*
 
FIGURE 1. B cells and DC from mice orally treated 
with NiCl2 display a tolerogenic phenotype. Spleen cells 
from mice given 10 mM NiCl2 in their drinking water for 
4 wk (bold curves) and untreated controls (shaded 
curves) were analyzed for their expression of CD40, 
CD38 and DEC-205, respectively. Dotted lines represent 
stainings with isotype-matched control mAb. Expression 
by MHC-IIhiCD11c+ DC of DEC-205 was analyzed by 
intracellular staining (A). Analysis of CD40 expression 
was restricted to MHC-IIhiCD11c+ DC (B) and CD19+ B 
cells (C). Histograms D and E show the expression of 
CD38 on CD19+ B cells and CD3+CD4+ T cells, 
respectively. Data are a representative of three 
independent experiments, yielding comparable results 
each time. 
 
 
FIGURE 2. APC from nickel-tolerant mice show 
decreased allostimulatory capacity in the MLR. Groups 
of C57BL/6 mice were tolerized by oral NiCl2 
treatment, or were left untreated, as indicated. 
Thereafter, the mice were sacrificed and their APC 
prepared and cultured  over night with (+) or without (-) 
NiCl2, before splenic T cells from untreated BALB/c 
mice  were  added  to  start  the  MLR.  Four  days  later,  
[3H]-thymidine incorporation was measured. In this and the subsequent figures, the symbol Ni denotes NiCl2, and the 
asterisks indicate a significant difference (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) between the groups compared by 
brackets. The results are taken from one of four experiments which yielded comparable results. In this and the 
following Figs., black bars indicate the decisive experimental groups (cf. text). 
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these T cells were then tested in the presence or absence of NiCl2. In comparison with the APC 
from untreated C57BL/6 mice (Fig. 2, bars 1 and 2), the APC from nickel-tolerant mice (Fig. 2, 
bars 3 and 4) showed a significantly reduced allostimulatory capacity, regardless of whether 
NiCl2 was present.  
 
APC from orally tolerized donors are able to transfer nickel tolerance to naive recipient mice 
Our previous studies demonstrated that as few as 102 bulk T cells from the spleens of nickel-
tolerant donors were able to adoptively transfer the tolerance to naive syngeneic recipients (17). 
Here we show that APC also can transfer nickel tolerance. As shown in Fig. 3A (bars 1 to 3), the 
transfer of 104, 103, and even as few as 102 APC from nickel-tolerant donors succeeded in 
transferring nickel tolerance to naive syngeneic recipients. The ear-swelling response in the  
 
Oral Ni
(mM)
Donors Recipients
none
Number of 
transferred
APC
Immun-
ization
Re-
challenge
no transfer
no transfer
104
104
104
104
103
102
0
0
10
10
10
10
10 101
DNFB
DNFB
Ni + H2O2
DNFB
Ni + H2O2
Ni + H2O2
Ni + H2O2
Ni + H2O2
DNFB
DNFB
Ni
DNFB
DNFB
Ni
Ni
Ni
Ni
Ear-swelling 
(x 10-2 mm + SEM)
15    17.5 20  22.5   25 
*
*
*
*
*
*
*
*
*
*
*
Ear-swelling 
(x 10-2 mm + SEM)
17.5 20.0 22.5 25.0 27.5
none
none
killed
irradiated
fixed
In vitro 
treatment of 
APC (103)
Ni loading
0
10
10
10
10
Oral Ni
(mM)
0
10
0
LPS-activated
LPS-activated
*
*
*
*
*
*
*
*
*
*
*
Donors RecipientsB
A
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
  
FIGURE 3. Intact APC from nickel-tolerant donors 
are able to adoptively transfer nickel tolerance. 
Prospective C57BL/6 donor mice were orally tolerized 
or left untreated, as indicated. Specified numbers of 
APC from tolerant or naive donors were injected i.v. 
into naive syngeneic recipients. In A, the separated 
donor cells were not subjected to in vitro treatment 
prior to transfer; in B, the APC from tolerant donors 
were either left untreated, killed by repeated freezing 
and thawing, irradiated with 2000 rad, fixed with 
paraformaldehyde, or activated with LPS. APC from 
naive mice were either left untreated, activated with 
LPS, or loaded with nickel ions before transfer, as 
indicated. Twenty-four hours after the transfer, 
recipients were immunized by injection of NiCl2 / 
H2O2 into each flank, except for those which were 
painted with DNFB onto both flanks (A), as indicated. 
Ten days later, the mice were re-challenged at the ears 
with either NiCl2 or DNFB, and their ear-swelling 
response determined 2 days thereafter. The data shown 
represents the mean ear-swelling response + SEM 
from groups of 5 mice each. Results represent one of 
three experiments, which yielded comparable results. 
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recipients that received tolerogenic APC was as low as the background ear-swelling previously 
observed in mice which did not receive a cell transfer and were not immunized, but only were 
challenged with NiCl2 (16). Moreover, these ear-swelling values correlated with those of mice 
that received between 102 and 104 splenic T cells from nickel-tolerant donors, followed by 
immunization with NiCl2 / H2O2 and challenge with NiCl2 (17). However, the transfer of only 101 
APC from nickel-tolerant donors or of 104 APC from untreated donors (Fig. 3A, bars 4 and 5) 
failed to render the recipients resistant to subsequent immunization with NiCl2 / H2O2. As a 
specificity control, a group of recipients that had received 104 APC from nickel-tolerant donors 
were immunized and re-challenged with DNFB. The anti-DNFB response of the recipients was 
normal (Fig. 3A, bar 6), indicating that the APC conferred unresponsiveness to nickel, but not to 
DNFB. Consistent with this we showed previously that the mice orally tolerized to nickel failed 
to be generally immunosuppressed (17), even though this might be suggested by the tolerogenic 
phenotype (Fig. 1) and the reduced allostimulatory capacity (Fig. 2) of the APC of these animals. 
 
In vitro treatment of the APC from orally tolerized donors abrogates their tolerogenicity 
We then asked whether in vitro treatment of the tolerogenic APC prior to transfer would 
interfere with their tolerogenicity. This was indeed found to be the case since either killing, 
irradiation, or fixation could abrogate the tolerogenicity of the APC (Fig. 3B, bars 3 to 5). 
Furthermore, in accordance with other authors (13) we found that the immature phenotype of the 
APC (Fig. 1) was needed for their tolerogenic function in vivo. If the APC from tolerant donors 
were activated with LPS, and thus lost their immature phenotype ((19, 20); and data not shown), 
they also lost their tolerogenic activity (Fig. 3B, bar 6). Hence, for the successful transfer of 
nickel tolerance the APC must be intact cells that have neither been activated nor inactivated or 
killed. 
 
In vitro nickel-loading of APC from naive donors fails to render them tolerogenic 
The adoptive transfer data presented above clearly indicated that the APC from orally-
tolerized donors were tolerogenic. In contrast, the transfer of 103 APC from naive donors, which 
had been pulsed in vitro with a concentration of NiCl2 known to activate nickel-specific T cells 
(16, 17), failed to tolerize the recipients (Fig. 3B, bar 8). Thus, the transfer of tolerance with APC 
from orally tolerized donors was not due to simple passive transfer of nickel ions to the 
recipients. Consistent with this, APC from naive mice incubated with NiCl2 in vitro, also failed to 
be hypostimulatory in the allo-MLR (Fig. 2). These findings indicate that the APC of the orally 
tolerized donors possessed a tolerogenic property that was not present in the nickel-loaded APC 
of untreated mice. 
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The tolerogenic capacity of APC from orally tolerized mice is transient 
Both APC and T cells from orally tolerized mice were able to transfer nickel tolerance, when 
the respective donors were sacrificed after a treatment-free interval of 1 wk following oral 
tolerance induction (Fig. 4, bars 1 and 4). Moreover, consistent with our previous findings (17) 
nickel tolerance could be transferred with bulk T cells as late as 20 wk after the termination of 
oral NiCl2 treatment (Fig. 4, bar 5). Obviously, T cells with a long-lasting suppressive capacity, 
specific for nickel, were formed during the 4-week period of oral tolerance induction. In contrast 
to T cells, the APC from these mice had completely lost their capacity to transfer tolerance after a 
treatment-free interval of 20 wk (Fig. 4, bar 2). The biological half-life of nickel ions is so short 
that, in men, 50% of the nickel ions in the body are eliminated within 2 to 3 days (21). Hence, it 
is likely that after a treatment-free interval of 20 wk the concentration of nickel ions in the orally 
tolerized donors was too low to induce new tolerogenic APC. In all likelihood, the original 
tolerogenic APC that had been induced by the 4-week period of oral nickel treatment were lost 
because of their short life-time. The reduction of allostimulatory capacity of the APC from orally 
treated mice (Fig. 2) also was a transient phenomenon that disappeared if the oral NiCl2 treatment 
was followed by a treatment-free interval of 20 wk (data not shown). Thus, although the APC in 
the orally tolerized mice were found to be an essential element in nickel tolerance, the T cells of 
these animals are the responsible factor for the long-term maintenance of tolerance.  
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FIGURE 4. Unlike T cells, APC lose their 
tolerogenicity during a treatment-free interval of 20 wk 
after the termination of oral NiCl2 treatment. Prospective 
C57BL/6 donor mice were orally tolerized or left 
untreated, as indicated. Following a treatment-free 
interval of 1 wk or 20 wk, as indicated, 104 APC or T 
cells from tolerant or naive donors were injected i.v. into 
naive syngeneic recipients. Twenty-four hours after the 
transfer, all recipients were immunized by injection of 
NiCl2 / H2O2 into each flank. Ten days later, the mice 
were re-challenged at the ears with NiCl2  and  their  ear- 
swelling  responses determined 2 days thereafter. Data depicted data represents the mean ear-swelling response + 
SEM from groups of 5 mice each. Results represent one of two experiments, which yielded comparable results. 
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Amongst the APC from orally tolerized donors, it is the B cells which primarily carry the 
tolerogenicity 
The 102 splenic APC from orally tolerized donors, which were found to transfer nickel 
tolerance (Fig. 3), consisted of mostly (90-95%) B cells and only a few (1-3%) DC. Therefore, 
we asked whether B cells alone were able to transfer the tolerance. Indeed, we were able to 
transfer the tolerance with 103 purified B cells that were devoid of DC (Fig. 5, bar 1). Since the 
purified B cell fraction contained maximal 0.5 % of T cells, at most five T cells could have been 
transferred alongside the purified B cells. We have previously shown that this T cell number is 
too low for successful transfer of tolerance (17).  
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Demonstration of infectious tolerance: both APC and T cells are involved 
In order to investigate the role of infectious tolerance in our model, serial adoptive cell transfers 
were performed. These involved orally tolerized mice as primary cell donors, a first set of 
recipient mice which in turn became the secondary cell donors, and, finally, a second set of 
recipient mice which were assayed for tolerance induction after immunization with NiCl2 / H2O2 
and re-challenge at the ears. To be able to distinguish the cells from the primary donors from 
those of the recipients, congenic C57BL/6 mice, which express Ly5.1 on the surface of all 
lympho-hematopoietic cells were used as the primary donors, instead of the Ly5.2+ wildtype 
mice. As shown in Fig. 6, 104 T cells or APC from orally tolerized or untreated Ly5.1+ primary 
donors were transferred to the first set of Ly5.2+ recipients, which were immunized with NiCl2 / 
H2O2 one day later. After a further 10 days, APC or T cells, were isolated from the first recipients 
FIGURE 5. Purified B cells from nickel-tolerant 
donors are able to adoptively transfer the tolerance. 
Prospective C57BL/6 donor mice were orally tolerized 
or left untreated, as indicated. As depicted, specified 
numbers of splenic B cells or T cells from tolerant or 
naive donors were injected i.v. into naive syngeneic 
recipients. Twenty-four hours after the transfer all 
recipients were immunized by injection of NiCl2 / H2O2 
into each flank. Ten days later, the mice were re-
challenged at the ears with NiCl2, and their ear-swelling 
responses determined 2 days thereafter. The data shown 
 represents the mean ear-swelling response + SEM from groups of 5 mice each. Results represent one of two 
experiments, which yielded comparable results. 
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and depleted of any contaminating Ly5.1+ cells remaining from the primary donors. These cells 
(104 / mouse) were then transferred into the second set of Ly5.2+ recipients. If the latter received 
T cells or APC from those first recipients which themselves had been tolerized by injection of the 
opposite cell type (APC and T cells, respectively) originating from the orally tolerized Ly5.1+ 
donors, they were unresponsive to immunization (Fig. 6, bars 1 and 4). Consequently, Ly5.1+ 
cells derived from the primary donors possessed the ability to infectiously spread nickel tolerance 
to the first recipients (and prospective secondary donors), indicating that, indeed, infectious 
tolerance operates in orally induced nickel tolerance. Both T cells and APC from the Ly5.1+ 
primary donors were able to initiate this cascade mechanism of tolerance in vivo. Interestingly 
however, although the tolerance was successfully transferred by T cells of the primary donors to 
APC of the first recipients and, vice versa, by APC of the primary donors to T cells of the first 
recipients, there was no direct tolerance transfer from either donor T cells to host T cells or from 
donor APC to host APC (Fig. 6, bars 3 and 6).  
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The results shown in Fig. 6 demonstrate that the successful tolerance transfer from the primary 
Ly5.1+ donors to the second set of Ly5.2+ recipients involved infectious tolerance. We ruled out 
the possibility that the transfer or tolerance was due to a contamination through residual Ly5.1+ 
cells derived from the tolerant primary donors, because immunofluorescent staining showed that 
FIGURE 6. Infectious tolerance is the amplification 
mechanism accounting for the transfer of nickel 
tolerance in vivo; in order to be effective, T cells and 
APC must cooperate in this process. Prospective Ly5.1+ 
donor mice were orally tolerized to nickel or left 
untreated, as indicated. Thereafter, T cells or APC from 
the Ly5.1+ primary donors were transferred (104 cells 
per recipient) to a first set of Ly5.2+ recipients. The 
latter were injected with NiCl2 / H2O2 within 24 h after 
transfer. On day 11, T cells and APC from these first 
recipients were isolated and depleted of donor Ly5.1+ 
cells, and subsequently transferred (104 cells per 
recipient) into a second set of Ly5.2+ recipients. As 
control groups for nickel tolerance and allergy (bottom), 
104 nylon  wool-enriched  T cells  from tolerant or naive 
Ly5.2+ donors were transferred into groups of Ly5.2+  recipients, as indicated. All recipients were immunized, re-
challenged, and the ear-swelling responses determined in accordance to the standard protocol. The displayed data 
represents the mean ear-swelling response (+ SEM) from groups of 5 mice each. Results represent one of two 
experiments, which yielded comparable results. 
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amongst the cells isolated from the first set of Ly5.2+ recipients there was a maximum of 0.1% 
contaminating Ly5.1+ cells. Thus, along with the 104 cells obtained from the first recipients and 
transferred to each mouse in the second set of Ly5.2+ recipients, a maximum of 101 cells derived 
from the Ly5.1+ primary donors could have been co-transferred. This small contamination was 
negligible because neither 101 T cells (17), nor 101 APC (Fig. 3, bar 4) from orally tolerized 
donors were able to transfer the tolerance. Another reason why this small contamination was 
negligible came from the observation that the second set of recipients failed to be tolerized when 
they received 104 T cells from those first Ly5.2+ recipients which themselves were rendered 
tolerant by the injection of T cells from the primary Ly5.1+ donors (Fig. 6, bar 6). Although the 
first recipients (and, thus, the secondary donors) taken for this T cell -> T cell transfer were 
identical with those used for the T cell -> APC transfer, only the APC isolated from the first 
recipients were found to tolerize the second set of recipients (Fig. 6, bar 3 vs. bar 4). These 
tolerogenic APC, however, contained the same percentage (≤ 0.1%) of contaminating Ly5.1+ 
cells as the ineffective T cell fraction isolated from the same animals. 
 
Immunization is needed for the infectious spread of tolerance in recipient mice 
Next, we asked whether both signal 1 and signal 2 were required for the infectious spread of 
tolerance from donor T cells to host APC and vice versa. Previously, we proposed that Ni2+ ions, 
unlike other sensitizing metal ions (22-25), would be unable to upregulate the expression of co-
stimulatory molecules, whereas the administration of NiCl2 together with H2O2 would induce 
both signal 1 and signal 2 (17). Here, the validity of this hypothesis has been confirmed. 
Focussing on CD80 and CD86 as recognized primary markers of costimulation, we determined 
the expression of CD80 and CD86 on APC, that is, DC (as gated in Fig. 7A) and B cells, in the 
draining axillary lymph nodes after immunization of naive mice at the flanks. Indeed, the 
expression of CD80 and CD86 on DC (Fig. 7C and D) as well as B cells (Fig. 7E and F) was 
higher after the injection of NiCl2 / H2O2, or H2O2 alone than after an injection of NiCl2 alone, or 
saline. These results confirmed our concept that NiCl2 alone induces only signal 1 (neoantigens) 
on APC, while NiCl2 in conjunction with H2O2 induces both signal 1 and signal 2 (costimulation) 
and H2O2 alone induces only signal 2. 
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To test if signal 1 and a danger signal (26) were needed for the spread of tolerance, APC from 
the Ly5.1+ primary donors were transferred to Ly5.2+ recipients. Ten days after priming with 
either NiCl2 / H2O2, NiCl2 alone, or H2O2 alone, as indicated in Fig. 8A, T cells of the first Ly5.2+ 
recipients were depleted of Ly5.1+ cells and transferred to a second set of Ly5.2+ recipients. The 
latter recipients were then immunized and tested for tolerance to nickel. Only when the first set of 
recipients were immunized with NiCl2 / H2O2, could the transferred Ly5.1+ APC succeed in 
infecting their host T cells so that these cells could in turn transfer the tolerance to the second set 
of Ly5.2+ recipients (Fig. 8A, bar 1). Hence, for the infectious spread of tolerance from Ly5.1+ 
APC to Ly5.2+ T cells both signal 1 and a danger signal were needed. The same was true for the 
infectious spread of tolerance from Ly5.1+ donor T cells to Ly5.2+ APC (Fig. 8B, bar 1). While 
signal 1 can be clearly defined as nickel-induced neoantigens, the relevant molecules induced by 
the danger signal remain unresolved. Whether this is indeed CD80/CD86 or some other 
costimulatory or coinhibitory molecule(s) requires further investigation. 
FIGURE 7. Contrary to immunization with NiCl2 / 
H2O2, an injection of NiCl2 alone fails to upregulate 
CD80 and CD86 on the APC in the draining lymph 
nodes. Groups of three mice were injected into both 
flanks with either NaCl, NiCl2 alone, NiCl2 / H2O2, or 
H2O2 alone, as indicated. After 1, 2, 3, and 4 days the 
draining axillary lymph nodes were prepared and their 
cells stained for surface MHC-II, CD11c, and CD80 
or CD86. DC were gated as CD11c+ MHC-IIhi cells, 
as shown in A. The CD80 and CD86 expression of the 
gated DC were plotted in histograms, as shown for 
CD80 in B (day 1). The bold curve represents the 
staining of DC from mice immunized with NiCl2 / 
H2O2, the shaded curve shows the staining of DC 
from mice immunized with NiCl2 alone, and the 
dotted line the staining obtained with the isotype 
control mAb. The kinetics of CD80 and CD86 
expression, shown as mean fluorescent intensities 
(MFI), on DC are displayed in graphs C and D, 
respectively, while the kinetics of CD80 and CD86 
expression on B cells (CD19+MHC-II+) are displayed 
in graphs E and F, respectively. Results represent one 
of three experiments, which yielded comparable 
results. 
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Tolerance can spread from Ly5.1+ T cells to Ly5.2+ T cells and from Ly5.1+ APC to Ly5.2+ APC, 
if the Ly5.2+ recipients are immunized twice  
When cells from the orally tolerized Ly5.1+ donors were transferred into the first recipients 
that were immunized once after the transfer, the tolerance failed to spread from donor T cells to 
host T cells or from donor APC to host APC (Fig. 6, bars 3 and 6). In view of the finding that 
complete immunization was needed for each spread of tolerance from one cell type to the 
opposite one (Fig. 8A and B), we hypothesized that the one-time immunization protocol used for 
the experiment shown in Fig. 6 would not have given sufficient immunizing efficacy and/or time 
to first engage the respective opposite cell type into the tolerance spread, and, eventually, reach 
the homologous cell type of the host. If this is true, this would mean that for the spread of 
tolerance from a given donor cell type to the homologous cell type in the recipients, the latter 
would  require a double  immunization: the first time  to induce  the spread  of tolerance  from the 
FIGURE 8. Both NiCl2 and H2O2 are required for 
the infectious spread of tolerance from donor APC 
to host T cells (A) and from donor T cells to host 
APC (B). Prospective Ly5.1+ donor mice were 
orally tolerized to nickel or left untreated, as 
indicated. Thereafter, APC (A) or T cells (B) of the 
primary Ly5.1+ donors were transferred (104 cells 
per recipient) to a first set of Ly5.2+ recipients. 
Within 24 h after transfer, the first recipients were 
injected with either NiCl2 / H2O2, NiCl2, or H2O2, as 
indicated. On day 11, T cells (A) and APC (B) of 
the first recipients were isolated and depleted of 
donor Ly5.1+ cells, before they were transferred (105 
cells per recipient) into a second set of Ly5.2+ 
recipients. As control groups for tolerance and 
allergy (bottom), 104 nylon wool-enriched T cells 
from tolerant or naive Ly5.2+ donors were 
transferred into groups of Ly5.2+ recipients, as 
indicated. All recipients were then immunized with 
NiCl2 / H2O2, re-challenged, and the ear-swelling 
responses determined. Data shown represent the 
mean ear-swelling response (+ SEM) from groups of 
5 mice each. Results represent one of two 
experiments, which yielded comparable results. 
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respective donor cell type to the opposite host cell type, and the second time, to allow the 
subsequent spread from the first host cell type to the second one. Consequently, the second cell 
type would be homologous with that of the primary Ly5.1+ donor cell type. To test this 
hypothesis, we performed serial transfer experiments in which the first set of recipients were 
immunized with NiCl2 / H2O2 twice, the first time within 24 h after transfer and the second time 
on day 11. With the second cell transfer, which was performed on day 21, we could show that the 
recipients of Ly5.1+ Ts cells, indeed, possessed tolerant Ly5.2+ T cells if they had been 
immunized twice (Fig. 9, bar 2). Corresponding experiments performed with APC showed the 
spread of tolerance from donor APC to host APC (Fig. 9, bar 5). We conclude that both the long-
lived Ts cells and the APC (Fig. 4) from orally tolerized donors can, indeed, spread the tolerance 
to the same cell type in the recipients, but only if they encounter the tolerogen, NiCl2, in 
conjunction with a danger signal, in our case H2O2, more than once. 
 
 
DISCUSSION 
In the present study, we first focussed on the characterization of the APC from orally tolerized 
mice and then studied the two-way interactions between Ts cells and APC in the infectious 
tolerance pathway in vivo. Compared with splenocytes of untreated control mice, the APC from 
FIGURE 9. Infectious tolerance spread from a given 
donor cell type, T cell or APC, to the homologous cell 
type in the recipients requires a double immunization 
of recipient mice. Prospective Ly5.1+ donor mice 
were orally tolerized to nickel or left untreated, as 
indicated. Thereafter, T cells or APC from these 
primary Ly5.1+ donors were transferred (104 cells per 
recipient) into a first set of Ly5.2+ recipients. The first 
set of recipients were immunized (with NiCl2 / H2O2) 
twice on days 1 and 11. On day 21, T cells and APC 
from the first recipients were isolated and depleted of 
Ly5.1+ donor cells, before they were transferred 
(105 cells  per  recipient)  into a  second  set  of Ly5.2+ 
recipients. As control groups for tolerance and allergy 
(bottom),  104   nylon  wool-  enriched  T  cells   from 
 tolerant or naive Ly5.2+ donors were transferred into groups of Ly5.2+ recipients, as depicted. All recipients were 
immunized, re-challenged, and the ear-swelling responses determined. The data shown represents the mean ear-
swelling response (+ SEM) from groups of 5 mice each. Results represent one of two experiments, which yielded 
comparable results. 
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animals orally tolerized to nickel exhibited an increase in DEC-205 expression by DC, an 
increase in CD38+ on B cells, and a striking decrease in the expression of CD40 on DC and, in 
particular, B cells. This tolerogenic phenotype of DC and B cells in the spleens of orally tolerized 
mice conforms not only with the remarkable efficiency of their APC to adoptively transfer the 
tolerance but also with their reduced allostimulatory capacity. DEC-205 is mainly expressed by 
CD8α+ DC in the spleen (27), a subpopulation of DC that has been associated with tolerance 
induction in both CD4+ (28, 29) and CD8+ T cells (30, 31). In the absence of maturation stimuli, 
the DC loaded with Ag through targeting the DEC-205 receptor in vivo were shown to present 
the Ag in a tolerogenic fashion to CD4+ and CD8+ T cells. Thereafter, the T cells underwent an 
abortive activation, and the few cells that survived appeared to be anergic (29, 31, 32). The other 
marker, CD40, whose expression was reduced on the APC of nickel-tolerized mice, is 
constitutively expressed on B cells, macrophages, and DC; when it interacts with CD40 ligand 
(CD40L) on CD4+ T cells, the APC start to upregulate the costimulatory activity and cytokine 
production required for priming and expansion of Ag-specific CD4+ and CD8+ T cells (for 
reviews, see ref. (33)). The CD40-CD40L interaction required for T cell priming has been noted, 
amongst others, in a mouse model of contact hypersensitivity (34). In most models, when the 
CD40-CD40L interaction was interrupted, the administration of Ag failed to induce an immune 
response, but instead induced tolerance (35). The spontaneous down-regulation of CD40, which 
we noted on the APC of nickel-tolerized mice, is comparable with that described for other 
conditions of T cell unresponsiveness in mice and men (36, 37). For instance, in an in vitro 
system with human PBMC (37), CD8+CD28- Ts cells were found to inhibit CD40 upregulation 
on the APC which included B cells. NiCl2, which lacks intrinsic adjuvanticity (ref. (16); Fig. 7), 
apparently promotes the induction of tolerogenic, nickel-presenting APC. Consequently, the 
reduced costimulation of these APC after activation could restrict for T cell priming towards 
nickel. Conceivably, the administration of NiCl2 via the oral route corroborates this effect. Once 
the nickel-specific Ts cells were induced through nickel exposure without costimulation, 
activation of these Ts cells by injection of NiCl2 and H2O2 might have prompted them to inhibit 
the upregulation of costimulatory signals (7, 8, 37) or induce coinhibitory signals (38) on APC. 
Consistent with this, it has been noted recently that the injection of NiCl2 / H2O2 into orally 
tolerized mice failed to upregulate CD80/CD86 expression on the APC in the draining lymph 
nodes (M. Fang, unpublished result). The induction of oral tolerance towards nickel also resulted 
in a notable upregulation of CD38 expression on splenic B cells. CD38 is widely expressed on a 
variety of different cell types, including B cells and T cells (39). The ligation of CD38 induces 
Ca2+ influxes and has been shown to enhance cell proliferation (39, 40). While the functional 
significance of the enhanced CD38 expression by B cells of orally tolerized mice is unknown, 
this observation in consistent with the other findings reported here, which all point to an active 
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contribution by B cells to initiate and transfer tolerance towards nickel. A CD38+ T cell 
population with suppressive properties has been reported (41), but in our model an alteration in 
CD38 expression by T cells could not be detected.  
Like the nickel-specific, anergic Ts cells from orally tolerized donor mice (17), APC also 
proved capable of transferring nickel tolerance, and here, with as few as 102 cells too. This 
transfer of tolerance by APC from orally tolerized donors was not due to a simple passive transfer 
of nickel, but involved intact cells that actively contributed to the induction of tolerance in the 
recipients. Why was it so relatively easy to demonstrate the tolerogenic function of APC in 
orally-induced tolerance to nickel? Nickel ions can be considered as haptens that differ 
qualitatively and quantitatively from conventional Ag: they distribute ubiquitously within the 
body (17), do not need to be processed, and do not have to enter into peptide competition for 
MHC binding sites, because most nickel ion-induced neoantigens result from exogenous 
attachment of the metal ions to MHC molecules and those self peptides that are presented anyway 
(16, 42). Theoretically, each nickel ion could form a neoantigen so that virtually all APC from 
orally tolerized mice would carry those neoantigens. Therefore, both the number of tolerogenic 
APC and the density of nickel ion-induced neoantigens carried by them probably are much higher 
if compared with the APC in those tolerant hosts that presented more common antigens, such as 
foreign peptides. The unusually low numbers, not only of bulk T cells but also APC, which we 
found capable of transferring specific unresponsiveness, accentuates the enormous infectivity 
and, hence, the dominance of T cell tolerance towards nickel. We are aware of only one other 
investigation, in which a comparatively small number of tolerogenic APC sufficed to induce 
tolerance; in that experiment, an injection of only 20 peritoneal exsudate cells, which were 
treated in vitro with Ag and TGF-β, induced tolerance in the recipient mice (43). Interestingly, 
these cells also showed a reduced CD40 expression (44). 
Amongst the donor APC fraction, primarily B cells were found to carry the tolerogenicity. 
Previous studies have demonstrated that B cells from tolerant donor mice can, indeed, induce Ts 
cells upon adoptive transfer (45, 46). For instance, in the ACAID (anterior chamber-associated 
immune deviation) model B cells were found to become tolerogenic through contact with 
tolerogenic macrophages. Even though those B cells were unable to directly suppress the 
development of delayed-type hypersensitivity, they were capable of inducing specific Ts cells 
(45). For this to occur, B cells were required to present the Ag, which they had acquired from the 
tolerogenic macrophages, in the context of Qa-1 (45). Qa-1 is a MHC class Ιb molecule known to 
guide the suppressive activity of CD8+ T cells in a variety of different experimental models (47). 
Also in the ACAID model, the eye-derived tolerogenic macrophages and splenic B cells in the 
marginal zone needed to express CD1 (48); only then were CD1d-reactive NKT cells in the 
Infectious spread of nickel tolerance in vivo 
91 
spleen sufficiently activated to produce IL-10 which, in turn, promoted the differentiation of 
specific Ts cells ((49), reviewed in ref. (44)). It remains to be seen whether or not splenic B cells 
in orally-induced nickel tolerance are also rendered tolerogenic through contact with tolerogenic 
macrophages and/or DC and subsequently induce Qa-1 restricted CD8+ T cells. The similarity 
between the ACAID model and oral tolerance to nickel is further supported by the fact that in 
both models, mice which lack NKT cells, fail to become tolerant ((44); K. Roelofs-Haarhuis, 
unpublished result).  
Infectious tolerance was, indeed, found to account for the spread of tolerance upon cell 
transfer. The infectious tolerance pathway was found to comprise a spread of tolerance from 
Ly5.1+ donor Ts cells to Ly5.2+ host APC, and, vice versa, from tolerogenic Ly5.1+ donor APC 
to Ly5.2+ T cells of the host; a prerequisite for the successful spread of tolerance was that the 
hosts were immunized with NiCl2 / H2O2 before transferring their cells to the second set of 
recipients. As far as Ts cells are concerned, in vivo experiments have shown previously that 
activation of the immune system is required for them to act as Ts effector cells (47, 50). In fact, 
immunization of animals that are thought to harbor Ts cells is an essential element in all assay 
systems used to detect functional Ts cells in vivo (45, 46). The requirement for immunization in 
order to spread the tolerance from Ts cells to APC in vivo has not been reported before. As far as 
the potentially tolerogenic donor APC are concerned, there is only one other model showing a 
requirement of recipient immunization for the tolerance to spread from the APC to T cells (51, 
52). However, in that model a Th2 response was suppressed and not a Th1 response, as in the 
present investigation. How in our model very small numbers of dormant, potentially tolerogenic 
APC (from the Ly5.1+ donors) succeeded to tolerize the naive T cells of the recipients, if the 
recipients were deliberately immunized, needs to be unraveled. The phenomenon, however, is of 
general interest because it can explain how an otherwise immunizing maneuver may be converted 
into its contrary, tolerization. These observations might have implications, for instance, in 
attempts aiming at immunotherapy of tumors.  
Our concept that nickel-specific Ts cells need APC as intermediate cells, in order to confer 
suppressive activity on new cohorts of T cells in the recipients, was further substantiated by the 
following observation. While one-time immunization of recipient mice sufficed to spread the 
tolerance from donor T cells to host APC and, vice versa, from donor APC to host T cells, the 
tolerance spread from donor T cells to host T cells or from donor APC to host APC, actually 
required two immunizations of the recipients. This observation suggests that the tolerance spread 
from T cells to T cells, or from APC to APC, did not simply occur via direct cell-cell contact, but 
first required ‘infection’ of the respective opposite cell type, i.e., APC in the former case and T 
cells in the latter. Recently, the existence of an inhibitory feedback loop between tolerogenic 
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APC and regulatory T cells in vivo has been suggested by Min et al. (53). However, although 
these authors induced transplantation tolerance in vivo, the capacity of the regulatory T cells and 
tolerogenic APC to infectiously spread the tolerance to the opposite cell type was restricted to in 
vitro experiments. Moreover, since T cell responsiveness to major histocompatibility alloantigens 
were tudied in their system, it was not possible to experimentally dissect signal 1 from signal 2 
and, hence, to demonstrate a requirement for costimulation for the tolerance to spread. In the in 
vitro model of infectious tolerance studied by Dieckmann et al. (14) and Jonuleit et al. (15), 
human CD4+CD25+ regulatory T cells required pre-activation (provided in an Ag-nonspecific 
manner) to enable them to spread the tolerance through cell-cell contact to activated conventional 
T cells present in the same culture However, in contrast to those in vitro studies, for the different 
Ag-reactive T cells to meet in vivo and specifically suppress or be suppressed, APC are 
apparently needed to act as bridges and, as discussed before, also as mediators of suppression.  
Taken together, our results demonstrate that infectious tolerance in vivo involves a reciprocal 
interplay of specific Ts cells and tolerogenic APC that is driven by immunization. With regard to 
the consequences of immunization, however, we noted a striking difference between the 
induction phase of T cell suppression (which can be defined as the time period of oral nickel 
treatment) and the effector phase (defined here as the time period following adoptive cell transfer 
and the subsequent immunization of the recipients). Prior to or early on in the induction phase, 
Ag administration together with enhanced costimulation, as inducible by H2O2, would obviate the 
tolerization. The opposite effect is achieved, when Ag and a source of ‘danger’ (26), such as 
H2O2, intrude into an immune system that harbors a few anergic Ts cells or tolerogenic DC and B 
cells: in the effector phase of suppression, immunization with NiCl2 / H2O2 led to a dramatic 
spread of tolerance. Thus, once Ts cells and tolerogenic APC were induced by oral administration 
of nickel, the tolerance proved to be self-enhancing and self-maintaining when the Ts cells and 
tolerogenic APC were exposed to Ag in the presence of danger. Under these conditions 
tolerogenic APC and the Ts effector cells engaged naive T cells and normal APC, respectively, 
into the tolerization process so that unresponsiveness prevailed. 
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ABSTRACT 
Previously, oral administration of nickel to C57BL/6 wild-type (WT) mice 
was shown to render both their splenic T cells and APCs (i.e., T cell-depleted 
spleen cells) capable of transferring nickel tolerance to naive syngeneic 
recipients. Moreover, sequential adoptive transfer experiments revealed that 
upon transfer of tolerogenic APCs and immunization, the naive T cells of the 
recipients differentiated into regulatory T (Treg) cells. Here, we demonstrate 
that after oral nickel treatment Jα18-/- mice, which lack invariant NKT (iNKT) 
cells, were not tolerized and failed to generate Treg cells. However, transfer of 
APCs from those Jα18-/- mice did tolerize WT recipients. Hence, during oral 
nickel administration, tolerogenic APCs are generated which require iNKT cell 
‘help’ for the induction of Treg cells. To obtain this help, the tolerogenic APCs 
must address the iNKT cells in a CD1-restricted manner. When Jα18-/- mice 
were used as recipients of cells from orally tolerized WT donors, the WT Treg 
cells transferred the tolerance, whereas WT APCs failed to do so, although they 
proved tolerogenic upon transfer to WT recipients. However, Jα18-/- recipients 
did become susceptible to the tolerogenicity of transferred WT APCs when they 
were reconstituted with IL-4- and IL-10-producing CD4+ iNKT cells. We 
conclude that CD4+ iNKT cells are required for the induction of oral nickel 
tolerance and, in particular, for the infectious spread of tolerance from APCs to 
T cells. Once induced these Treg cells, however, can act independently of iNKT 
cells.  
 
 
INTRODUCTION 
NKT cells have been identified as a heterogeneous lymphoid lineage that is distinct from 
conventional T cells and NK cells since they express both a TCR and the NK cell marker NK1.1 
(1). The majority of NKT cells express an invariant TCR which in mice is encoded by the Vα14 
and Jα18  (formerly Jα281) gene segment paired with a limited TCR β chain repertoire (2). These 
invariant NKT (iNKT) cells recognize glycolipids in a CD1d-restricted manner (3, 4). CD1 
molecules are non-polymorphic, MHC class I-like surface proteins that are constitutively 
expressed on many lympho-hemopoietic cell types, including DCs and B cells from the splenic 
marginal zone (1, 5). To date only a few iNKT cell-activating glycolipids have been identified 
(6). Examples of these include the well studied α-galactosylceramide (α-GalCer), a component of 
a marine sponge (7), and the disialoganglioside GD3, a cell membrane component in men and 
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mice (4).  
The importance of CD1-restricted iNKT cells in promoting peripheral T cell tolerance was 
suggested after observing the reduced frequency and function of these cells in patients with 
autoimmune diseases (8, 9). The pathogenic significance of this association was then 
experimentally proven by demonstrating that the spontaneous development of autoimmune 
diseases could be prevented by either over-expression (10) or in vivo activation of iNKT cells 
(11), or their adoptive transfer to iNKT cell-deficient mice (12). Furthermore, CD1-reactive 
mouse iNKT cells are required for survival of rat islet xenografts in mice (13), and for the 
induction of anterior chamber-associated immune deviation (ACAID) (14). Moreover, CD1-
reactive NKT cells were also required for the commencement of specific suppression of delayed-
type hypersensitivity (DTH) induced by Ag administration via the oral route or the portal vein 
(15). Although the oral administration of Ag is an established protocol leading to peripheral T 
cell tolerance, its underlying mechanisms remain elusive (16). A consequence of orally-induced 
T cell tolerance, and thus a possible mechanism, is the reported development of regulatory T 
(Treg) cells after high doses of tolerogen (17, 18). Upon TCR engagement, these Treg cells were 
shown to secrete large amounts of IL-4, IL-10, and TGF-β1, cytokines renowned for their ability 
to down-regulate Th1 responses (17). For mechanisms in the immediate stages of tolerance 
induction possible candidates include the rapid cytokine release from activated iNKT cells. These 
cytokines are now considered to modulate immune responses by shifting the balance between Th1 
and Th2 (19). This iNKT cell-mediated modulation of the Th1/Th2 balance could, in turn, depend 
upon the mode or duration of iNKT cell activation. For example, whereas a single injection of α-
GalCer was found to induce a Th1 response (20), multiple injections were observed to promote a 
Th2 response (11). Alternatively, other studies suggest that it is the maturation state of the APCs 
during their interaction with iNKT cells that is the critical aspect for the iNKT cell-mediated 
regulation of the Th1/Th2 balance (21-23). To expand further on this point, it has been shown that 
in contrast to CD40-activated DCs, which polarized iNKT cells to secrete Th1-type cytokines, 
blockade of CD86 costimulation resulted in a shift towards Th2-type cytokines (22, 23). 
Our previous work has shown that oral administration of Ni2+ ions, as present in NiCl2 and 
NiSO4, resulted in a long-lasting immunological tolerance towards the neo-Ags generated by the 
contact allergen nickel (24). Adoptive transfer of 102 bulk T cells or 102 splenic APCs (T cell-
depleted spleen cells) from orally tolerized C57BL/6 wild-type (WT) donors into naive syngeneic 
recipients protected the latter from sensitization to nickel; sensitization in this model is induced 
by the coadministration of NiCl2 and hydrogen peroxide (H2O2) as an adjuvant (24-26). The fact 
that such a small number of T cells or APCs, which contained mainly B cells, from the orally 
tolerized donors succeeded to tolerize naive recipient mice was further demonstrated to occur via 
infectious tolerance. In short, after adoptive cell transfer we observed that tolerance did indeed 
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infectiously spread from the donor T cells and the donor APCs to the APCs and T cells of naive 
recipients, respectively (25). Thus, although infectious tolerance represents an impressive 
amplification loop in the development of peripheral T cell tolerance, the cellular and molecular 
mechanisms involved are far from resolved (27).  
In the present study, we now observe that iNKT cells are not only required for the oral 
induction of nickel tolerance, but also for its infectious spread from tolerogenic donor APCs to 
the naive T cells of the recipients. However, once the oral nickel administration to WT donor 
mice induced Treg cells specific for nickel, the suppressive abilities of these cells was largely 
independent from the presence of iNKT cells in the recipients. 
 
 
MATERIALS AND METHODS  
 
Mice   
Specific pathogen-free female C57BL/6J WT mice, which express Ly5.2 (CD45.2), were obtained 
from Janvier (Le Genest St. Isle, France). Congenic Ly5.1+ (CD45.1+) C57BL/6J (B6.SJL-PtPrca Pep3b 
/BoyJ), IL4-/- (C57BL/6-IL-4tm1Nnt), IL-10-/- (C57BL/6-IL-10tm1Cgn), and INF-γ-/- (C57BL/6-Infgtm1Ts) 
females were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Jα18-/- mice were created 
at Chiba University (Chuoku Chiba, Japan) and backcrossed nine times with C57BL/6 mice (28); they 
were a kind gift from Dr. Balk (Beth Israel Deaconess Medical Center, Harvard University, Boston, 
USA). CD1-/- mice were bred at Beth Israel Deaconess Medical Center and backcrossed six times with 
C57BL/6 mice (29); they were a kind gift from Dr. S. Kaufmann (Max-Planck-Institute of Infection 
Biology, Berlin, Germany). Mice received food and water ad libitum, as described (24, 26), and were 6 to 
14 weeks old at the onset of experiments. 
 
Reagents  
NiCl2·6H2O (further referred to as NiCl2) was purchased from Sigma-Aldrich Chemie (Steinheim, 
Germany), and H2O2 was obtained from E. Merck (Darmstadt, Germany).  
 
Antibodies 
The following anti-mouse mAb were purchased from BD PharMingen (Heidelberg, Germany): APC-
labeled anti-CD3ε (clone 145-2C11), PE- or PerCP-labeled anti-CD4 (clone RM4-5), PE-labeled anti-
CD8β.2 (clone 53-5.8), APC-labeled anti-CD11c (clone HL3), FITC-labeled anti-CD19 (clone 1D3), 
APC-labeled anti-B220 (clone 30-F11), PE-labeled anti-CD45.1 (clone A20), FITC-labeled anti-CD45.2 
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(clone 104), FITC-labeled anti-I-Ab (clone AF6-120.1), PE- or PerCP-labeled anti-NK1.1 (clone PK136) 
and FITC-labeled anti-TCRβ chain (clone H57-597). Magnetically-labeled anti-CD4, anti-CD11c, anti-
CD19, anti-CD90, anti-B220, anti-MHC-II, anti-FITC, and anti-PE mAb were purchased from Miltenyi 
Biotec GmbH (Bergisch Gladbach, Germany).  
 
Oral tolerance induction 
Mice were treated with 10 mM NiCl2 in the drinking water (24) for at least 4 up to a maximum of 8 
wks. Unless mentioned otherwise, they were continuously treated until sacrifice to remove their spleen. 
Age- and sex-matched control mice received tap water without any additional NiCl2. 
 
Immunization of mice 
Mice were immunized as described previously (24, 26). In the case of Ni, mice were primed by 
intradermal (i.d.) injection into both flanks (50 µl each) with either 10 mM NiCl2 in sterile, pyrogen-free 
saline, or 10 mM NiCl2 in saline containing 1% H2O2. In the case of DNFB, mice were primed by painting 
0.5% (w/v) DNFB on the shaved flanks (25 µl each); DNFB was resolved in a 4:1 (v/v) mixture of 
acetone and olive oil.  
 
Challenge for recall and ear-swelling test  
Ten days after immunization, mice were rechallenged by injecting 50 µl of 10 mM NiCl2 in sterile, 
pyrogen-free saline into the pinna of each ear. Forty-eight hours after rechallenge with NiCl2, delayed-type 
hypersensitivity reactions were determined by measuring the increment in ear thickness in comparison to 
the prechallenge values. To determine the prechallenge values, mice were anaesthetised with diethylether, 
whereas for the measurement after challenge, mice were killed by asphyxiation with CO2. Measurements 
were performed in a ‘blind’ fashion (24, 26), using a micrometer gauge (Oditest D 1000 gauge, The Dyer 
Co., Lancaster, PA, USA). The results are shown as the mean ear-swelling response from groups of 5 to 6 
mice, and are expressed in units of mm x 10-2 + SE. 
 
Sorting of T cells and APCs for adoptive transfer studies 
For the transfer of T cells, single-cell suspensions of erythrocyte-free spleen cells, which contained 30-
35% T cells, 60-65% B cells, and 1-2% DC, were passed through nylon wool columns, and then depleted 
of CD11c+, CD19+, and MHC-II+ cells using a magnetic cell sorter (autoMACS, Miltenyi Biotec). To 
transfer APCs, single-cell suspensions of erythrocyte-free spleen cells were depleted of CD4+, CD8+, and 
CD90+ T cells using the autoMACS. The remaining cells, containing 90-95% CD19+MHC-II+ B cells and 
1-3% CD11c+MHC-IIhi DC, will be referred to as APCs. The purity of the resulting T cell and APCs 
fractions was determined by FACS analysis, and were found to be contaminated with less than 0.5% 
CD19+MHC-II+ and CD11c+MHC-IIhi APCs and less than 0.5% CD4+CD3+ and CD8+CD3+ T cells, 
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respectively. In some experiments, purified T cells or total spleen cells were depleted of NK1.1+ cells or 
CD4+ cells by using PE-conjugated anti-NK1.1 mAb and PE-conjugated anti-CD4 mAb, respectively, and 
then counterstained with anti-PE MicroBeads. After the stained cells were applied to the MACS, the 
negative fractions contained less then 0.1 % TCRβ+NK1.1+ cells and CD3+CD4+ T cells, respectively.  
For sequential adoptive transfer experiments on day 0, APCs of primary, orally tolerized donors were 
transferred to a first set of recipients differing in Ly5. On day 1, these recipients were immunized with 
NiCl2/H2O2 and were used 10 days later as donors of T cells to be transferred to a second set of recipients. 
The T cell fraction obtained from the first set of recipients (or the secondary donors) went through an 
additional depletion step which was based on the difference in the markers Ly5.1 and Ly5.2 between the 
primary donors and the first set of recipients (25). This depletion step served to exclude the possibility that 
the tolerance induction in the second set of recipients was simply due to contamination by tolerogenic 
APCs that were carried over from the primary donors. After this depletion, less than 0.1 % of the T cells 
transferred originated from the primary donors. 
 
Adoptive cell transfers 
Cell suspensions, containing the type and the number of cells indicated, were diluted in sterile, 
pyrogen-free PBS and injected i.v. into recipient mice (150 µl). One day later, mice were immunized with 
NiCl2/H2O2 or the control compounds indicated. Ten days thereafter, the recipients were rechallenged at 
the ears, and 48 h later, their ear-swelling response measured. An exception to this protocol was the first 
set of recipients in the experiments on infectious tolerance, since these animals were not rechallenged after 
the immunization. Unless otherwise mentioned, each group of mice evaluated in the ear-swelling test 
consisted of 5 animals. 
  
Statistical analysis  
Statistical significances were determined by analysis of variance (ANOVA) followed by Newman-
Keuls test. 
 
 
RESULTS 
 
iNKT cells are required for the induction of oral tolerance towards nickel, but not for nickel 
sensitization. 
As previously reported (26), intradermal injection of NiCl2 and H2O2 sensitizes C57BL/6 WT 
mice to nickel so that after rechallenge with NiCl2 in the ears they exhibit an increased ear-
swelling response (Fig. 1, bar 1). Jα18-/- mice, which lack iNKT cells (30), also developed an 
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increased ear-swelling after immunization with NiCl2/H2O2 and rechallenge with NiCl2, the 
magnitude of this response being comparable with that of equally treated WT mice (Fig. 1, bars 3 
and 1, respectively). Hence, iNKT cells are not required for either de novo sensitization or 
specific recall of nickel hypersensitivity in vivo. As also shown previously (24), the ear-swelling 
in WT mice immunized with NiCl2/H2O2 and challenged with NiCl2, which had received 10 mM 
NiCl2 in the drinking water for 4 weeks prior to sensitization, was as low as the background ear-
swelling previously observed in mice that were not immunized, but only challenged with NiCl2 
(26). The background response in the WT mice indicates the development of tolerance (Fig. 1, 
bar 2). In contrast, orally treated Jα18-/- mice showed a high ear-swelling after immunization with 
NiCl2/H2O2 and rechallenge with NiCl2 (Fig. 1, bar 2 versus bar 4), indicating that their lack of 
iNKT cells rendered them insensitive to the induction of oral tolerance towards nickel. Orally 
treated Jα18-/- mice that were immunized with NiCl2 in the absence of H2O2 only showed a 
background response (Fig. 1, bar 5). The tolerance induced in Jα18-/- mice by oral administration 
of NiCl2 was specific for Ni ions, because these mice showed a normal immune response to 
DNFB (Fig. 1, bar 6).  
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iNKT cell-deficient mice as donors: iNKT cells are required for the induction of nickel-specific 
Treg cells, but not for the generation of tolerogenic APCs. 
In view of the resistance of Jα18-/- mice to tolerization, we investigated whether both their T 
Figure 1. In contrast to WT mice, Jα18-/- mice fail to 
develop nickel tolerance after a 4-week course of 10 
mM NiCl2 in the drinking water. WT and Jα18-/- mice 
received 10 mM NiCl2 in the drinking water for a 
period of 4 wks or remained untreated, as indicated. 
After immunization with NiCl2/H2O2, and challenge for 
recall with NiCl2 at the ears, their ear-swelling response 
was determined. As negative control, Jα18-/- mice, 
which were orally treated with NiCl2, received i.d. 
injections of NiCl2, instead of NiCl2/H2O2 at the flanks 
(bar 5). To control the specificity, Jα18-/- mice, which 
were orally either treated with NiCl2 or not, were 
immunized and re-challenged with DNFB (bars 6 and 
7); untreated Jα18-/- mice  which were only challenged 
with DNFB served as background control (bar 8). In 
this  and  the  subsequent  Figs.,  the asterisks indicate a 
significant  difference  (*, p  ≤  0.05, **,  p  ≤ 0.01, and  ***, p ≤ 0.001) between the groups compared by brackets. 
Results represent one of two experiments, which yielded comparable results. In this and the following Figs., white 
bars indicate the critical experimental groups. 
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cells and APCs failed to be affected in a tolerogenic way or whether only one of the two cell 
populations failed to respond to the oral tolerance treatment. To address this question adoptive 
transfer experiments were performed in which each cell population was tested separately (24, 25). 
Either 104 splenic T cells or APCs (i.e., T cell-depleted spleen cells) from Jα18-/- donors, which 
had been orally treated with 10 mM NiCl2 for 4 wks, were transferred to naive WT recipients; 
following cell transfer, the latter were immunized with NiCl2/H2O2 at the flanks and rechallenged 
with NiCl2 at the ears (Fig. 2). In contrast to the T cells from orally treated WT donors, those 
from orally treated Jα18-/- donors failed to tolerize naive WT recipients as the latter showed an 
increased ear-swelling response (Fig. 2, bars 2 and 4). Interestingly however, the APCs from 
orally treated Jα18-/- donors did induce tolerance upon transfer to naive WT recipients (Fig. 2, bar 
6). Hence, although iNKT cell-deficient mice failed to be tolerized (Fig. 1) and were unable to 
generate the nickel-specific Treg cells they did possess tolerogenic APCs after this treatment. 
Thus, iNKT cells are required for the induction of nickel-specific Treg cells, but not for that of 
tolerogenic APCs.  
 
iNKT cell-deficient mice as recipients: iNKT cells are non-essential for the suppressor- effector 
function of nickel-specific Treg cells. 
In order to test whether iNKT cells have an essential role in the effector phase of T cell-
mediated suppression, 104 T cells from orally tolerized WT donors were transferred into naive 
Jα18-/- recipients, followed by the usual experimental protocol of immunization with NiCl2/H2O2, 
rechallenge with NiCl2 at the ears, and measurement of the ear-swelling response (Fig. 3). The 
successful transfer of tolerance by unseparated spleen cells from orally treated, but not from 
 
Figure 2. Jα18-/- mice possess tolerogenic APCs after 
the oral administration of nickel, but lack Treg cells. 
Prospective WT and Jα18-/- donor mice were orally 
treated with NiCl2 or remained untreated, as indicated. 
Splenic T cells or APCs, i.e. T cell-depleted spleen 
cells, from these donors were injected i.v. into naive 
syngeneic WT recipients (104 cells/recipient). The 
recipients were immunized and their ear-swelling 
responses determined, as described in the legend to 
Fig. 1. Results represent one of three experiments, 
which yielded comparable results. 
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untreated WT donors, indicates that the lack of iNKT cells in the recipients did not prevent the 
induction of tolerance in the latter (Fig. 3, bars 1 and 2). We then separated WT spleens into T 
cells, which contain NKT cells, and APCs, which lack NKT cells, and used the separated cell 
populations as donor cells. Interestingly, 104 splenic T cells from orally tolerized WT donors 
were capable of transferring the tolerance into Jα18-/- recipients, whereas 104 APCs from the 
same donors proved unable to do so (Fig. 3, bars 4 and 5).  However, in contrast to the previously 
reported tolerance transfer by as few as 102 T cells from orally tolerized WT donors to WT 
recipients (31), tolerance could only be transferred to Jα18-/- mice with 104, but not with 102 or 
103 T cells from orally tolerized WT donors (Fig. 4, bars 1, 2 and 3). A possible explanation for 
the higher number of Treg cells needed to transfer tolerance to Jα18-/- recipients could be the 
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Figure 3. Jα18-/- mice can be tolerized by the transfer of 
Treg cells, but not of tolerogenic APCs, obtained from 
orally tolerized WT donors. Prospective WT donor mice 
were orally tolerized or remained untreated, as indicated. 
Spleen cells, splenic T cells, or APCs from these tolerant 
or naive WT donors were injected i.v. into naive Jα18-/- 
recipients (104 cells/recipient). Twenty-four hours after 
the transfer, all recipients were immunized and their ear-
swelling responses determined, as described in the legend 
to Fig. 1. Results represent one of three experiments, 
which yielded comparable results. 
. 
Figure 4. iNKT cells are not essential for the 
functional activity of Treg cells that were generated in 
mice orally tolerized to nickel. Prospective WT donor 
mice were orally tolerized or remained untreated, as 
indicated. Indicated numbers of splenic T cells, or 
splenic T cells depleted of NK1.1+ cells from tolerant 
or naive WT donors were injected i.v. into naive  
Jα18-/- recipients. Twenty-four hours after the transfer, 
the recipients were immunized and their ear-swelling 
responses determined, as described in the legend to 
Fig. 1. Results represent one of three experiments, 
which yielded comparable results. 
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need for the presence of a small number of iNKT cells. Conceivably, these were supplied as a 
small fraction of iNKT cells present among the WT donor Treg cells that were used to transfer 
nickel tolerance to the Jα18-/- recipients. If this were correct, then the transfer of WT Treg cells 
depleted of contaminating iNKT cells should no Jα18-/- longer be able to tolerize the Jα18-/- 
recipients. However,  104 WT donor Treg cells depleted of NK1.1+ cells were still able to transfer 
the tolerance to Jα18-/- recipients (Fig. 4, bar 5), and, in fact, the dose-response curves obtained 
with undepleted T cells and those depleted of NK1.1+ T cells were quite similar (Fig. 4, bars 1-4 
and 5-8). These results indicate that iNKT cells are not required for the suppressor-effector 
functions of Treg cells that arise in WT mice orally tolerized to nickel. Apparently, once the Treg 
cells have been generated (in an iNKT cell-dependent fashion (Fig. 2)), they are able to perform 
their actions in the absence of iNKT cells. However, why 103 and 102 WT donor Treg cells, 
depleted of NK1.1+ cells or not, did not suffice to transfer the tolerance to the Jα18-/- recipients 
(Fig. 4, bars 2, 3, 6 and 7), remains unresolved. 
 
Sequential adoptive cell transfers: iNKT cells enable the tolerogenic donor APCs to tolerize 
naive T cells and induce specific Treg cells. 
Whereas APCs can acquire tolerogenicity in the absence of iNKT cells (Fig. 2), the transfer of 
104 tolerogenic APCs from WT donors failed to induce tolerance in iNKT cell-deficient 
recipients (Fig. 3). Conceivably, the tolerogenic donor APCs need iNKT cells as an additional 
cell type to allow them to convey the tolerogenic signals to the T cells of the recipient and induce 
new Treg cells. To test this hypothesis, infectious tolerance experiments involving two 
consecutive cell transfers were performed (Fig. 5). In previous experiments with WT mice (25), 
APCs from donors orally tolerized towards nickel were adoptively transferred into a first set of 
recipients. One day later, the latter were immunized with NiCl2/H2O2, and 10 days thereafter their 
T cells, depleted of cells from the primary donors, were transferred to a second set of recipients; 
this was followed by the usual experimental protocol of recipient immunization, rechallenge, and 
measurement of the ear-swelling response. In this way, we have previously established that APCs 
(from orally tolerized Ly5.1+ congenic donors) can infectiously spread the tolerance to naive T 
cells (of WT recipients possessing Ly5.2) and thus enable them to prevent sensitization of the 
second set of Ly5.2+ recipients (25). Here, we aimed to elucidate why transfer of APCs from 
Jα18-/- (Ly5.2+) donors, which were orally treated with nickel, not only induced systemic 
tolerance in WT recipients (Fig. 2), but are also able to render their T cells suppressive. 
Therefore, we adapted the experimental design so that the cells of the primary Jα18-/- donors were 
eliminated from those of the first set of recipients before the second transfer. Because the Jα18-/- 
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mice used as the first donors are Ly5.2+, we used congenic Ly5.1+ C57BL/6 mice, instead of the 
usual Ly5.2+ C57BL/6 WT mice, as the first set of recipients; WT mice served as the second set 
of recipients (Fig. 5A). The obtained results showed that T cells from those first recipients, which 
possessed iNKT cells, acquired suppressive properties from the APCs of the orally treated 
primary donors, irrespective of whether the donor mice were iNKT cell-deficient or not (Fig. 5A, 
bars 2 and 4). Hence, in the presence of iNKT cells in the first recipients, not only the APCs from 
orally tolerized WT donors, which were iNKT cell-sufficient, but also those from orally treated 
Jα18-/- donors could infectiously spread the tolerance to T cells of naive recipient mice. Thus, the 
APCs of orally treated Jα18-/- mice were capable of inducing Treg cells, notwithstanding the fact 
that the orally treated Jα18-/- mice themselves failed to develop systemic tolerance towards nickel 
(Fig. 1) and their T cells failed to be suppressive (Fig. 2).  
Since APCs from orally tolerized WT donors failed to spread the tolerance to naive T cells in 
Jα18-/- recipients (Fig. 3), we further investigated whether this inability to spread the tolerance 
was due to the iNKT cells-deficient environment. For these experiments we reverted back to 
congenic Ly5.1+ C57BL/6 mice as donors and used both Ly5.2+ WT mice (Fig. 5B, bars 1 and 2), 
Figure 5. Tolerogenic donor APCs require iNKT cells 
to spread the tolerance to naive T cells and render 
them suppressive. In A, prospective Ly5.2+ WT (bars 
1 and 2) and Ly5.2+ Jα18-/- (bars 3 and 4) donor mice 
were orally treated with nickel or remained untreated, 
as indicated. Thereafter, APCs from the different 
Ly5.2+ primary donors (104 cells/recipient)  were 
transferred to a first set of congenic Ly5.1+ recipients. 
In B, prospective Ly5.1+ congenic donor mice were 
orally treated with nickel or remained untreated, as 
indicated. Thereafter, APCs from the Ly5.1+ primary 
donors (104 cells/recipient) were transferred into a 
first set of Ly5.2+ WT (bars 1 and 2) or Jα18-/- (bars 3 
and 4) recipients. In both A and B, all recipients were 
immunized with NiCl2/H2O2 within 24 h after transfer. 
On day 11, T cells from the first set of recipients were 
isolated, depleted of primary donor cells, and 
subsequently transferred to a second  set  of  Ly5.2+  
WT  recipients. The latter were immunized, 
rechallenged, and their ear-swelling responses 
determined in accordance with the standard protocol. 
The  displayed  data  represent  the  mean ear-swelling 
 responses + SE from groups of ten mice each. Results represent one of three experiments, which yielded 
comparable results. 
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and Ly5.2+ Jα18-/- mice as the first recipients (Fig. 5B, bars 3 and 4). As can be seen, if the first 
recipients were devoid of iNKT cells, transfer of the tolerogenic APCs failed to render their T 
cells suppressive (Fig. 5B, bar 4). This is evident from the fact that adoptive transfer of T cells 
from Jα18-/- first recipients, which had received APCs from orally tolerized Ly5.1+ donors, to the 
second set of recipients failed to prevent sensitization of the latter. We conclude that iNKT cells 
are indeed required as intermediates for the infectious spread of tolerance from tolerogenic APCs 
to naive T cells in that they promote differentiation of naive T cells into Treg cells. 
 
CD1-deficient mice as donors: tolerogenic APCs need to address iNKT cells in a CD1-restricted 
manner to induce tolerance in WT recipients.  
With the now known relevance of CD1-restricted iNKT cells in tolerance we investigated 
whether tolerogenic donor APCs have to cooperate with the recipient’ iNKT cells in a CD1-
restricted manner in order to induce nickel tolerance. Therefore, APCs from orally treated CD1-/- 
mice were adoptively transferred to WT recipients. Since CD1-/- mice in addition to CD1 also 
lack iNKT cells, they failed, as expected, to be tolerized by oral treatment with 10 mM NiCl2 for 
4 wks (data not shown). Hence, in this respect they were comparable with orally treated Jα18-/- 
mice (Fig. 1). However, differences did emerge when APCs from these orally treated Jα18-/- and 
CD1-/- donors were adoptively transferred into WT recipients (Fig. 6). Whereas the APCs of 
orally treated Jα18-/- donors were able to induce tolerance (Fig. 6, bar 4), the APCs of orally 
treated CD1-/- donors proved unable to do so (Fig. 6, bar 6). Hence, it appears that transferred 
tolerogenic APCs need to activate the recipients’ iNKT cells in a CD1-restricted fashion in order 
to induce tolerance in WT recipients.  
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Figure 6. Tolerogenic APCs need to address iNKT 
cells in a CD1-restricted manner in order to induce 
tolerance in WT recipients. Prospective WT, Jα18-/-, 
and CD1-/- donor mice were orally treated with NiCl2 
or were left untreated, as indicated. Splenic APCs, i.e. 
T cell-depleted spleen cells, from these donors were 
injected i.v. into naive WT recipients (105 
cells/recipient). Twenty-four hours after the transfer, 
the recipients were immunized and their ear-swelling 
response was determined as described in the legend to 
Fig. 1. Results represent one of two experiments, 
which yielded comparable results. 
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NKT cell-deficient mice as recipients: reconstitution with CD4+ iNKT cells renders Jα18-/- 
recipients susceptible to tolerance induction by transfer of APCs from orally tolerized WT 
donors.  
Since tolerogenic APCs appear to require CD1-restricted iNKT cells to infectiously spread the 
tolerance to T cells, we asked whether tolerogenic APCs would be able to tolerize Jα18-/- 
recipients when the latter were reconstituted with iNKT cells. As a source of iNKT cells, 
splenocytes (107) from naive WT donors were used (Fig. 7A). As expected, the transfer of naive 
spleen cells alone failed to tolerize the Jα18-/- recipients, as did the transfer of 105 tolerogenic 
APCs from orally tolerized WT donors (Fig. 7A, bars 1 and 3). However, co-transfer of 
tolerogenic APCs and iNKT cell-containing spleen cells from naive WT donors enabled the 
tolerogenic APCs to exert their tolerogenic function in the Jα18-/- recipients (Fig. 7A, bar 4). The 
results shown in Fig. 7B demonstrate that the iNKT cells within the naive spleens used to 
reconstitute the Jα18-/- recipients were, indeed, the missing cell population. To be more exact, 
tolerogenic WT APCs failed to induce tolerance in Jα18-/- recipients when they were co- 
transferred with naive spleen cells from Jα18-/- donors (Fig. 7B, bar 3) or with either spleen 
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Figure 7. Co-transfer of tolerogenic WT APCs 
together with naive WT spleen cells, which contain 
iNKT cells, induces tolerance in Jα18-/- recipients. 
Prospective WT donor mice were orally tolerized or 
were left untreated, as indicated, and naive Jα18-/- 
mice served as recipients. In A, the Jα18-/- mice were 
injected i.v. with total spleen cells obtained from 
tolerized or naive WT donors (bars 1, 2 and 4) and/or 
splenic APCs from tolerized or naive WT donors 
(bars 3-5). In B, all Jα18-/- mice were injected i.v. with 
splenic APCs from tolerized WT donors. In addition, 
they received either total spleen cells obtained from 
naive WT donors (bar 2), total spleen cells obtained 
from naive Jα18-/- donors (bar 3), or naive WT spleen 
cells depleted of NK1.1+ or CD4+ cells (bars 4 and 5). 
In both A and B, both cell fractions were mixed before 
the co-transfer. Twenty-four hours after the transfer, 
the recipients were immunized and their ear-swelling 
response was determined, as described in the legend 
to Fig. 1. Results represent one of three experiments, 
which yielded comparable results. 
. 
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cells from naive WT donors after the depletion of NK1.1+ cells or CD4+ cells (Fig. 7B, bars 4 and 
5). Therefore, the data suggests that reconstitution with CD4+ iNKT cells enables Jα18-/- 
recipients to become tolerized after transfer of tolerogenic APCs from WT donors.  
 
iNKT cell-deficient mice as recipients: IL-4 and IL-10 producing iNKT cells aid tolerogenic 
APCs to spread tolerance . 
Jα18-/- recipients can be tolerized by the transfer of tolerogenic WT APCs and simultaneous 
reconstitution with iNKT cells (Fig. 7). Therefore, the significance of cytokines secreted by those 
iNKT cells was analyzed. For this purpose, experiments were conducted in which tolerogenic 
WT APCs were transferred with naive iNKT cell-containing spleen cells from either IL-4-/-, IL-
10-/-, or INF-γ-/- donors into Jα18-/- recipients (Fig. 8). The percentage of T cells (both CD3+CD4+ 
and CD3+CD8+), NKT cells (NK1.1+TCRβ+), B cells (B220+MHCII+), and DCs 
(CD11c+MHCIIhigh) among the splenocytes of the three gene-defective strains were virtually  
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identical with those detected in the splenocytes of WT mice, as determined by flow cytometry 
(data not shown). In contrast to the co-transfer of tolerogenic APCs and spleen cells from INF-γ-/- 
donors, which did transfer tolerance (Fig. 8, bar 5), the co-transfer of tolerogenic APCs with 
spleen cells from either IL-4-/- or IL-10-/- donors failed to do so (Fig. 8, bars 3 and 4). Thus, 
tolerogenic APCs appear to depend on IL-4- and IL-10-producing, but not IFN-γ-producing 
iNKT cells to spread the nickel tolerance to naive T cells. 
Figure 8. Tolerogenic APCs require IL-4- and IL-10-
producing iNKT cells to induce tolerance in Ja18-/- 
recipients. Prospective WT donor mice were orally 
tolerized or were left untreated, as indicated. Slenic 
APCs (105 cells/recipient) from tolerant WT donors 
and spleen cells (107 cells/recipient) from naive WT, 
IL-4-/-, IL-10-/-, or INF-γ-/- donors were isolated, mixed 
and injected i.v. into naive Jα18-/- recipients. Twenty-
four hours after the transfer, the recipients were 
immunized and their ear-swelling response was 
determpined as described in the legend to Fig. 1. 
Results represent one of three experiments, which 
yielded comparable results. 
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DISCUSSION 
The results of the present study demonstrate that iNKT cells are required for the induction of 
specific Treg cells in both experimental systems studied here, namely oral administration of 
NiCl2 (no adoptive transfer involved) and the infectious tolerance spread upon adoptive transfer 
in which tolerogenic donor APCs induce specific Treg cells in the recipients. The iNKT cells 
promoting the infectious tolerance were CD4+ and CD1d-restricted and had to be capable of 
producing IL-4 and IL-10, but not IFN-γ. However, iNKT cells were not necessary for either the 
induction of DTH to nickel, the generation of tolerogenic APCs, or the tolerance transfer 
mediated by the fully functional Treg cells generated during the oral tolerization of WT donors. 
The actual where, when, and how iNKT cells interact with other immune cells in the induction 
of oral tolerance and Treg cells is still unknown. One line of thought proposes that the liver could 
function as a second security line after the gut, to ensure tolerance towards Ags that are orally 
ingested (32), and indeed, hepatic NKT cells were shown to be required for the induction of oral 
tolerance in TNBS-induced colitis, a Th1-mediated disease (33, 34). Furthermore, oral 
administration of colitis-extracted proteins, without an exogeneous adjuvant, was shown not only 
to increase the number and cytolytic function of these NKT cells, but also shifted their Th1-
cytokine response to a Th2-type response (35, 36). In vivo, the depletion of NK1.1+ cells can 
prevent this shift, and subsequently prevent the ability to induce tolerance (37). Thus, hepatic 
NKT cells can polarize an orally induced immune response to Ags, which lack costimulatory 
capacity, towards a Th2 response. However, other authors (32) who induced oral tolerance by a 
single, high dose of OVA, reported that iNKT cells were dispensable for the induction of oral 
tolerance.  
Even though Jα18-/- mice failed to develop tolerance and generate specific Treg cells upon oral 
nickel administration, the generation of tolerogenic APCs was not impaired in these iNKT cell-
deficient animals. However, these APCs required signals from iNKT cells in order to generate 
Treg cells, and these findings are comparable to those observed in the ACAID model. In ACAID, 
intraocular CD1+F4/80+ APCs were found to acquire their tolerogenic capacity through contact 
with immunosuppressive factors, such as TGF-β, that are present in the intraocular fluid (38). 
Special features of those tolerogenic APCs are a reduced expression of CD40, upregulation of 
CD1d, a reduced capacity to produce the Th1-inducing cytokine IL-12, and an autocrine 
production of TGF-β. After capturing Ag, the tolerogenic, Ag-transporting APCs were shown to 
migrate from the anterior chamber to the splenic marginal zone. There, they produced a variety of 
chemokines and formed clusters with CD1+ B cells, CD1d-reactive CD4+ iNKT cells, and CD8+ 
T cells (39, 40). From these results a hypothesis emerged that in these cell clusters, IL-10 
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producing CD4+ iNKT cells together with the tolerogenic CD1+ APCs, induced the Ag-specific 
CD8+ Treg cells which were shown to mediate the suppression of DTH responses in ACAID 
(41).  
The number of common features in the ACAID and our model of oral nickel tolerance can be 
extended even further. In both models, the tolerogenic APCs were found to have a reduced 
expression of CD40 (25, 42). iNKT cell production of IFN-γ, which polarizes the Th1/Th2 
balance towards Th1, requires APCs to produce IL-12 in a CD40-dependent manner (23). 
Therefore, in our experiments it is conceivable to assume that the reduced CD40 expression by 
the transferred tolerogenic donor APCs shifted the cytokine production by iNKT cells towards 
Th2 and, thus, prevented the induction of Th1-mediated nickel hypersensitivity in the recipients. 
In the ACAID model, transferred tolerogenic splenic B cells indirectly suppressed the 
recipients’ DTH reaction via the induction of specific Treg cells (43). Similarly, in orally induced 
nickel tolerance splenic APCs, and even the B cells alone isolated from those APCs, were able to 
transfer the tolerance (23). We now show that APCs from orally treated donors must cooperate 
with iNKT cells in order to induce Treg cells (Fig. 5). Therefore, iNKT cells are required for 
mediating the infectious spread of tolerance from tolerogenic APCs to naive T cells. This 
conclusion is further corroborated by the results of the reverse experimental approach, showing 
that the APCs from orally treated Jα18-/- donors succeeded in tolerizing the iNKT cell-containing 
WT recipients (Fig. 2); there, in the presence of iNKT cells, they were able to induce a new 
generation of Treg cells (Fig. 5).  
There are two distinguishable subpopulations of iNKT cells, CD4+ and CD4-CD8- (double-
negative) iNKT cells. In humans, the double-negative iNKT cells selectively produce Th1-type 
cytokines, whereas the CD4+ iNKT cells can produce both Th1- and Th2-type cytokines 
including IL-10 (44, 45). Whereas most studies report a regulatory role of NKT cells in human 
autoimmune diseases (46), Lee et al. failed to find differences in CD4+ iNKT cells frequency and 
IL-4 production between patients suffering from insulin-dependent diabetes and healthy controls 
(47). It should be noted, however, that in the human studies only surface markers of and cutokine 
production by NKT cells were investigated. In contrast, the functional role of NKT cells in T cell 
tolerance has been well established in different animal models (10-15). The present investigation 
performed in mice confirms and extends this concept. We showed that the iNKT cells that are 
required by tolerogenic APCs for the generation of Treg cells are CD4+ and have to produce IL-4 
and IL-10, but not IFN-γ (Fig. 7 and 8). This strongly suggests that it is the CD4+ iNKT cell 
subset, and not the double-negative subset, that is involved here.  
We have demonstrated that iNKT cells are required not only during the induction of tolerance 
Chapter 4  
114 
by oral administration of nickel, which occurs in the absence of costimulation, but also during the 
infectious spread of tolerance which is activated after immunization with NiCl2/H2O2. Although 
this immunization induces a specific DTH reaction in otherwise untreated mice (26), in the 
presence of tolerogenic donor APCs it apparently leads to the production by iNKT cells of IL-4 
and IL-10 which in turn prevents the DTH response. This polarized cytokine response by the 
iNKT cells might be explained by the following two observations. First, the donor APCs show a 
strongly reduced CD40 expression (21), and second, it is these tolerogenic donor APCs 
(majoritively B cells), and not the recipient’s APCs, that are needed to activate the iNKT cells 
(Fig. 6). Due to their reduced CD40 expression, the tolerogenic donor APCs can only activate the 
iNKT cells via a CD40-independent pathway, which consequently leads to a Th2-cytokine 
production by the iNKT cells (48) and, hence, the prevention of DTH responses (49). 
After the transfer of APCs from orally tolerized donors, the infectious spread of tolerance to T 
cells in the recipients requires immunization of the recipient with NiCl2/H2O2 (25). The reason 
why it takes immunization not only with NiCl2, but also adjuvant, i.e., H2O2, for the tolerance 
spread remains yet unanswered. Several mechanisms can be considered to play a role here, in 
particular cell migration to and from the draining lymph node(s). In the first three days after the 
immunization, there is an upregulation of CD80 and CD86 on the DCs of the draining lymph 
nodes (25), and possibly the nickel-reactive host T cells migrate there and undergo an initial 
activation before they are silenced. Whether or not the tolerogenic donor APCs and the iNKT 
cells interact with each other in the draining lymph node, the spleen, or both is unsolved. In any 
event, following our experimental protocol for the study of infectious nickel tolerance (25), the 
‘infected’ T cells of the first recipients were obtained from the recipients’ spleen. 
In conclusion, although in the model studied here the Ag is administered orally wheras in 
ACAID it is injected intro-ocularly, there are a number of striking parallels between both models. 
The infectious tolerance cascade initiated by the transfer of only a few tolerogenic APCs in our 
model of oral nickel tolerance strongly resembles the cellular and molecular cascade underlying 
ACAID. In fact, ACAID might be considered an intra-individual infectious tolerance process. In 
both models, there is a requirement for CD1d-restricted CD4+ iNKT cells which produce IL-10 
(in our model also IL-4) in order to translate and amplify the tolerogenic signals emitted by donor 
APCs to naive T cells and to render these cells suppressive. Extending the knowledge obtained 
from the ACAID model, we further demonstrated that once functional Treg cells were induced by 
the oral nickel administration they exerted their suppressive function independently of iNKT 
cells. Thus iNKT cells serve to build up, but not to exert the specific suppressive mechanisms by 
Treg cells. 
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ALLERGIC CONTACT DERMATITIS TO NICKEL  
In industrialized countries, nickel is a constituent of a great variety of different alloys, 
including stainless steel, and hence occurs in numerous items of daily life, such as custom 
jewelry, buttons, and belt buckles. Because of its ubiquity and potential for sensitization, nickel 
is the most common cause of allergic contact dermatitis (ACD) affecting  mainly the female 
population, 20% vs. 5% in male (1).  ACD is a delayed-type hypersensitivity reaction that is 
characterized by a T cell-mediated damage of keratinocytes and clinically manifests itself as 
eczema (2, 3). In sensitized individuals, ACD can be elicited by dermal exposure to Ni2+ ions as 
present, for instance, in NiCl2 and NiSO4 (3). Albeit it has been reported that even a single skin 
contact with a hapten is sufficient to induce ACD (4), the classical form requires both a 
sensitization phase and an elicitation phase essential for the recruitment and activation of specific 
T cells at the site of skin challenge.   
 
Sensitization phase 
In the sensitization phase, the presentation of nickel-induced neoantigens on antigen-
presenting cells (APCs), together with an up-regulation of costimulatory molecules on these cells, 
induces the differentiation of naive T cells into nickel-specific effector and memory T cells. 
Despite nickel being a common contact allergen and at high concentrations (100 to 300 µM) in 
vitro being able to up-regulate costimulatory molecules on DCs (5), most people exposed to 
nickel-containing items on their skin (13 µmol/cm2/week) fail to be sensitized (6). Similarly, 
injection of NiCl2 into the skin of conventionally-reared mice fails to sensitize the animals (7). 
However, it has been known for decades that nickel allergy usually develops in irritated or 
inflamed skin, for instance, after ear-piercing (8). Conceivably, during contact with the intact skin 
the amount of nickel released from nickel-containing alloys does not suffice to create ‘danger’ (9) 
and thus to up-regulate costimulatory molecules to the level needed for priming of nickel-specific 
T cells. In contrast, due to the enhanced costimulation in the inflamed skin the amount of nickel 
released from alloys would suffice for de novo sensitization without a need for additional 
adjuvant administration.  
Hence, in the intact skin of humans and conventionally-reared mice Ni2+ ions by themselves seem 
to have insufficient capacity to up-regulate costimulation and, thus, provide signal 2 needed for 
the priming of nickel-specific T cells. However, these concentrations are able to generate 
neoantigens, or signal 1, and thus activate already existing nickel-specific T cells, consistent with 
the notion that primed T cells are less dependent on costimulation than naive T cells (7, 10).  
Apart from piercing, direct and prolonged skin contact with nickel-containing custom jewelry 
is a special risk factor for human sensitization because of the sweat produced underneath the 
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jewelry. The sweat has two different effects: first, it enhances the corrosion of nickel-containing 
alloys so that there is an increased release of Ni2+ ions, and second, sweat irritates the local skin 
and increases the permeability for these Ni2+ ions (6). Essentially the same applies to other 
situations of frequent skin contact with nickel-containing items, for instance metal tools. In this 
context it is noteworthy that the prevalence of nickel sensitization in Denmark remarkably 
decreased since the nickel concentration in the few alloys known to have frequent skin contact 
was restricted by the regulatory agency (3). 
Hence, frequent skin contact with nickel-containing alloys is not only a risk factor for the de novo 
sensitization to nickel, but also for the elicitation of ACD in individuals already sensitized. 
 
Nickel-induced neoantigens 
Although certain human CD4+ and CD8+ T cell clones specific for nickel can be restimulated 
in an MHC-independent manner, the vast majority of murine and human T cell clones specific for 
nickel exhibited typical MHC restriction (7, 11, 12). In both mice and men, the nickel-induced 
neoantigens presented by MHC molecules can be formed by either a processing-dependent or, 
more frequently, a processing-independent pathway (7, 13). As far as processing-dependent 
nickel-induced neoantigens are concerned, these appear to be either self-peptides haptenated by 
Ni2+ ions or cryptic self-peptides  (7, 14, 15). It should be realized, however, that those self-
proteins, such as serum albumin, which transport and deliver Ni2+ ions to the APCs, are not the 
ones which provide the haptenated self-peptides ultimately presented as nickel-induced 
neoantigens (7, 14). Precedents for the presentation of cryptic peptides due to metal exposure of 
protein were previously reported for Au3+ and Hg2+ (15, 16). Binding of the heavy metal ions to 
(self-) proteins resulted in conformational changes of the protein, which altered antigen 
processing and, thus, induced the presentation of normally cryptic (self-)peptides.  
Processing-independent nickel-induced neoantigens are generated by direct binding of nickel 
to MHC-embedded self-peptides and/or the MHC molecules themselves (7, 17). Unlike organic 
haptens, Ni2+ ions fail to undergo covalent protein binding, but form coordination complexes with 
protein. Some of these complexes are not very stable (17), explaining why Ni2+ ions show a 
promiscuous binding to proteins, such as serum albumin and MHC-embedded self-peptides. 
Within a given metal-protein coordination complex, one Ni2+ ion may bind to up to six protein 
side-chains as ligands. As the chemical nature of the preferred ligands shows a considerable 
variability, in principle each of these ligands may have a different chemical nature, the basic 
chain of histidine just being one of the variety of different candidates. Therefore, the protein side-
chains engaged in complex formation by Ni2+ may vary from complex to complex (9). As a 
consequence, Ni2+ ions probably can induce a great variety of different neoantigens (Fig.1).  
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Ni 
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Fig. 1. Concept of Ni2+ ions acting as a ‘bioinorganic glue’ 
in the MHC-TCR interaction, based on the work of Weltzien 
and colleagues (9, 22). Ni2+ ions are loosely bound (7, 13) to  
the surface of an APC or target cell by engaging a sub-
maximal number of ligands provided by MHC-embedded 
self-peptides and/or a conserved portion of the MHC 
molecule itself on (18). These Ni2+-induced neoantigens are 
recognized by the TCR so that the TCR engagement results 
in signalling and T cell activation. This would not be the 
case in the absence of Ni2+ ions, as the TCR affinity for 
MHC-embedded self-peptides is too low. 
 
 
T-cell recognition of nickel-induced neoantigens 
There is evidence for a preferential engagement of certain nickel-binding TCR elements in the 
formation of the bimolecular complexes and, hence, the T-cell recognition of nickel-induced 
neoantigens (Fig. 1). The CD4+ T cells obtained from the peripheral blood or skin of patients 
with severe nickel-induced ACD were found to exhibit a significant over-expression of certain 
TCR Vβ17 sequences capable of binding nickel (18-20). Hence, Ni2+ ions may, indeed, form and 
stabilize inter-molecular bridges, such as those between a nickel-binding TCR on the one hand 
side and a certain MHC-embedded self-peptide and/or a conserved portion of the MHC molecule 
on the other hand side (18). This results in signaling between a given T cell and an APC, which 
would not occur in the absence of nickel. Due to positive selection in the thymus all peripheral T 
cells possess a basal anti-self affinity. With certain T cell clones it has been shown that this basal 
affinity could be enhanced by those nickel-induced inter-molecular bridges (18). 
In other words, Ni2+ ions seem to be able to induce a great variety of different neoantigens. In 
addition nickel can act as a multivalent bioinorganic glue when applied to the TCR-MHC/peptide 
interaction. Taken together, this could explain the relatively high frequency of nickel-reactive T 
cells reported (18). 
 
Elicitation phase 
In the elicitation phase after dermal re-exposure to contact allergen, the migration of specific 
effector T cells in humans is mediated by the skin-homing receptor CLA (cutaneous lymphocyte-
associated antigen) (21, 22). The murine homologue of CLA has not been identified yet, but in 
both species the accumulation of the different subpopulations of effector T cells was shown to be 
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guided and regulated by their differential expression of chemokine receptors (23). Clinically, this 
accumulation may result in the typical eczema seen in patients with ACD. 
Cavani and  coworkers demonstrated that specific, INF-γ-producing Tc1 and Th1 cells induce 
cytotoxic damage of nickel-loaded human keratinocytes (2). Due to the high expression of the 
chemokine receptor CXCR3 on nickel-specific Tc1 and Th1 cells, the recruitment of these 
effector T cells to the nickel-challenged human skin is guided by its ligands, CXCL9 (Mig), 
CXCL10 (IP-10), and CXCL11 (I-TARC) (23). However, the existence of nickel-specific type 1 
T cells alone cannot account for the pathogenesis of nickel-induced ACD, because T cells with 
the same characteristics have also been isolated from peripheral blood of non-allergics (24). 
Although previous studies have suggested that IL-4-producing Th2 cells can suppress Th1 
responses, Borg et al. found, surprisingly, that the synthesis of IL-4 and IL-5, but not of INF-γ 
and TNF-α, by peripheral blood T cells from nickel-allergics was significantly higher than that 
found in non-allergic individuals (25). Consistent with this, nickel-specific Th2 cells were 
detected in nickel-induced ACD skin lesions (26, 27), and, although these cells were not directly 
involved in the cytotoxic effector mechanism, they were found to enhance the ACD (28). 
Albanesi et al. showed that IL-4 acts synergistically with INF-γ on the activation of human  
keratinocytes and that this, in turn, leads to an enhanced secretion of CXCR3 ligands, and, thus, 
enhances the recruitment of CXCR3+ nickel-specific effector T cells (28). The recruitment of 
these Th2 cells is mediated by the constitutive expression of CCR4 and the inducible expression 
of CCR8 (28). Triggering of CCR4 by the chemokines CCL17 (TARC) and CCL22 (MDC) 
augments the integrin-dependent adhesion of T cells to endothelial intercellular adhesion 
molecule 1 (ICAM-1) expressed by activated endothelium (29). The ligand of CCR8, i.e., CCL1 
(I-309) is expressed early on in skin lesions of individuals with nickel-induced ACD, but not in 
unaffected skin lesions (30).  
Hence, not only the prototypic nickel-specific effector Tc1 and Th1 cells, but also nickel-specific 
Th2 cells are involved for the development of nickel-induced ACD. 
 
 
IMMUNE TOLERANCE TOWARDS NICKEL 
The clinical observations mentioned above (i.e., nickel contact via the intact skin vs. inflamed 
skin) as well as animal experiments indicate that the conditions under which the immune system 
first encounters nickel ions are decisive for all future re-encounters with this potential sensitizer. 
Presumably, the anatomical site where nickel is first recognized by an individual’s T cells also 
conditions the immune response to this potential sensitizer. Whereas a reduced dermal nickel 
contact decreased the incidence of newly sensitized individuals to nickel (3), some investigators 
reported that a reduced environmental exposure to nickel had the opposite effect, i.e., increased 
the incidence of nickel ACD (32). This does need to be conflicting evidence though. As most of 
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the body burden of nickel is taken up via the oral route (33) and as this route is known to favor 
the induction of tolerance, it is likely that the reduced incidence of ACD associated with high 
environmental nickel exposure was caused by an increased oral uptake of nickel. This assumption 
is based on epidemiological findings in humans and experiments in animals. In humans, oral 
contact with nickel-releasing dental braces reduced the incidence of nickel-sensitized individuals, 
but only if fitting of the braces preceded the potentially sensitizing events, such as ear-piercing 
(34).  
 
Role of immunologically privileged sites in oral tolerance 
It remains an open question why the nickel released from dental braces and taken up 
orally should be able to exert significant protective effects, when quantitatively its contribution to 
the total daily uptake of nickel from food is marginal (see Table 2, column 1). There are two, 
mutually not exclusive possibilities to account for this difference. First, nickel ions in the food are 
complexed to proteins and this could partly hinder their release and absorption via the intestinal 
mucosa. The protein: nickel ion relation in the oral cavity is supposed to be lower, probably 
leading to a higher local concentration and absorption rate of nickel ions via the oral mucosa. 
Second, the anatomic site of nickel uptake might contribute to the greater tolerogenicity of nickel 
released from the dental braces. In contrast to the nickel in daily food, which does not remain in 
the oral cavity for an extended period of time and is mainly absorbed via the intestine, much of 
the nickel continuously released from the dental braces is presumably absorbed via the buccal 
mucosa in the cheek pouches. In hamsters, the cheek pouch is known to be an immunologically 
privileged anatomic site (34). By definition, antigen administration at an immune-privileged site 
fails to sensitize, but induces a state of tolerance.  
If we suppose that the buccal mucosa in men is also an immunologically privileged site, this 
would explain why nickel entering the body through this site can be even more tolerogenic than 
larger amounts of nickel taken up from the intestine. Hence, the above mentioned observations 
from epidemiological studies can be explained by this concept of immunologically privileged site 
in oral tolerance. 
 
 
ANIMAL MODELS FOR ORALLY INDUCED TOLERANCE TO NICKEL 
 
Induction of oral tolerance to nickel in mice 
Three groups of investigators developed mouse models of nickel hypersensitivity and 
demonstrated that oral nickel administration prevented the subsequent sensitization to nickel 
(Table 1).  
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Table 1:  Overview of different mouse models of oral tolerance to nickel.  
 Model described by 
 van Hoogstraten et al. 
(37) 
Ishii et al. (38) Artik et al. 
(36) 
Environment metal-free cages metal-containing cages metal-
containing cages 
Sensitization  2.4 µmol NiSO4  
in CFA 
20% NiSO4 solution 
covered and fixed with a 
bandage to the clipped 
flanks for 7 days 
2 µmol NiCl2  
in H2O2 
Tolerization regimen 
(in the drinking water)  
0.75 mM NiSO4  
for 3 weeks 
20 mM NiSO4  
for 7 weeks 
10 mM NiCl2  
for 4 weeksa  
a  Oral treatment with less than 10 mM NiCl2 or for less than 4 weeks were, but failed to induce complete 
tolerance (36).   
 
Dose dependence of orally- induced nickel tolerance 
As already mentioned, a high environmental nickel exposure of humans was found to be 
associated with a reduced incidence in hypersensitivity to nickel (32). That, indeed, there is an 
inverse causal relationship between oral nickel exposure and nickel hypersensitivity was proven 
by the pioneering work of van Hoogstraten et al. (39) and, later, the findings of  Wu et al. (X.Wu, 
unpublished data). Van Hoogstraten et al. wondered whether the relative resistance of 
conventionally-reared mice to the induction of nickel hypersensitivity could be due to oral uptake 
of nickel ions released from the metal covers of the cages and the drinking bottles covered with 
stainless-steel lids (39). Indeed, when the continuous oral uptake of nickel was reduced by 
breeding the mice for two generations under conditions of greatly reduced ambient nickel, their 
sensitization to nickel (Ni2+ ions in CFA emulsion) was greatly facilitated (37). The reduction of 
environmental nickel was achieved by replacing the stainless-steel cage covers and the stainless-
steel lids of the drinking bottles by glass items. Mice bred under these conditions were defined as 
nickel-free mice by the group of van Hoogstraten (39). Noteworthy, these mice were still exposed 
to a basal level of nickel, as provided, for instance, by the normal diet and tap water they 
received. Therefore, we prefer to term them Nivery low mice (cf. Table 2).  
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Table 2: Overview of oral nickel uptake by humans and different kinds of C57BL/6 mice used to study the 
dose dependence of orally induced tolerance. 
 
Humans Nivery low mice Nilow mice Nihigh mice 
Environment 
cover of the cage 
lid of drinking bottles 
Daily oral uptake  
by     food 
drinking water 
dental brace 
 
 
 
 
5 µg/kga 
5-150 ng/kga 
20 ng/kga 
 
plastic  
glass 
 
5-10 µg/kgc 
≤ 19 ng/kgb 
 
stainless steel 
stainless steel 
 
5-10 µg/kgc  
163 ng/kgb  
 
stainless steel 
stainless steel 
 
5-10 µg/kgc  
118 mg/kgb 
a
 K. Heim, NiPERA; personal communication, b ref (36), c X. Wu et al., unpublished data 
 
Recently, X. Wu compared the T cell reactivity to nickel of three types of C57BL/6 mouse 
(Table 2, columns 2 to 4): (i) conventionally-reared animals which received additional nickel (10 
mM NiCl2 for 4 weeks) in the drinking water (Nihigh mice), (ii) untreated conventionally-reared 
animals (Nilow mice), and (iii) animals that were reared for two generations in a nickel-poor 
environment by using cage covers and water-bottle lids made from plastic and glass, respectively 
(Nivery low mice). As already mentioned, the Nihigh mice showed complete, long-lasting tolerance, 
whereas the Nilow mice could be sensitized by injecting them with NiCl2 together with H2O2, 
albeit not by injection of NiCl2 alone (36). Interestingly, however, the Nivery low mice could be 
sensitized not only with NiCl2 in H2O2, but also with NiCl2 alone (X. Wu, unpublished data). 
Hence, in conventionally-reared mice the oral uptake of nickel ions, which are released from the 
stainless-steel cage covers and water bottle lids by saliva in combination with gnawing and 
licking, apparently induces some degree of T cell tolerance which cannot be broken by the 
injection of NiCl2 alone. Indeed, the Nilow mice were shown to possess a certain nickel-specific 
Treg cell activity. Upon adoptive transfer of Nivery low recipients, splenic T cells from Nilow donors 
were able to suppress the in vivo induction and reactivation, respectively, of the nickel-specific T 
memory/ effector cells induced in the Nivery low recipients by injection of NiCl2 alone. However, 
these Treg cells, in contrast to the ones of Nihigh mice, failed to suppress the T cells of those 
Nivery low mice sensitized by injection of NiCl2/H2O2 (X. Wu, unpublished data). It is unknown at 
the present whether the different suppressive capacity of the Treg cells obtained from Nilow mice 
and Nihigh mice is due to differences in their numbers or their quality.  
From these findings we conclude that the higher the oral uptake of nickel the higher the 
suppressive capacity of Treg cells and, hence, the more difficult it is to sensitize to nickel (Fig. 
2). 
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Fig. 2. Schematic view of the inverse 
causal relationship between oral nickel 
exposure, Treg cell activity, and the ease 
of being sensitized to nickel (based on the 
unpublished date of X. Wu et al.). The 
higher the oral uptake of nickel, the higher 
the suppressive capacity of Treg cells and, 
hence, the greater the difficulty of being 
sensitized.  
 
 
THE INDUCTION PHASE OF TREG CELLS IN NiHIGH MICE 
A considerable body of evidence strongly suggests that the regulatory capacity of Treg cells 
which arise in the periphery is acquired through contact with antigen presented by tolerogenic 
APCs, in particular DCs (10). We have shown that orally induced nickel tolerance starts with the 
generation of tolerogenic APCs (i.e., T cell-depleted spleen cells), which can transfer the 
tolerance into naive recipients (40). Although it should be noted that the majority of cells among 
these T cell-depleted splenocytes are B cells, they also contain tolerogenic DCs. Both cell 
populations were found to display a reduced expression of CD40 and a reduced allostimulatory 
capacity (41).  
The reduced expression of CD40 on tolerogenic DCs could be crucial for the generation of 
Treg cells, because it reduces the CD40-dependent secretion of the Th1-cytokine IL12 by DCs. In 
this regard, the tolerogenic DCs were comparable with those described in other tolerance models 
in which tolerogenic DCs are characterized by a reduced capacity to produce the Th1-inducing 
cytokine IL-12, a reduced expression of CD40, the expression of CD1, and an enhanced 
production of IL-10 and/or TGF-β (42).  
An additional cell population which could mediate in generation of Treg cells are invariant 
NKT cells. These NKT cells express a limited αβTCR repertoire which is dominated by the 
invariant Vα14-Jα18 TCR (formally Vα14-Jα281 TCR) in mice and the Vα24-Jα15 TCR in 
humans (43). Through this TCR, iNKT cells recognize glycolipid antigens presented by the non-
polymorphic, MHC-class-I-like protein CD1d. When activated, iNKT cells rapidly produce large 
quantities of IFNγ, IL-4, IL-10 and yet other cytokines which allows them to exert strong 
regulatory activity (43). The reduced expression of CD40 on tolerogenic CD1d+APCs could 
trigger the CD1-restricted CD4+CD8- iNKT cells to produce IL-4 and/or IL-10, but not CD40-
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dependent INF-γ, which, in turn, leads to the generation of Treg cells. The increased expression 
of IL-4 and the reduced expression of INF-γ might shift the Th1-mediated ACD reaction towards 
a Th2-response.  
 
 
Fig.3. Scheme of the induction phase of Treg cells in Nihigh mice. For the 
 induction of Treg cells a complex interplay between various cell types is needed. First Ni-loaded 
tolerogenic B cells have to undergo apoptosis which is mediated by CD4+ iNKT cells. These 
apoptotic bodies are taken up, processed and presented in a tolerogenic fashion by CD8α+ DCs 
towards T cells thereby rendered to the regulatory phenotype. For more detailed information on this 
process see the text “The induction phase of Treg cells in Nihigh mice” 
 
Since the iNKT cells need to express FasL in order to convey orally-induced nickel tolerance 
from tolerogenic APCs to Treg cells (M. Nowak and F. Kopp, unpublished data), it is 
conceivable that splenic iNKT cells recognize CD1+CD40low tolerogenic, nickel-loaded 
passenger cells, such as B cells, and kill them by Fas/Fas-L-mediated apoptosis. This would 
explain our observation that pure B cells from tolerized donors were able to transfer tolerance 
(41). We assume that these B cells undergo apoptosis and thereupon are taken up by CD8α+ DCs, 
which present nickel-induced neoantigens in a tolerogenic fashion by both their MHC class I and 
II molecules to CD8+ and CD4+ T cells, respectively. Some studies showed that the 
CD8α+CD11c+ DCs can enhance Th1 differentiation, whereas they transmit a tolerogenic signal 
to T cells following the uptake of apoptotic cells (44, 45). In fact, it is known that apoptotic B 
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iNKT 
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“apoptotic bodies”  
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Apoptosis 
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cells are sampled by splenic marginal zone CD11c+ DCs of the recipients (46). After uptake and 
processing of the apoptotic bodies, these DCs acquire CD8α and mobilize towards T-cell areas of 
splenic follicles (46). Although CD8α+CD11c+ DCs are known to suppress an ongoing immune-
response, induce specific CD4+ Treg cells, and cross-tolerize CD8+ T cells, they fail to induce 
Treg cells after treatment with an agonistic anti-CD40 Ab. Hence, the tolerogenic capacity of 
CD8α+CD11c+ DCs upon uptake of apoptotic vesicles may be due to an impaired maturation 
(44).   
Participation of splenic macrophages in Treg cell induction cannot be excluded since upon 
phagocytosis of apoptotic cells, macrophages secrete IL-10 and TGF-β, whereas the uptake of 
necrotic cells results in their secretion of IL-12 (47). The secretion of IL-10 or TGF-β  by the 
macrophages and of IL-10 by the iNKT cells modified DCs towards a tolerogenic phenotype (48, 
49), in addition, IL-10 is known to tolerize T cells directly (50). 
In conclusion, during the induction phase of oral nickel tolerance, the nickel-loaded apoptotic 
passenger cells, such as B cells, the iNKT cells, macrophages and tolerogenic DCs seem to create 
a immunosuppressive micro-environment which may lead to the induction of nickel-specific Treg 
cells.  
 
 
THE EFFECTOR PHASE OF NICKEL-SPECIFIC TREG CELLS IN NiHIGH 
MICE 
 
T cell anergy 
Clonal anergy of T cells is a growth arrest state induced by an impaired triggering of the IL-2 
receptor pathway. Hence, T cells become anergic when they are weakly or incompletely 
activated, as is the case when they receive a strong TCR signal in the absence of costimulation or 
are restimulated by a low-affinity ligand in the presence of costimulation (51). Anergic T cells 
are functionally inactivated and unable to initiate a productive response even when antigen is 
encountered in the presence of full co-stimulation. Anergy of nickel-reactive T cells is part of the 
complex mechanism underlying the nickel tolerance in Nihigh mice (36). This conclusion is based 
on the following experimental findings: (i) impaired in vitro restimulation by NiCl2 of T cells 
from Nihigh mice which were injected with NiCl2/H2O2 (36); (ii) reversibility of this defect by 
addition of exogenous IL-2 (X. Wu, unpublished data); and (iii) the fact that oral nickel tolerance 
in the Nihigh mice developed in the presence of nickel-induced neoantigen (signal 1) and the 
absence of costimulation (signal 2). 
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Taams and coworkers, who induced T cell anergy by T-T presentation of antigen in vitro, 
demonstrated that there are at least three different levels of anergy (52). (i) A low (suboptimal) 
dose of tolerogen induced a reversibly anergic T cell phenotype without suppressive capacity. (ii) 
An intermediate dose of tolerogen induced a reversibly anergic phenotype with suppressive 
capacity. (iii) A high dose of tolerogen induced an irreversibly anergic and suppressive 
phenotype; these suppressive T cells could impair the capacity of APCs to up-regulate 
costimulatory molecules. Comparable dose-dependent mechanisms might be involved in oral 
nickel tolerance. As explained earlier, the higher the oral uptake of nickel the more difficult it is 
to sensitize to nickel and, thus, the higher the suppressive capacity of Treg cells (see Fig. 2). This 
idea is further supported by the finding that transfer to Nilow recipients of T cells from the Nihigh 
mice, but not from the Nilow mice, can impair the up-regulation of costimulatory molecules on the 
DCs that is seen normally when Nilow mice are immunized with NiCl2 and H2O2  (M. Fang, 
unpublished data). This capacity of the Treg cells from Nihigh mice to prevent costimulation could 
account for the failing nickel sensitization seen in both the Nihigh mice themselves and the 
recipients of their Treg cells (36). 
Treg cells obtained from mice exposed to different doses of oral nickel also differ in the 
capacity to suppress the secondary immune response, i.e., costimulation-independent in vitro 
restimulation of nickel-specific effector T cells. Nilow mice contain T cells which can suppress the 
restimulation of T cells primed with NiCl2 alone, but not with NiCl2 and H2O2. In contrast, the 
Treg cells from Nihigh mice were found to suppress both the restimulation of effector T cells 
induced by NiCl2 alone, but also by NiCl2 and H2O2 (X. Wu, unpublished data).  
In conclusion, nickel-specific Treg cells not only suppress costimulation, which can prevent the 
induction of a primary nickel response, but also the restimulation of nickel-primed effector/ 
memory T cells and, hence, the secondary nickel response. 
 
Regulatory T cells 
Different groups of investigators tried to characterize the phenotype of nickel-specific Treg 
cells. Van Hoogstraten et al. reported that oral nickel tolerance in their Nihigh mice was mediated 
by CD8+ T cells (37). Consistent with the finding of van Hoogstraten et al. (37), the tolerance 
induced in our Nihigh mice (36) is also mediated by CD8+ T cells, since 103 splenic CD8+ T cells 
from such donors transferred the tolerance to naive Nilow recipients (K. Roelofs-Haarhuis, 
unpublished data). However, for the transfer of tolerance with only 102 T cells, the lowest 
number of T cells from Nihigh donors effective, cotransfer of 5 x 101 CD8+ and 5 x 101 CD4+ T 
cells from the same donors was required (36). This raises the question as to the purity of the 107 
and 103 CD8+ T cells transferred by van Hoogstraten et al. (37) and Roelofs-Haarhuis 
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(unpublished data), respectively. Conceivably, both of these CD8+ T cell populations still 
contained a small number of CD4+ T cells which sufficed to cooperate with the CD8+ T cells in 
the tolerance transfer. Hence, Tregs of Nihigh mice definitely contain CD8+ T cells and a 
contribution of CD4+ T cells to their suppressor activity is likely, but needs to be studied more 
thoroughly. Synergism between so-called suppressor-inducer CD4+ T cells and suppressor-
effector CD8+ Treg cells was repeatedly described in the older literature, but the mechanism of 
their interaction remained obscure (53). More recently, progress in this matter was reported by 
Ferguson et al. (44) who induced tolerance to TNP by i.v. injection of TNP-coupled syngeneic 
splenocytes. Adoptive transfer of the tolerance by CD8+ Tregs required either the cotransfer of 
TNP-specific CD4+ T cells from the same donors or injection into the recipient mice of agonistic 
anti-CD40 mAb (44).  
These findings suggest that the CD8+ Treg cells act as suppressor-effector cells, but in order to 
become effective they require CD40-dependent help from CD4+ T cells, which act as suppressor-
inducer cells.  
 
 
PARALLELS BETWEEN ORAL NICKEL TOLERANCE AND ACAID 
In trying to put the different pieces of the nickel tolerance puzzle together so that a 
comprehensive picture emerges, we compared the different experimental findings obtained in the 
Nihigh mice with those obtained in other tolerance models described in the literature, in particular 
the ACAID model which has been analyzed by the Streileins and their coworkers and the group 
of Niederkorn (reviewed in (42, 54)). They elaborated the mechanism by which inoculation of a 
minute amount of antigen into the anterior chamber (a.c.) of the eye, a classical immune-
privileged site, leads to the generation of CD8+ suppressor-effector and CD4+ suppressor-inducer 
Treg cells. The CD8+ Tregs induce ACAID by suppressing the elicitation of a Th1 inflammatory 
response to that antigen or, in other words, the secondary T cell response in vivo. In more detail, 
it was demonstrated that the injected antigen is taken up by ocular F4/80+ mononuclear APCs, 
which have a tolerogenic phenotype because they reside in an environment with high 
concentrations of suppressive cytokines, such as TGF-β. After capture of the antigen, the ocular 
APCs migrate to the splenic marginal zone where they secrete MIP-2, which recruits iNKT cells 
to that zone. These iNKT cells, in turn, are triggered in a CD1-restricted manner by the CD1+ 
F4/80+ APCs and CD1+ marginal zone B cells to release RANTES. RANTES was shown to 
recruit additional APCs and T cells to the iNKT cells in the splenic marginal zone. Thus, through 
the secretion of the chemokines MIP-2 and RANTES the number of tolerogenic cell clusters, 
which included CD1+ F4/80+ macrophages or DCs, CD1+ B cells, iNKT cells, and CD8+ T cells, 
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was increased. The iNKT cells within the cell clusters also released IL-10, a cytokine known to 
be essential for the differentiation of naive CD8+ T cells to CD8+ suppressor-effector Treg cells 
(reviewed in (42, 54)). In addition, CD4+ T cells are required as suppressor-inductor cells for the 
generation of the CD8+ Treg cells (42), but the exact phenotype of CD4+ Treg cells in ACAID is 
still controversial. Whereas Skelsey et al. provided evidence that the IL-10 is produced by 
classical CD4+CD25+ Treg cells (55), recent data of Nakamura et al. indicate that these CD4+ 
Treg cells are, in fact, IL-10-producing CD4+CD8- iNKT cells (56). 
The striking similarities between ACAID and oral tolerance exist at several different levels, 
one of them being the level of the APCs. Both the APCs isolated from gut-associated lymphoid 
tissue (i.e., T cell-depleted cells from the Peyer’s patches) of animals fed with a high dose of 
antigen (57) and the APCs migrating from the a.c. after antigen inoculation (42) were 
characterized by a reduced capacity to produce the Th1-inducing cytokine IL-12, and enhanced 
secretion of TGF-β and/or IL-10, the expression of CD1, and a reduced expression of CD40. 
Furthermore, in both models CD1-restricted CD4+CD8- iNKT cells are needed for the generation 
of CD8+ Treg cells (40, 42). A difference between both models is the cytokines produced by 
those iNKT cells. In ACAID, the iNKT cells only need to produce IL-10, whereas in the oral 
nickel tolerance model, the iNKT cells need to produce both IL-4 and IL-10 to spread the 
tolerance from the transferred B cells of Nihigh mice to the naive T cells of Nilow mice (40, 42). 
In the past, there have been doubts as to the general validity of ACAID as a model to study the 
mechanisms involved in peripheral T cell tolerance. These concerns can now be resolved, since it 
unfolds that the mechanisms operating in ACAID are so impressively similar to those operating 
in orally induced tolerance. 
 
 
INFECTIOUS TOLERANCE  
A hallmark of peripheral T cell tolerance is its dominance, and this is based on the capacity for 
specific suppression. Following the adoptive transfer of T cells from specifically tolerized 
donors, the recipients’ own T cells not only became unresponsive to immunization with the 
specific antigen studied, but they also acquired the capacity for suppression of new cohorts of 
specific T cells. The term infectious tolerance has been coined for this phenomenon observed in 
vivo (58) and, of course, it is reminiscent of the tolerance spread from one cell type to another 
seen in vitro (59). A formal demonstration that the specific unresponsiveness and suppressive 
capacity, indeed, were transmitted from the donor Treg cells to T cells of recipient mice has come 
from adoptive transfer experiments that used genetic markers to distinguish donor cells from host 
cells (60).  
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In oral nickel tolerance bulk T cells from Nihigh donors proved to be able to transfer the 
tolerance to Nilow recipients. The finding that only 102 cells were needed to transfer tolerance, 
strongly suggested that a powerful amplification mechanism has to take place in the recipient. 
Indeed, an infectious tolerance spread was formally shown to underlie the tolerization of the 
recipient (41).Surprisingly, not only the T cells of Nihigh donors, but also their APCs (i.e., T cell-
depleted spleen cells) and even purified B cells can transfer nickel tolerance, indicating that 
several different cell types are involved in oral nickel tolerance and its infectious spread. The role 
of APCs as intermediates in the conveyance of tolerance from Treg cells to naive T cells was 
investigated in more detail. 
 
Infectious spread of nickel tolerance from donor Treg cells to recipient’s APCs.  
 As mentioned before, after transfer of bulk T cells from Nihigh donors to a first set of Nilow 
recipients rendered the latter unresponsive to sensitization with NiCl2/H2O2 (36). In addition, the 
Nilow recipients were found to contain tolerogenic APCs, which could transfer the nickel 
tolerance to a second set of Nilow recipients (41). Albeit they were unresponsive to the nickel 
sensitization and contained the tolerogenic APCs, the first recipients of the Treg cells failed to 
contain nickel-specific Treg cells of their own detectable in the sequential transfer system (41). 
These  experiments clearly indicate that in vivo nickel tolerance fails to be spread by the direct T-
T cell contact observed in vitro (59). We think that in vivo APCs are indispensable as mediators 
for the infectious spread of tolerance from activated Treg cells to naive T cells (41). In this 
context (i.e., in the recipients of nickel-specific Treg cells) the term APCs is meant to primarily 
connote DCs; in contrast, in the Nihigh donors this term is used to primarily connote B cells.  
Both CD4+ and CD8+ Treg cells carry the profound, long-lived tolerance of the Nihigh mice 
(36), but a more precise phenotype of these cells is missing. In the literature, different 
subpopulations of CD4+ Treg cells have been described which can render APCs tolerogenic by 
using different mechanisms. On the one hand side there are Th3 cells producing TGF-β (61) and 
Tr1 cells producing IL-10 (50) and on the other hand side there are CD4+CD25+ Treg cells (62). 
Th3 and Tr1 cells might convey tolerance to APCs by down-regulating the expression of 
costimulatory molecules, such as CD80 and CD86, in a antigen-non-specific, cell-cell contact 
independent, and cytokine-dependent manner when they re-encounter the antigen (61). In 
contrast, CD25+CD4+ Treg cells down-regulate these costimulatory molecules on APCs in a cell-
cell contact-dependent, antigen-specific, and cytokine-independent fashion (63). Furthermore, 
CD25+CD4+ Treg cells express the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 or 
CD152), a well-known negative regulator of the activation of both CD4+ and CD8+ T cells (62). 
Recently, an additional mechanism of action of CTLA-4 has been discovered in that CTLA-4 was 
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found to act bidirectionally and also affects DCs. (64) The binding of CTLA-4 on the Treg cells 
to B7 on the CD8α+ DCs induces the latter to secrete INF-γ which, in an autocrine fashion, 
initiates production by the DCs of the tryptophan-catabolizing enzyme IDO (indoleamine 2,3-
dioxygenase). Antigen-presenting CD8α+ DCs expressing high levels of IDO, in turn, may exert 
a tolerogenic effect on T cells by two different mechanisms. First, they may inhibit T cell 
proliferation due to the IDO-induced consumption of the essential aminoacid tryptophan and, 
second, they may induce T cell apoptosis due to production of pro-apoptotic tryptophan 
metabolites. As described earlier, uptake of apoptotic material by CD8α- DCs might render the 
latter to tolerogenic CD8α+ DCs (46). 
Hence, there are several subtypes of Treg cells which in their effector phase convey tolerogenic 
properties to DCs by different mechanisms, such as the production of suppressive cytokines, cell-
cell contact dependent interaction, and the induction of IDO. Tolerogenic DCs on the other hand, 
including those taking up apoptotic material, operate in the induction phase of Treg cells. There 
thus is a reciprocal interplay between DCs and Treg cells in the induction and maintenance of 
peripheral T cell tolerance. 
 
Infectious spread of nickel tolerance from tolerogenic donor APCs to host T cells.  
 As mentioned above, transfer of  APCs (i.e., T cell-depleted spleen cells), or purified splenic B 
cells, from Nihigh donors to Nilow recipients prevented the induction of nickel allergy. In analogy 
to the sequential transfer of T cells, tolerogenic donor APCs proved to spread tolerance to the T 
cells but not the APCs within the  first set of recipients (41). 
The mechanisms underlying the infectious tolerance spread from tolerogenic APCs of Nihigh 
donors to the T cells of Nilow recipients are thought to be identical with those operating in the 
induction phase of the nickel-specific Treg cells of Nihigh mice (see Fig. 2). However,in contrast 
to orally induced tolerance in which nickel is administered without further costimulation, the 
recipient mice need to be immunized with NiCl2/H2O2 for the infectious tolerance mechanism to 
become effective (41). The exact reason for this requirement is unknown, but several, mutually 
not exclusive possibilities may be considered. First of all, the immunization could serve to up-
regulate Fas on the tolerogenic donor B cells and/or FasL on the recipient’s DCs, thus 
strengthening apoptosis induction. Second, in the presence of tolerogenic APCs, immunization 
could induce the production of IL-4 and IL-10 by iNKT cells creating an immunosuppressive 
micro-environment. However, considering the low number (102 to 103) of tolerogenic donor 
APCs and B cells, respectively, that are needed for the infectious tolerance, the immunization 
might also be needed for the recruitment of the involved cells. Thus tolerogenic B cells, iNKT 
cells, naive T cells, and recipient DCs migrate to appropriate sites in the draining lymph nodes 
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and spleen, where the infectious tolerance spread takes place.  
In conclusion, our experiments showed that in vivo nickel tolerance failed to be spread by direct 
T-T cell contact, but that APCs are indispensable as mediators for the infectious spread of 
tolerance from activated Treg cells to naive T cells. 
 
 
NICKEL-SPECIFIC REGULATORY T CELLS IN HUMANS 
In experimental animals it is the induction phase of nickel-specific Treg cells that has been 
analyzed best up until now. By contrast, in men the effector phase of these cells has been studied 
more extensively. Here, we shall compare the nickel-specific Treg effector cells of mice and men. 
The group of Cavani demonstrated that nickel-specific CD4+ T cells isolated from skin lesions 
of patients suffering from nickel allergy or from the peripheral blood of nickel-allergic and non-
allergic individuals were able to down-regulate the secondary immune response to nickel in vitro 
(65). These CD4+ Treg cells produced high amounts of IL-10, variable amounts of TGF-β, low or 
undetectable INF-γ, and no IL-2, which qualifies them as Tr1 cells. When activated with nickel in 
vitro, these Tr1 cells blocked the maturation and function of DCs in a cell-cell contact-
independent, but IL-10-dependent fashion. These DCs thereupon displayed an impaired capacity 
to activate Tc1 and Th1 effector cells specific for nickel or other antigens (65). More recently, 
Cavani et al. showed that in contrast to the CD4+CD25+ T cells obtained from persons who were 
non-allergic to nickel, those obtained from allergics proliferated in response to this agent and 
failed to suppress the proliferative response of nickel-specific effector T cells and naive 
CD45RA+ T cells to nickel (66). Furthermore, this group of investigators showed that nickel-
reactive CD4+CD25+ Treg cells express CCR7 and CLA; whereas  expression of the former 
molecule enables them to migrate to the lymphoid organs where they can regulate the primary 
response, the expression of CLA allows them to enter the skin and  suppress the secondary 
response upon a renewed dermal contact with the allergen (66). However, the capacity of these 
CD4+CD25+ Treg cells to suppress alloreactive T cells was comparable to CD4+CD25+ Treg cells 
of non-allergic persons (66). Interestingly, whereas the CD4+CD25+ Treg cells appear to be able 
to suppress and prevent nickel allergy in a cell-cell contact dependent manner (66), nickel-
specific Tr1 cells regulate the ACD by releasing cytokines (65).  
Cavani et al. suggested the convey of nickel tolerance from CD4+CD25+ Treg cells to Tr1 
cells (66). This concept of infectious spread of tolerance from Treg cell to naive T cells, has 
already been shown by Jonuleit et al. (67) and Dieckmann et al. (68). They could demonstrate 
that CD4+CD25+ Treg cells which were recently activated by antigen can infectiously spread the 
tolerance to naive CD4+ cells and render these into Tr1 effector cells producing suppressive 
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cytokines. The latest work of Stassen et al. showed that α4β1+ CD4+CD25+ Treg convey 
suppressor activity by inducing TGF-β-producing “Th3” cells, whereas α4β7+ CD4+CD25+ Treg 
induce IL-10-producing “Tr1” cells (59). In their systems DCs were not required, but this direct 
T-T cell interaction has only been shown in artificial in vitro settings up to now. As mentioned 
before, we tend to believe that in vivo APCs are indispensable as mediators for the infectious 
spread of tolerance from T cell to T cell. This hypothesis is supported by recent data from the 
group of Matzinger clearly demonstrating that Treg cells form orally tolerized donors can educate 
DCs, which then in turn convey tolerance to a new cohort of T cells (69). They suggested that in 
this education of DCs is mediated by both IL-4- and IL-10-dependent as well as cell-cell contact-
dependent mechanisms. We assume that not only either cell-cell contact-dependent mechanisms 
or cytokine-dependent mechanisms are involved in the convey of tolerance from T cells to T cells 
by the DCs, but believe that a concept involving both mechanisms depicts most likely the 
situation in vivo.  
Taken together, the concept of infectious tolerance as we have shown it in our serial transfer 
experiments, seems to function not only from donor cells to recipient cell, i.e., inter- individually, 
but also plays a role intra-individually, i.e., from one cell type to another within the same 
organism.  
 
 
EXTRAPOLATING FROM MICE TO MEN 
The findings of Cavani et al. (66) indicate that the immune system of non-allergic humans is 
not just indifferent or naive toward nickel, but, instead, responds to this ubiquitous environmental 
agent by generating Treg effector cells. Indirectly, this implies that the nickel concentration taken 
up and absorbed from food and beverages is high enough to be perceived by human T cells and to 
differentiate into Treg cells. Hence, non-allergic humans appear to resemble our Nilow mice not 
only with regard to the amount of oral nickel uptake (see Table 2), but also with regard to their 
incomplete nickel tolerance which, by definition, allows for a partial susceptibility to de novo 
sensitization. Both Nilow mice and non-allergic humans possess nickel-specific Treg cells and, as 
a consequence, cannot be sensitized by dermal exposure to Ni2+ ions alone. However, if the oral 
nickel uptake of humans were as low as that of our Nivery low mice, they probably would lack 
nickel-specific Treg cells and the incidence of human nickel allergy presumably were much 
higher. Therefore, whereas lowering the nickel concentration in items of frequent dermal contact 
was shown to lower the incidence of de novo sensitization to nickel in men (3) a reduction of the 
nickel concentration in food and drinking water presumably would have the opposite effect 
(although it can be beneficial for individuals already sensitized and suffering from severe nickel 
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allergy). In all likelihood, the nickel-specific Treg cells of most non-allergic humans are inferior 
to those of the Nihigh mice as far as number and/or suppressive strength is concerned. This 
presumably explains the susceptibility of humans to sensitization if the nickel exposure occurs in 
the context of ‘danger’.  
Another issue that needs to be clarified is the phenotypic difference between the nickel-
specific Treg cells characterized in humans and those identified in our Nihigh mice. In the human 
situation the CD4+ Treg cells (i.e., Tr1 cells and CD4+CD25+ Treg cells) seem to be more 
important as effector Treg cells (65, 66), whereas in our Nihigh mice CD8+ T cells predominantly 
function as suppressor-effector cells ((37), and K. Roelofs-Haarhuis, unpublished data). We 
assume that this difference is not due to a species difference between man and mouse, but rather 
due to the different nickel exposure. As can be seen in Table 2 the amount of nickel provided to 
Nihigh mice by drinking is about 106 times higher that in men. If indeed the involvement of 
anergic CD8+ Treg cells in the Nihigh mice as due to their higher oral uptake of nickel, we suggest 
that in the Nilow mice CD4+CD25+ Treg cells and/or Tr1 cells would be the predominant 
suppressor-effector cells, as it was shown for humans by Cavani et al.. 
 
 
CONCLUSIONS 
In this review, we compared the experimental findings in our oral nickel tolerance model with 
other models of peripheral tolerance described in the literature. This makes us realize that the 
mechanisms of various systems converge with each other, although these models might have 
different routes of tolerogen administration. Thus, detailed aspects obtained from different 
tolerance models might serve as little pieces in the complex puzzle of peripheral tolerance. 
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The aim of this thesis was to investigate the mechanism of tolerance, induced by oral 
administration of nickel, which prevents the development of nickel-induced ACD in mice. 
Therefore, the mechanism of oral tolerance induced by a 4-week course of 10 mM NiCl2 in the 
drinking water was studied in detail.  
The research presented in this thesis has resulted in the following conclusions: 
• APCs induced by application of 10 mM NiCl2 in the drinking water for 4 weeks have a 
tolerogenic phenotype, displayed by the reduced expression of CD40, reduced stimulatory 
capacity, and the capacity to transfer tolerance. 
As discussed in chapter 4 and 5, we assume that orally induced nickel tolerance starts with the 
generation of tolerogenic DCs. After oral uptake of low concentration of nickel, the initial 
generation of tolerogenic DCs might be confined to the GALT, while the continuous 
administration of a high nickel dose could lead to the additional generation of tolerogenic DCs in 
the liver and spleen. The tolerogenic DCs might spread the tolerance to other APCs, such as B 
cells, through the production of TGF-β as shown in the ACAID model. In addition, DCs might 
also become tolerogenic by the uptake of nickel-containing apoptotic vesicles, such as apoptotic 
B cells (see below). 
 
• CD1-restricted, IL-4- and IL-10-producing CD4+ iNKT cells are not only needed to convey 
tolerance from tolerogenic APCs to T cells during orally induced tolerance, and thus in the 
absence of costimulation, but also during tolerance induced by transfer of tolerogenic APCs, 
which is in the presence of costimulation. 
Tolerogenic DCs spread the tolerance to naive T cells, but therefore, they need to cooperate 
with CD1-restricted CD4+ iNKT cells that produce IL-4 and IL-10. One mechanism could be that 
iNKT cells recognize CD1+CD40low tolerogenic, nickel-loaded cells, such as B cells, and kill 
them by Fas/Fas-L-mediated apoptosis. Thereafter, DCs take up the apoptotic material and 
present nickel-induced neoantigens in a tolerogenic fashion by both their MHC class I and II 
molecules to CD8+ and CD4+ T cells, respectively. Furthermore, the secretion of IL-10 by the 
iNKT cells is known to tolerize DCs and T cells directly whereas IL-4 produced by iNKT cells 
might shift the specific nickel response from a Th1-mediated DTH reaction towards a Th2 
response.  
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• T cells from these orally tolerized mice were anergic, and suppressed the secondary nickel 
response in vivo and in vitro. Most interestingly, comparable to splenic APCs, transfer of as few 
as 102 splenic T cells from orally tolerized donors is sufficient to prevent the generation of nickel 
allergy in the recipients.  
Treg cells might prevent both types of nickel responses by the suppression of costimulation on 
DCs, that normally ensures sensitization with NiCl2/H2O2, and the suppression of the stimulatory 
capacity of the DCs. However, other possibly involved mechanisms, such as the IDO-mediated 
immunosuppression, are currently under investigation.  
 
• The nickel-specific Treg cells not only suppress the nickel response via the APCs, but also 
modify APCs towards tolerogenic APCs.  
Upon adoptive transfer of only 102 splenic T cells from orally tolerized donors, the recipients 
are not only prevented from the developing a nickel allergy, but they also generate tolerogenic 
APCs. For this convey of tolerance from donor Treg cells, induced by oral administration of 
nickel, to APCs of the naive recipient, the latter needs to be immunized with nickel in the 
presence of H2O2. However, its still unknown if H2O2 is needed to activate the unknown pathway 
of infectious tolerance or only to lead to migration of all cells involved to the same place. 
Accordingly, tolerance can spread from Treg cells of the orally tolerized donor to T cells of the 
naive recipient, if the recipients are immunized twice. 
 
In this thesis the mechanism of oral tolerance is investigated in an experimental mouse model, 
and it is difficult to extrapolate this investigation to the human situation. Whereas in mouse 
models CD8+ T cells have shown to be the main Treg cells, in the human system, as investigated 
by Cavani et al., nickel-specific CD4+CD25+ Treg cells are the most pronounced Treg cells. 
Additional studies need to be done to show whether both models have a completely different 
mechanism or whether this difference between mice and humans is due to difference in the route 
and/or the dose of oral nickel uptake.   
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Summary 
Oral tolerance prevents hypersensitivity reactions towards ingested antigens. Although 
different underlying mechanisms are known, it is far from clear when a certain mechanism is 
involved. In our oral tolerance study we took the most common contact allergen, nickel, as model 
antigen, and studied the mechanism of oral nickel tolerance induced by a 4-week application of 
10 mM NiCl2 in the drinking water. 
Chapter 1 describes the current knowledge of nickel-induced allergic contactdermatitis, the 
most common delayed hypersensitivity reaction. Previously, our lab conceived evidence that Ni2+ 
ions, as present in NiCl2 and NiSO4, have a low intrinsic adjuvanticity. This explains the need for 
extra adjuvanticity, such as H2O2, to induce costimulation during nickel sensitization on one side. 
But, on the other side, it also explains the induction of nickel tolerance by NiCl2 alone, because it 
is known that presentation of the antigen in the absence of costimulation induces tolerance and 
anergy. Oral administration of nickel has been shown to induce T cell tolerance towards nickel. 
Although different mechanisms listed in this chapter can underlie oral tolerance, the one involved 
in oral nickel tolerance is far from clear. The aim of this thesis is to investigate the mechanism 
underlying this orally induced tolerance towards nickel. 
Chapter 2 shows evidence that a 4 week course of 10mM NiCl2 in the drinking water or 3 
weekly i.p. injections of 50 µl of 10 mM NiCl2 are the optimal conditions to prevent the 
induction of nickel-specific effector T cells, and thus to induce tolerance towards nickel for at 
least 20 weeks. The T cells from orally tolerized mice are anergic, because LNC of these mice, 
which were subjected to nickel sensitization in vivo and restimulation in vitro, failed to 
proliferate and produce IL-2 in response to NiCl2. Interestingly, the transfer of as few as 102 
splenic T cells, which have to contain both CD4+ and CD8+ T cells, from orally tolerized donors 
is sufficient to prevent the induction of a nickel allergy in the recipient. This means that at least 
2% of the CD4+ and 2% of the CD8+ T cells, and thus 4% or more from the splenic T cells from 
orally tolerized mice can recognize the nickel-induced neoantigens. An explanation for this high 
percentage of nickel-reactive T cells, which is comparable with the percentage allo-ractive T 
cells, is that Ni2+ ions can form many different metal-protein-complexes, and thus many different 
neoantigens with self-peptides presented by MHC-molecules. In addition, this chapter 
demonstrates that a complete desensitization in mice sensitized to nickel was only obtained by 
oral application (10 mM NiCl2 in the drinking water) for a period of 5 weeks. Unfortunately, this 
desensitization was transient. Only when the sensitized mice received an oral maintenance dose 
of 1 mM NiCl2 in addition to the 5 week treatment with 10 mM NiCl2 in the drinking water, the 
desensitization lasted for at least 20 weeks. Hence, oral administration of nickel can prevent the 
generation of nickel-specific effector T cells induced by NiCl2 and H2O2 (primary response), and 
in a lesser extent suppressed the activation of these effector T cells (secondary response), by the 
generation of anergic Treg cells. 
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In chapter 3, the role of APCs in orally induced tolerance is investigated. APCs from mice that 
were orally tolerized towards nickel display a tolerogenic phenotype, such as a reduced 
expression of CD40, and show a reduced allostimulatory capacity. Furthermore, comparable to T 
cells from orally tolerized donors, also APCs - which are T cell-depleted spleen cells and thus 
mainly B cells - or purified B cells from these donors, are able to transfer nickel tolerance to 
naive recipient mice with as few as 102 or 103 cells, respectively. However, in contrast to the 
suppressive capacity of the Treg cells, the tolerogenic capacity of APCs from orally tolerized 
mice is transient. This is in line with the immunological principle that in contrast to APCs, 
nickel-specific T cells have longtime memory specific for the nickel-induced neoantigens. To 
explain the low number of cells needed to transfer tolerance, this chapter also describes the 
infectious spread of tolerance from donor Treg cells, induced by oral administration of nickel, to 
APCs of the naive recipient or from tolerogenic APCs from this donor to naive T cells of the 
recipient, which is driven by immunization. Accordingly, tolerance can spread from Treg cells of 
the orally tolerized donor to T cells of the naive recipient and from tolerogenic APCs of this 
donor to APCs of naive recipients, if the recipients are immunized twice. Hence, APCs are 
needed as an intermediate cell type in the amplification of orally induced tolerance. 
Chapter 4 demonstrates the role of iNKT cells in nickel tolerance. iNKT cells are required for 
the induction of oral tolerance towards nickel, and the induction of nickel-specific Ts cells, but 
not for the generation of tolerogenic APCs. However, once Ts cells are generated, they can 
function independently of iNKT cells, hence they are not essential for the effector function of 
these specific Ts cells. iNKT cells are not only needed to induce tolerance by oral application of 
nickel, but also by the infectious spread of tolerance from tolerogenic donor APCs to naive T 
cells of the recipient. However, therefore tolerogenic APCs need to address iNKT cells in a CD1-
restricted manner and the iNKT cells need to be able to produce IL-4 and IL-10 in order to induce 
tolerance.  
Finally, chapter 5 summerizes the model for oral nickel tolerance induced by a 4-week course 
of 10 mM NiCl2 in the drinking water. This relatively high dose model is compared with other 
tolerance models described in the literature. Furthermore, the effects of the oral uptake of a low 
dose of nickel are discussed. In contrast to mice bred for at least two generations on a nickel poor 
environment, conventionally reared mice receive low oral doses of nickel since it is released from 
the metal cover of the box and metal outlet of the drinking bottle. Surprisingly, these mice 
contain Treg cells which can suppress the primary and secondary immune responses towards 
nickel induced by NiCl2 alone, but not a nickel response induced by NiCl2 and H2O2. Apparently, 
conventionally reared mice contain only Treg cells which prevent the upregulation of 
costimulatory molecules induced by NiCl2 alone. At last, we compare our mouse model for 
nickel tolerance with the human situation, as studied by Cavani et al.. However, during this 
comparison a lot of open questions arise that need further investigation. 
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Zusammenfassung 
Die wichtigste Aufgabe des Immunsystems ist, dass Krankheitserreger erkannt, angegriffen 
und abgebrochen werden. Leider kann das Immunsystem analog reagieren auf unschädliche 
Antigene, zum Beispiel in Form allergischer Reaktionen. Diesen unerwünschten 
Immunreaktionen kann man durch orales Eingeben des betreffenden Antigens vorbeugen. Dies 
wird auch orale Toleranz genannt. Obwohl unterschiedliche Mechanismen für orale Toleranz 
bekannt sind, ist es überhaupt nicht klar, wann welcher Mechanismus zutreffend ist. In der 
Studie, die in dieser Doktorartbeit beschrieben ist, ist das vielvorkommende Kontaktallergen 
Nickel als Modellantigen, für die Studie des Mechanismus der oralen Toleranz bei Mäusen, 
eingesetzt worden.  
Kapitel 1 beschreibt das heutige Wissen über den durch Ni2+-Ionen verursachten allergischen 
Kontaktdermatitis, die am meisten auftretende allergische Reaktion. In einer früheren Studie hat 
meine Kollegin Suzan Artik gezeigt, dass Ni2+-Ionen, so wie diese anwesend sind in NiCl2 und 
NiSO4, eine zu niedrige innere Adjuvanswirkung haben, um eine primäre Nickelreaktion zu 
erregen. Dies erklärt die Notwendigkeit des zusätzlichen Adjuvans, wie u.a. durch H2O2, während 
der Sensibilisierungsphase einer Nickelallergie erbracht. Auch kann dies eine Erklärung sein, 
weshalb orale Aufnahme der Ni2+-Ionen (ohne zusätzliches Adjuvans) eine Nickeltoleranz 
verursacht. Es ist bekannt, dass die Präsentation des Antigens mangels Kostimulation Anergie 
induziert. Obwohl mehrere Mechanismen für orale Toleranz, in denen anerge T-Zellen auch eine 
regulierende Kapazität haben, bekannt sind, und also als Regulator-T(Treg)-Zellen fungieren, ist 
der Treg-Zelle-abhängige Mechanismus der oralen Nickeltoleranz alles andere als deutlich. Ziel 
dieser Doktorarbeit ist, dieser Treg-Zelle-abhängige Mechanismus der Nickeltoleranz, bei dem 
die Toleranz  durch die Verabreichung relativ hoher Dosen NiCl2 über das Trinkwasser  induziert 
wird, zu untersuchen.  
Aus dem 2. Kapitel geht hervor, dass das Hinzufügen von 10 mM NiCl2 in das Trinkwasser 
über einen Zeitraum von 4 Wochen, oder drei mal pro Woche eine i.p. Injektion mit 50 µl 10 mM 
NiCl2, die bestmögliche Bedingungen bildet für die Induktion einer Treg-Zelle-abhängige 
Nickeltoleranz, die mindestens 20 Wochen der Sensibilisierungsphase einer Nickelallergie in 
Mäusen vorbeugt. Die T-Zellen dieser toleranten Mäusen sind anerg, weil sie nach In-vivo-
Sensibilisierung mit NiCl2 und H2O2 und In-Vitro-Restimulierung mit NiCl2 sich nicht vermehren 
und keine Interleukine-2 produzieren. Erstaunlich ist der Befund, dass der Transfer von lediglich 
102 T-Zellen der Milz der toleranten Mäuse, die sowohl CD4+ als auch CD8+ T-Zellen enthalten, 
ausreicht der Entwicklung einer Nickelallergie beim Empfänger vorzubeugen. Demnach müssen 
mindestens 2% der CD4+ und 2% der CD8+ T-Zellen, etwa 4% oder mehr der T-Zellen, in der 
Milz toleranter Mäuse die Ni-induzierten Neoantigene erkennen können. Eine Erklärung für 
diesen hohen Prozentsatz Ni-reaktiver T-Zellen, der dem alloreaktiver T-Zellen vergleichbar ist, 
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ist darin zu suchen, dass Ni2+-Ionen aufgrund ihrer Fähigkeit  verschiedenartige Metall-Protein-
Komplexe zu bilden, eine Vielzahl strukturell unterschiedlicher Neoantigene mit MHC-
präsentierten Selbstpeptiden bilden können. Auch zeigt dieses Kapitel, dass die mit Ni2+-Ionen 
sensibilisierten Mäuse, durch orale Aufnahme von 10 mM NiCl2 im Trinkwasser, in eine Spanne 
von 5 Wochen völlig desensibilisieren. Leider war diese Desensibilisierung vorübergehend. Nur 
wenn die mit Ni2+-Ionen sensibilisierten Tiere nach einer Behandlung mit 10 mM NiCl2 im 
Trinkwasser eine Spanne von 5 Wochen eine konstante orale Dosis von 1 mM NiCl2 empfangen, 
dauert die Desensibilisierung 20 Wochen an. Mit anderen Worten: die orale Aufnahme  der Ni2+-
Ionen kann die Entwicklung der durch NiCl2 und H2O2 induzierten nickelspezifischen Effector-T-
Zellen vorbeugen (primäre Immunreaktion gegen Nickel), und durch das Generieren der Treg-
Zellen die Aktivierung der bestehenden nickelspezifischen Effektor-T-Zellen (sekundäre 
Reaktion) vorübergehend unterdrücken. 
In Kapitel 3 wird die Rolle der Antigen-präsentierenden Zellen (APZs) in oraler Toleranz 
untersucht. APZs von nickeltoleranten Mäusen zeigen einen tolerogenen Phänotyp, wie z.B. eine 
verringerte Expressivität von CD40, und eine verringerte Kapazität, körperfremde T-Zellen zu 
aktivieren. Im Vergleich zu den Treg-Zellen toleranter Spender, können auch die 102 APZs, 
isoliert aus der Milz dieser Spender die Toleranz auf naive Empfänger übertragen. Diese APZs 
sind hauptsächlich aus B-Zellen und ein paar Prozent dendritische Zellen (DZs) 
zusammengesetzt. Diese DZs sind nicht wesentlich für die Übertragung von Nickeltoleranz der 
toleranten auf naive Mäuse, denn nur tolerogene B-Zellen können auch Nickeltoleranz 
übertragen. Im Gegensatz zu Treg-Zellen, ist die regulierende Kapazität der tolerogenen APZs 
vorübergehend. Der Transfer von APZs, isoliert aus Spendermäusen, die 20 Wochen zuvor 
tolerant wurden durch das orale Verabreichen von 10 mM NiCl2 über einen Zeitraum von 4 
Wochen, hat keinen Toleranztransfer zur Folge. Dies entspricht dem Prinzip des 
immunologischen Gedächtnisses: im Gegensatz zu APZ besitzen Treg-Zellen ein spezifisches 
Langzeitgedächtnis für die durch Ni2+-Ionen induzierten Neoantigene.  Als Erklärung für sowohl 
die minimale Zahl der Treg-Zellen als auch für die tolerogene APZs, die für den Transfer der 
Toleranz notwendig sind, beschreibt dieses Kapitel eine Verbreitung der Toleranz, von Treg-
Zelle auf APZ oder von tolerogenen APZs auf naive T-Zellen, die abhängig ist von der 
Immunisierung mit mit NiCl2 und H2O2. Dementsprechend, bei der Verbreitung von 
Nickeltoleranz der Treg-Zellen, gewonnen durch die Verabreichung von NiCl2 im Trinkwasser 
der Spender, auf T-Zellen der naiven Empfänger, sind APZs notwendig als intermediärer Zelltyp 
und soll der Empfänger zweimal mit NiCl2 und H2O2 immunisiert werden.  
Kapitel 4 beweist, dass Jα18+/+ natürliche Killer-T-(iNKT-) Zellen in der oralen Nickeltoleranz 
eine Rolle spielen. iNKT-Zellen sind nämlich notwendig für die Generierung der 
nickelspezifischen Treg-Zellen, aber nicht für die Generierung der tolerogenen APZs. Jedoch, 
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nachdem Treg-Zellen generiert worden sind, können sie unabhängig von iNKT-Zellen 
funktionieren. Mit anderen Worten, iNKT-Zellen sind nicht wesentlich für die Effektorfunktion 
dieser Treg-Zellen. iNKT-Zellen sind nicht nur notwendig während der Induktion der Treg-
Zellen durch die orale Verabreichung von Nickel, sondern auch bei der Verbreitung von Toleranz 
der tolerogenen Spender-APZs auf die naiven T-Zellen des Empängers. Aus meiner Studie geht 
hervor, dass für diese Verbreitung der Nickeltoleranz, die tolerogenen APZs die iNKT-Zellen 
über einen CD1-abhängigen Mechanismus aktivieren müssen, so dass IL-4 und IL-10 produziert 
wird. 
Zum Schluss wird in Kapitel 5 das Modell für orale Nickeltoleranz zusammengefasst. Es 
betrifft hier das Modell, das induziert wird indem man 4 Wochen lang 10 mM NiCl2 in das 
Trinkwasser hinzufügt. Dieses Modell wird mit anderen Toleranzmodellen, die in der Literatur 
beschrieben werden, verglichen. Auch werden, im Gegensatz zu diesem Toleranzmodell, bei dem 
eine relativ hohe Dosis Antigen gegeben wird, die Folgen der oralen Verabreichung einer relativ 
niedrigen Dosis NiCl2 besprochen. Im Gegensatz zu Mäusen, die mindestens zwei Generationen 
in einer Umgebung mit einer minimalen Konzentration Ni2+-Ionen gehalten worden sind, erhalten 
die konventionell großgezogene Mäuse über den Metalldeckel des Käfigs und über den 
Metallnippel der Trinkflasche eine niedrige Dosis orale Ni2+-Ionen. Es ist überraschend, dass 
auch diese konventionelle Mäuse Treg-Zellen enthalten, die die primäre und sekundäre 
Immunreaktion gegen Nickel, induziert durch lediglich NiCl2, unterdrücken, aber nicht die 
Nickelreaktion induziert durch NiCl2 und H2O2. Konventionelle Mäuse enthalten offenbar nur 
Treg-Zellen, die einer erhöhten Expression kostimulierender Moleküle induziert durch lediglich 
NiCl2 vorbeugen. Zum Schluss wird versucht dieses Mausmodell für Nickeltoleranz mit der 
menschlichen Lage zu vergleichen, wie diese von Cavani und anderen schon untersucht worden 
ist. Dieser Vergleich ruft so viele neue Fragen hervor, dass zusätzliche Forschungsarbeiten 
wünschenswert sind.  
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Nederlandse samenvatting 
De belangrijkste opgave van het immuunsysteem is ervoor te zorgen dat ziekteverwekkers 
worden herkend, aangevallen en afgebroken. Helaas kan het immuunsysteem op analoge wijze 
reageren op onschadelijke antigenen bijvoorbeeld in de vorm van overgevoeligheidsreacties. 
Deze ongewenste immuunreacties kunnen worden voorkomen door orale toediening van het 
betreffende antigeen. Dit wordt ook wel orale tolerantie genoemd. Hoewel verschillende 
mechanismen voor orale tolerantie bekend zijn, is het verre van duidelijk wanneer welk 
mechanisme van toepassing is. In de studie beschreven in dit proefschrift is het veel 
voorkomende contactallergeen nikkel als modelantigeen gebruikt voor het bestuderen van het 
mechanisme van orale tolerantie bij muizen. 
Hoofdstuk 1 beschrijft de huidige kennis over de door Ni2+ ionen veroorzaakte allergisch 
contact dermatitis (ACD), de meest voorkomende vertraagde overgevoeligheidsreactie. In een 
eerdere studie heeft mijn collega Suzan Artik laten zien dat Ni2+ ionen, zoals aanwezig in NiCl2 
en NiSO4, een te lage intrinsieke adjuvant werking hebben om een primaire nikkel response op te 
wekken. Dit verklaart de noodzaak van extra adjuvant, zoals o.a. geleverd door H2O2, tijdens de 
sensibilisatiefase van een nikkelallergie. Tevens kan dit een verklaring zijn waarom orale opname 
van Ni2+ ionen (zonder extra adjuvant) een nikkeltolerantie veroorzaken. Het is bekend dat de 
presentatie van het antigeen bij gebrek aan co-stimulatie anergie induceert. Hoewel er 
verschillende studies over orale tolerantie gepubliceerd zijn waarin anerge T cellen ook een 
regulerende capaciteit hebben, en dus als regulator T (Treg) cellen fungeren, is het Treg cel-
afhankelijke mechanisme van orale nikkeltolerantie verre van duidelijk. Het doel van dit 
promotieonderzoek is dit Treg cel-afhankelijke mechanisme van nikkeltolerantie te onderzoeken, 
waarbij de tolerantie wordt geïnduceerd door de toediening van relatieve hoge doses NiCl2 via 
het drinkwater. 
Uit hoofdstuk 2 blijkt dat toevoeging van 10 mM NiCl2 in het drinkwater gedurende een 
periode van 4 weken of 3x per week een i.p. injectie met 50 µl 10 mM NiCl2 de optimale 
condities vormen voor de inductie van een Treg cel-afhankelijke nikkeltolerantie die minstens 20 
weken de sensibilisatiefase van een nikkelallergie in muizen verhinderd. De T cellen van deze 
tolerante muizen zijn anerg, omdat ze na in vivo-sensibilisatie met NiCl2 en H2O2 en in vitro-
restimulatie met Ni2+ ionen, zich niet vermeerderen en geen IL-2 produceren. Indrukwekkend is 
de bevinding dat de transfer van slechts 102 T cellen van de milt van tolerante muizen, die zowel 
CD4+ als CD8+ T cellen bevatten, volstaat om de ontwikkeling van een nikkelallergie in de 
ontvanger te verhinderen. Dit betekent dat minstens 2% van de CD4+ en 2% van de CD8+ T 
cellen, en dus 4% of meer van de T cellen in de milt van tolerante muizen het door nikkel 
geïnduceerde neoantigen herkennen. Een verklaring voor dit hoge percentage aan 
nikkelspecifieke T cellen, dat vergelijkbaar is met het percentage aan alloreaktieve T cellen, is 
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dat Ni2+-ionen op basis van de verschillende metaal-proteine-complexen die ze kunnen vormen, 
vele verschillende neoantigenen met de door MHC-complexen gepresenteerde lichaamseigen-
peptiden vormen. Ook toont dit hoofdstuk aan dat de met Ni2+ ionen gesensibiliseerde muizen 
door orale opname van 10 mM NiCl2 in het drinkwater voor een periode van 5 weken volledige 
desensibiliseren. Helaas was deze desensibilisatie tijdelijk. Alleen als de met Ni2+ ionen 
gesensibiliseerde dieren na de behandeling met 10 mM NiCl2 in het drinkwater voor een periode 
van 5 weken een constante orale dosis van 1 mM NiCl2 ontvangen, houdt de desensibilisatie voor 
de duur van 20 weken aan. Met andere woorden, de orale opname van Ni2+ ionen kan de 
ontwikkeling van door NiCl2 en H2O2 geïnduceerd nikkelspecifieke effector T cellen voorkomen 
(primaire immuunreactie tegen nikkel), en de activering van bestaande nikkelspecifieke effector 
T cellen (secundaire reactie) tijdelijk onderdrukken door het genereren van Treg cellen. 
In hoofdstuk 3 wordt de rol van antigeen presenterende cellen (APCs) in orale tolerantie 
onderzocht. APCs van nikkeltolerante muizen vertonen een tolerogeen fenotype, zoals een 
verminderde expressie van CD40, en een verminderde capaciteit om lichaamsvreemde T cellen te 
activeren. Vergelijkbaar met de Treg cellen van tolerante donoren, kunnen ook de 102 APCs, 
geïsoleerd uit de milt van deze donoren de tolerantie overdragen aan naïeve ontvangers. Deze 
APCs bestaan hoofdzakelijk uit B cellen en een paar procent dendritische cellen (DCs). Deze 
DCs zijn niet essentieel voor de overdracht van nikkeltolerantie van tolerante donoren op naïeve 
ontvangers want alleen tolerogene B cellen kunnen nikkeltolerantie overdragen. In tegenstelling 
tot Treg cellen, is de regulerende capaciteit van tolerogene APCs van voorbijgaande aard. De 
transfer van APCs geïsoleerd uit donormuizen die 20 weken daarvoor tolerant werden door de 
orale toediening van 10 mM NiCl2 over een periode van 4 weken, resulteert niet in een transfer 
van tolerantie. Dit komt overeen met het immunologische principe dat in tegenstelling tot APCs, 
nikkelspecifieke Treg-cellen een lange-termijn geheugen bezitten dat specifiek de door Ni2+ 
ionen geïnduceerde neoantigenen herkent. Als verklaring voor zowel het minimale aantal Treg 
cellen als tolerogene APCs die nodig zijn voor de transfer van tolerantie, beschrijft dit hoofdstuk 
een verspreiding van tolerantie van Treg cellen naar APCs of van tolerogene APCs naar naïeve T 
cellen. Deze verspreiding vindt alleen plaats na het immuniseren met NiCl2 en H2O2. 
Dienovereenkomstig, bij de verspreiding van nikkeltolerantie van Treg cellen, verkregen door het 
toedienen van NiCl2 in het drinkwater van de donoren, naar T cellen van naïeve ontvangers, zijn 
APCs noodzakelijk als een intermediair celtype en moet de ontvanger 2x geïmmuniseerd worden 
met NiCl2 en H2O2.  
Hoofdstuk 4 toont aan dat iNKT cellen in orale nikkeltolerantie een rol spelen. iNKT cellen 
zijn namelijk vereist voor het genereren van nikkelspecifieke Treg cellen, maar niet voor die van 
tolerogene APCs. Echter, nadat Treg cellen gegenereerd zijn, kunnen ze onafhankelijk van iNKT 
cellen functioneren. Met andere woorden, iNKT cellen zijn niet essentieel voor de effectorfunctie 
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van deze Treg cellen. iNKT cellen zijn niet alleen vereist tijdens de inductie van Treg cellen door 
de orale toediening van nikkel, maar ook bij de verspreiding van tolerantie van tolerogene donor 
APCs aan de naïeve T cellen van de ontvanger. Uit mijn onderzoek blijkt dat voor deze 
verspreiding van nikkeltolerantie de tolerogene APCs de iNKT cellen via een CD1-afhankelijke 
pathway moeten activeren tot de productie van IL-4 en IL-10. 
Tot slot wordt in hoofdstuk 5 het model voor orale nikkeltolerantie, geïnduceerd door relatief 
hoge dosis Ni2+-ionen, nog eens samengevat. Dit model wordt met andere in de literatuur 
beschreven tolerantiemodellen vergeleken. Ook worden, in tegenstelling tot dit tolerantiemodel 
waarbij een relatief hoge dosis antigeen gegeven wordt, de gevolgen van orale toediening van een 
relatief lage dosis NiCl2 besproken. In tegenstelling tot muizen die tenminste twee generaties in 
een omgeving zijn gehouden met een minimale concentratie aan Ni2+ ionen, ontvangen de 
conventioneel grootgebrachte muizen een lage dosis oraal Ni2+ ionen via het metalen deksel van 
de kooitjes en de metalen nippel van de drinkfles. Verrassend is dan ook dat deze conventionele 
muizen Treg cellen bevatten die wel de primaire en secundaire immune reactie tegen nikkel 
geïnduceerd door enkel NiCl2 onderdrukken, maar niet de nikkelreactie geïnduceerd door NiCl2 
en H2O2. Deze Treg cellen in conventionele muizen kunnen blijkbaar alleen de expressie van 
costimulatoire moleculen geïnduceerd door enkel NiCl2 verhinderen. Tot slot proberen wij om dit 
muismodel voor nikkeltolerantie met de menselijke situatie te vergelijken, zoals die door Cavani 
et al. is onderzocht. Deze vergelijking roept zoveel vragen op dat nader onderzoek wenselijk is.  
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ACAID anterior chamber-associated 
immune deviation 
ACD allergic contact dermatitis 
Ag antigen 
ANOVA analysis of variance  
APC antigen presenting cells 
CDR complementarity-determining 
region 
CFA complete Freund’s adjuvant 
CLA cutaneous lymphocyte-associated 
antigen 
CTLA-4 cytotoxic T lymphocyte-
associated antigen 4 
DC dendritic cell 
bw body weight  
DNBS dinitrobenzene sulfonic acid 
DNFB dinitrofluorobenzene 
DTH delayed-type hypersensitivity 
FACS fluorescence activated cell sorter 
FITC fluorescein isothiocyanate 
GALT gut-associated lymphoid tissue 
GITR glucocorticoid-induced tumor 
necrosis factor receptor 
GM-CSF granulocyte-macrophage colony-
stimulating factor 
IEL intraepithelial lymphocytes 
INF interferon 
iNKT cell invariant natural killer T cell  
IL interleukin 
i.p. intraperitoneally 
i.v.  intravenously 
LC langerhans cell 
LNC  lymph node cell  
LP lamina propria 
mAb monoclonal antibody 
MACS magnetic activated cell sorter 
MHC major histocompatibility complex 
MFI mean fluorescent intensity 
MLN mesenteric lymph node 
MLR mixed leucocyte reaction 
Ni nickel 
PBS phosphate buffered saline 
PE phycoerythrine 
PP peyer’s patches 
SD standard deviation 
SI stimulation index 
SE standard error 
SEM standard error of the mean 
Tc cell CD8+ cytotoxic T cell  
TCR T cell receptor 
TGF-β  transforming growth factor-β  
Th cell CD4+ helper T cell 
TNF tumor necrosis factor 
Treg cell regulatory T cell 
Ts cell suppressor T cell 
wk week 
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Dit proefschrift is niet alleen mijn werk, maar is met de hulp van velen tot stand gekomen. Ik 
wil dan ook graag iedereen bedanken die een bijdrage heeft geleverd aan dit proefschrift. 
Herr Gleichmann, ik wil u niet alleen bedanken voor de mogelijkheden die u me hebt geboden 
om dit onderzoek te doen, maar ook voor uw geduld (vooral tijdens het schrijven van publicaties) 
als mede voor uw enthousiasme bij de discussies waaruit veel van de in dit proefschrift 
beschreven experimenten zijn ontstaan. U bracht me van een student tot een ware doctor. Danke 
vielmals. 
Jenny, je eeuwige optimisme heeft ervoor gezorgd dat ik niet opgaf als het onderzoek eens wat 
minder voorspoedig verliep. Jouw ondersteuning in de afgelopen jaren is voor mij heel 
motiverend en belangrijk geweest en heeft er mede tot geleid dat dit boekje nu daadwerkelijk af 
is. 
Xianzhu, I have admiration for the way you aspire your ideals so far from home. Thanks for 
all the times that in spite of that you were busy with your own work, you helped me with the 
time-consuming and boring ear-swelling test. I will miss our discussions and your stories about 
China during these experiments. Ingo, auch dir möchte ich danken für deinen Einsatz und deine 
Hilfe. Du warst für mich ein fester Halt. Ohne dich wäre es im Labor ein großes Durcheinander. 
(Hoffentlich sagst du mir, wann deine nächste Theateraufführung ist). Des weiteren möchte ich 
Sabine danken. Du hast mir nicht nur im Labor geholfen, sondern du warst auch eine Freundin. 
Dein verständnisvolles Zuhören in guten und schlechten Zeiten habe ich sehr geschätzt. Heike, 
die Zusammenarbeit mit dir habe ich als äußerst angenehm erfahren. Schade dass du nicht schon 
eher bei uns gearbeitet hast. Es war immer angenehm, u.a. die Promotionszwischenfälle mit dir 
teilen zu können. Abermals vielen Dank für die Male, dass ich bei dir übernachten durfte und für 
die tollen dazugehörenden Abende! Michael, auch dir möchte ich ganz herzlich danken für das 
Lösen der vielen (für mich unerklärlichen) Probleme mit meinem Computer. Und natürlich auch 
für die vielen Übersetzungen vom Niederländischen in die deutsche Sprache. Von meinem 
Deutsch hast du immer richtige deutsche Sprache gemacht. Suzan, Frank, Min Fang, und 
Jianhong Zhang, auch ihr möchte ich danken. Ich habe viel von euch gelernt. Für mich habt ihr 
die vergangenen Jahre in Düsseldorf zu einer Zeit gemacht, die ich nie vergessen werde. 
Xianzhu, Heike, Michael, Frank und Min Fang, ich wünsche euch besonders viel Erfolg mit der 
Absolvierung eurer Doktorarbeit.  
 Marty, bedankt voor je inzet bij mijn komst naar Düsseldorf, maar ook voor de vele 
leerzame discussies (eerst in het Nederlands en later in het Duits). Laura, thanks for all the times 
that I could knock at your door to ask you for help with the English language. Auch möchte ich 
die Mitarbeiter des Tierlabors danken für die Pflege der Mäuse. Ohne eure Hilfe hätte ich die 
vielen Versuche nicht machen können. Mark, Markus und Michaela vom Pizzafreundeskreis 
möchte ich danken für die vielen gemütlichen Abende. Den Donnerstagabend ist für mich immer 
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noch der Pizza-abend. (Habt ihr übrigens schon jemanden gefunden, mit dem ihr das schlechte 
Spiel der deutschen Mannschaft besprechen könnt?). Obwohl ich nicht jeden beim Namen 
nennen kann, auch im Hinblick auf die Tatsache, dass ich eine Person vergessen könnte, möchte 
ich natürlich die übrigen Mitarbeiter des Labors danken für den Spaß, den wir zusammen, 
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ontspanning. Marleen, ondanks dat je het zelf niet gemakkelijk hebt gehad, had je altijd tijd voor 
mij. Marlies, Leonie, Leontien en Jeannet, de etentjes met jullie zijn altijd supergezellig. Ik hoop 
dat er nog vele zullen volgen want goede tradities moet je voortzetten. Over tradities gesproken; 
de jaarlijkse barbecue, de nieuwjaarsborrel, het vriendenweekend, en het Vriendenkoor, de 
Wining and Diningclub (in de lokale volksmond ook wel “vretten en zoepen”) het is maar een 
greep van activiteiten waar ik elke keer weer naar uitkijk. Ik wil dan ook Rik, Heidi, Ben, 
Angelique, Jan, Dianne, Ronald, Rob, Ida, Gerben, Susan, Koen, Daan en Nadine bedanken voor 
jullie meeleven en belangstelling tijdens mijn promotietijd in Düsseldorf, maar vooral ook voor 
de adviezen hoe ik zo snel mogelijk mijn werkzaamheden kon afronden om toch ook weer terug 
te kunnen komen. Hans, je belangstelling voor de medemens, tot het einde toe, heeft diepe indruk 
op mij gemaakt en Dianne, ik bewonder de manier waarop je de draad weer probeert op te 
pakken. 
Henny en Hermien, bedankt voor je belangstelling en medeleven ook al is het verplaatsen in 
mijn wetenschappelijke omgeving soms lastig. Het is jammer dat Sanny dit niet mag meemaken. 
Ingrid en Eric, en ook Tim en Lotte, bedankt voor al die keren dat jullie me hebben laten zien dat 
er nog wat anders in het leven is dan het werk. Het werkt blijkbaar aanstekelijk! Pa en Ma, ik wil 
jullie bedanken voor de vrijheid die jullie mij gegeven hebben om mijn eigen keuzes te maken. 
Ook al was het vaak moeilijk te begrijpen wat mijn werk allemaal inhield, toch waren jullie een 
onvoorwaardelijke steun voor mij. Dank voor het onbegrensde vertrouwen en jullie geloof in mij. 
Het was soms moeilijk om mijn ambities met het thuisfront te combineren. Erik, ik heb het je 
niet altijd gemakkelijk gemaakt. Maar in plaats van daar over te klagen, was je er voor mij als ik 
het weer eens moeilijk had: je talloze, vaak telefonische peptalks zal ik nooit vergeten. Het is 
bijzonder te ervaren dat je ondanks de afstand toch zo dichtbij kunt zijn en in deze hectische 
periode toch zo dicht naar elkaar toe kunt groeien. Bedankt Erik, zonder je eindeloze geduld, 
steun en vertrouwen had ik deze promotie niet kunnen volbrengen.  
  
 
 
 
 
Burning with blind ambition 
I wanted to set the world alight 
nothing else mattered much to me. 
 
Driven by dedication 
I felt so confident inside 
a passion had got a hold on me. 
 
Took me a while to realize 
that every goal must have its price 
I needed more to make my life complete. 
 
The journey has been so long 
but now I’m coming back home 
back home to where my heart belongs. 
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